Studies with plasminogen activators by McNicol, George P
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
STUDIES WITH PLASMINOGEN ACTIVATORS
by
GEORGE P .  McNICOL
M ,D .# U m versity  of Glasgow, 
M .R *C ,P# (Glasgow and Edinburgh)
L e c tu re r  in  Medicine* U niversity  D epartm ent 
of Medicine* Glasgow Royal In firm ary .
T hesis subm itted  fox- the degree of 
D octor of Philosophy, U niversity  of Glasgow#
Volume 1,
ProQuest Number: 10646042
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uesL
ProQuest 10646042
Published by ProQuest LLO (2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
t / ft• f .
Studies with plasminogen activators.
George P. McNicol,
M.D, Glasgow, M.B.C.P. (Glasgow and Edinburgh)
Lecturer in Medicine, University Department of Medicine,
Glasgow Royal Infirmary.
Thesis submitted for the degree of Doctor of Philosophy.
In the past decade, stimulated by the availability of fibrinolytic 
agents suitable for use in man in the treatment of thrombo-embolic 
vascular occlusion, there has been a great increase in interest in the 
components and functions of the fibrinolytic enzyme or plasminogen-plasmin 
system. This thesis reports studies with plasminogen activators, that is 
substances which activate the plasminogen-plasmin system and so bring about 
fibrinolysis•
The thesis begins with a brief historical review of the development 
of ideas in fibrinolysis, and an account of current concepts of the 
components and functions of the plasminogen-plasmin system. There follows 
an account of the laboratory methods used in the thesis, including the 
euglobulin lysis and fibrin plate tests for plasminogen activator, 
plasminogen and fibrinogen assays, and as an index of the fibrinolytic 
coagulation defect, the thrombin clotting time* A description is given 
of a simple original method of preparing fibrinogen tagged with radioactive 
iodine, and of the electrophoretic and chromatographic properties of this 
tagged fibrinogen. Its use in a modified plasminogen-enriohed radioactive 
clot/
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clot assay system for plasminogen activator is described.
The thesis continues with an account of the biochemical effects of 
administration to man of a variety of plasminogen activators. Streptokinase, 
an activator of bacterial origin, was given to six subjects and intense 
plasminogen-plasmin system activity was induced, with a serious associated 
coagulation defect. The need for individualisation of initial dosage 
because of varying levels of antibody to streptokinase was confirmed.
A commercial preparation of urokinase, a physiological plasminogen 
activator present in human urine, was studied. Serum was found to inhibit 
urokinase and the preparation studied had coagulative properties in vitro 
and in vivo.
Actase, a commercial **plasmin** preparation found to consist largely 
of streptokinase, was given to two subjects and the fibrinolytic response 
investigated; little activity was produced by administration of the 
manufacturer's recommended dosage,
Complamin, a nicotinic acid-theophylline ester, fibrinolytically 
inert in vitro, was found to be a potent stimulus to production of plasma 
fibrinolytic activity when injected intravenously. However, the fibrinolytic 
response was transient and resistance to Complamin developed rapidly. 
Experiments involving study of the fibrinolytic responses to Complamin and 
exercise are described, which suggest that resistance to Complamin was not 
due to exhaustion of the body's reserve of fibrinolytic activity.
Most of the tissues of the body are rich in plasminogen activator, 
and tissue activator is an obvious possible source of plasminogen activator 
for/
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for therapeutic use. For this reason, plasminogen-plasmin system 
activity in surgical operations, in which tissue activator may he released 
into the circulation, was studied. A similar pattern of fibrinolytic 
activity to that produced by streptokinase was found, with liability to 
a serious coagulation defect. Tissue activator does not therefore appear 
on the basis of these observations to have unique merits as a potential 
therapeutic agent*
The thesis concludes with an account of experiments with artificial 
thrombi prepared in vitro by a modification of the method of Chandler 
(Chandler, A.B., 1938, Lab. Invest., 110). Such thrombi were perfused 
with streptokinase in an artificial circulation and factors affecting 
their response were studied. Thrombi made from blood with normal or raised 
platelet counts were found to release platelet emboli into the circulation, 
whereas thrombi made from thrombocytopenic blood were almost completely 
digested.
The findings suggest that in vivo thrombolytic agents might cause 
breakdown of thrombi into platelet emboli, which would represent an obvious 
hazard in the case of coronary and cerebral thrombosis* Thrombi made from 
hyperlipidaemic blood were markedly resistant to lysis, an observation 
supporting the view that hyperlipidaemia may predispose to thrombotic 
vascular occlusion*
Despite intensive efforts in many laboratories, the goal of routine 
therapeutic use of plasminogen activators has not yet been achieved. Some 
of the biochemical considerations involved in their use are presented in 
this thesis. From attempts made to solve the many problems which still 
remain/
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remain should emerge more understanding of the components and functions 
in health and disease of the fibrinolytic enzyme system*
Much of the data in this thesis has already been published, or 
accepted for publication, as shown below:-
1. McNicol, G.P*, Douglas, A.S., Bayley, C. (1962)
Experience with streptokinase infusions. Lancet, 2, 1297*
2* McNicol, G.P., Gale, S.B., Douglas, A.S. (1963)
In vitro and in vivo studies of a preparation of urokinase*
Brit. med. J., 1, 9O9 *
3* McNicol, G.P., Reid, W., Bain, W.H., Douglas, A.S* (1963)
Treatment of peripheral arterial occlusion by streptokinase 
perfusion. Brit* med. J., 1, 1508*
4. McNicol, G.P*, Douglas, A.S. (1964)
The fibrinolytic enzyme system, in, Recent Advances in 
clinical pathology, series IV, Churchill, London, p. 187.
3# McNicol, G.P., Douglas, A.S. (1964)
Urokinase and non-enzymatic fibrinolytic agents*
Scand. J. Lab. clin. Invest., I6 , suppl. 7 8, 34*
6* McNicol, G.P., Douglas, A.S. (1965)
Studies with Complamin, a nicotinic acid-theophylline 
ester, as a fibrinolytic agent. Brit. med. J., 1, 1149*
7 . McNicol, G.P., Bain, W.H., Walker, F., Rifkind, B.M., Douglas, A.S.(l965) 
Thrombolysis studied in an artificial circulation.
Thrombi prepared in vitro in a Chandler's tube* Lancet, 1, 838.
8 * /
•3"
8* McNicol, G.P,, Barakat, A,A., Douglas, A.S,, Bayley, C. (1965)
Plasma fibrinolytic activity in renal disease.
Scot. med, J., I8 9*
9 . Clement, W.E., McNicol, G.P, (1939)
131The preparation and use of I tagged fibrinogen to 
demonstrate fibrinolysis. J, clin. Path., 12, 344.
10, Douglas, A.S,, McNicol, G.P, (1964)
Thrombolytic therapy. Brit. med. Bull., 228.
11. McNicol, G.P., Browne, M.K., Bayley, C., Douglas, A.S*
Pathological fibrinolytic states and their treatment with 
epsilon aminocaproic acid (%CA). Brit. J. 8urg* (in press).
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components and functions of the fibrinolytic enzyme dr plasminogen-plasmin 
system* This.thesis reports studies with plasminogen activators, that is 
substances which activate the plasminogen-plasmin system and so bring about 
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M#D, Glasgow, M ,R ,G ,P , (Glasgow and Edinburgh)
L e c tu re r  in  M edicine, U n iversity  D epartm ent of M edicine,
Glasgow Royal Infirm ary*
T hesis subm itted  fo r the degree of Doctor of Philosophy *
In the past decade, s tim ulated  by the availab ility  of 
fib rino ly tic  agents su itab le fo r use  in m an in  the trea tm en t of 
thromfoo**embolic v a sc u la r occlusion , th e re  has been a g rea t 
in c re a se  in  in te re s t  in  the com ponents and functions of the fib rino ly tic  
enzyme o r xalasm inogen-plasm in system* This th e s is  rep o rts  
stud ies with plasm inogen ac tiv a to rs , that is  substances which 
activate the plasminogen*»plasmin system  and so bring  about 
fibrinolysis*
The th es is  begins with a  b rie f h is to ric a l review  of the
developm ent of ideas in  fib rin o ly s is , and an account of cu rren t
concepts of the com ponents and functions of the p lasm inogen-p lasm in
system * T here follows an account of the lab o ra to ry  m ethods used
in  the thesis* A descrip tion  is  given of an o rig inal m ethod of
p reparing  fibrinogen tagged with radioactive iodine, and of the
p ro p e rtie s  of th is tagged fibrinogen* Its  use in  a  m odified 
p lasm inogen-enriched /
•2 -
plasm inogen-enriched  rad ioactive clot assay  system  fo r plasm inogen 
ac tiva to r is  described*
The th es is  continues with an account of the biochem ical 
effects of adm in istra tion  to m an of a v a rie ty  of plasm inogen 
ac tiv a to rs . S trep tok inase , an ac tiva to r of b ac te ria l o rig in , was 
given to six  sub jects and the in tense plasm inogen ’^ plasm in system  
activ ity  induced is  d esc rib ed . The se rio u s  asso c ia ted  coagulation 
defect was also  investigated , and the need fo r individualisation 
of in itia l dosage because of varying levels of antibody to s trep tok inase  
was confirm ed.
A com m erc ia l p rep ara tio n  of u rok inase , a physiological 
plasm inogen ac tiva to r p re sen t in  human u rine , w as studied. S erum  
was found to inhibit u rok inase  and the p repara tion  studied had 
coagulative p ro p e rtie s  in  v itro  and in vivo.
A ctase , a co m m erc ia l **plasmin'* p repara tion  found to 
consist la rge ly  of s trep to k in ase , was given to two subjects and the 
fib rino ly tic  response investigated; little  activ ity  was produced by 
adm in istra tion  of the m an u fac tu re r 's  recom m ended dosage*
Com plam in, a n icotin ic acid-theophylline e s te r ,  fib rino ly tic  ally 
in e r t  in v itro , was found to be a potent stim ulus to production of 
p lasm a fib rino ly tic  activ ity  when in jected  intravenously* However 
the I
the fibx’inoiytic response was tran s ien t and ré s is tan ce  to 
Com plam in developed rap id ly . E xperim ents a re  described  
which suggest that re s is ta n c e  to Com plamin was not duo to 
exhaustion of the body's re se rv e  of fib rino ly tic  activ ity .
M ost of the tis su e s  of the body a re  rich  in  plasm inogen 
ac tiv a to r, and tis su e  ac tiv a to r is  an obvious possib le source of 
plasm inogen ac tiva to r fo r therapeu tic  u se . F o r  th is reason , 
p lasm inogen-p lasm in  system  activ ity  in  su rg ica l operations, in 
which tis su e  ac tiva to r m ay be re leased  into the c ircu la tion , was 
studied, A s im ila r  p a tte rn  of fib rino ly tic  activ ity  to that 
produced by strep tok inase  w as found, with liab ility  to a  serious 
coagulation defect* T issue  ac tiva to r does not th e re fo re  appear 
on the basis  of these  observations to have unique m e rits  as a  
po ten tial therapeu tic  agent*
The th es is  concludes w ith an account of experim ents with 
a r tif ic ia l th rom bi p rep a red  in  v itro  by a m odification of the m ethod 
of C handler (C handler, A .B * , 1958, Lab* In v e s t., 110).
Such throm bi w ere perfused  w ith strep tok inase  in  an a r tif ic ia l 
c ircu la tion  and fac to rs  affecting th e ir  response w ere studied. 
Throm bi m ade from  blood with norm al o r ra ise d  p la te le t counts 
w ere /
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w ere found to re le a se  p la te le t em boli Into the c ircu la tion , 
w hereas th rom bi m ade from  throm bocytopenic blood w ere alm ost 
com pletely digested* Throm bi m ade from  hyperlip idaem ic blood 
w ere  m arkedly  re s is ta n t to ly s is . The possib le bearing  of 
these  findings on thoraxxeutic use  of plasm inogen activatox’S is  
discussed*
D espite in tensive effo rts in many lab o ra to r ie s ; the goal
ol routine therapeu tic  use of plasm inogen ac tiv a to rs  has not yet
been achieved* Some of the biochem ical considerations involved
in  th e ir  use have been p resen ted  in th is  th e s is . F ro m  attem pts
m ade to solve the many problem s which s till  rem ain  should em erge
m ore  understanding of the components and functions in health  and
d isease  of the fib rino ly tic  enzyme system .
Much of the data in  th is th esis  has a lready  been published,
o r p resen ted  fd r publication, as shown below :-
1* M cNicol, G .P . ,  Douglas, A .S*, Bayley, G* (1962)
Experience w ith s trep tok inase  infusions* L ancet, 2, 1297.
2. M cNicol, G * P ,, G ale, S ,B * , Douglas, A.S* (1963)
In v itro  and in  vivo stud ies of a  p repara tion  of urokinase* 
Brit* med* J* 1>- 909.
3. McNicol* G .P * , R eid, W*, Bain, W .H*, D ouglas, A .S . (1963)
T rea tm en t of p e r ip h e ra l a r te r ia l  occlusion by strep tok inase  
perfusion* Brit* med* J . 1, 1508.
4, M cNieoi, G .P . ,  D ouglas, A*S, (1964)
The fib rino ly tic  enzyme system , in , R ecent Advances in 
c lin ical pathology, s e r ie s  IV, C hurchill, London, p* 187,
5, M cNicol, G * P ,, D ouglas, A*S, (1964)
U rokinase and non-enzym atic fibrinoly tic  agents.
Scand, J , L ab, d in .  In v e s t . , 16, suppl, 78, 34.
6, M cNicol, G .P . ,  D ouglas, A .S . (1965)
Studies with C om plam in, a  nicotinic acid-theophylline 
e s te r ,  as a fib rino ly tic  agent, B rit, m ad. J , , 1, 1149.
7. M cNicol, G .P .,, B ain, W .H ., W alker, F „ , R ifkind, B .M .,
D ouglas, A .S . (1965)
Throm bolysis studied in  an a r tif ic ia l c ircu la tion .
Throm bi p rep a red  in  v itro  in  a  C hand ler's  tube.
L ancet, 836.
8. M cNicol, G#P#, B arak at, A .A . , Dduglas, A .S . , B ayley, C, (1965)
P la sm a  fib rino ly tic  activ ity  in renal d isease . Scot. m ed. J . , 
10, 189.
9. Clement# W .E .,  McNicol* G .P* (1959)
The p rep ara tio n  and use of tagged fibrinogen to 
dem onstra te  f ib rin o ly s is . J ,  clin . P a th .,  12, 544,
10. Douglas# A .S .,  McNicol* O .P . (1964)
Throm bolytic therapy . B rit, m ed. B u ll . , 20, 228.
11. M cNicol, G .P , ,  B rowne, M ,K ., Bayley, C . , D ouglas, A .S .
Pathological fib rino ly tic  s ta te s  and th e ir  trea tm en t with 
epsilon am inocaproic acid  (EACA), B rit . J ,  S urg , (in p re ss ) .
PREFA CE,
The experim ents p re sen ted  in  th is  th esis  w ere  c a rr ie d  out 
in  the U niversity  D epartm ent of M edicine, Glasgow Royal 
In firm ary , in  the lab o ra to ry  of P ro fe sso r  A, S, D ouglas, The 
w ork was perfo rm ed  while I was in  tu rn  a  r e g is t r a r ,  then an 
honorary  sen io r r e g is t r a r  supported by an individual re se a rc h  
g ran t from  the M edical R esea rch  Council, and finally a le c tu re r  
in medicine* Colleagues who co llaborated  in  the studies included 
P ro fe s s o r  Douglas, M r, W* H* Bain, M ies B* C, Bayley,
M r. M* K, Browne, M iss W* E, Clem ent, M iss S, B, G ale,
M r, W. R eid, D r. B, M. Rifkind and D r. F ,  W alker. Much of 
the data has a lready  been published, o r has been accepted for 
publication, as shown below:
1. M cNicol, G ,P . ,  D ouglas, A .S .,  Bayley, C. (1962)
E xperience with s trep tok inase  infusions. L ancet, ^  1297,
2. M cNicol, G .P , ,  G ale, S .B , ,  Douglas, A .S . (1963)
In  v itro  and in  vivo studies of a  p repara tion  of u rok inase ,
B rit, m ed, J . 1, 909*
3. M cNicol, G . P . , Reid, W ., Bain, W-H*, Douglas, A .S . (1963)
T rea tm en t of p e rip h e ra l a r te r ia l  occlusion by strep tok inase  
perfusion , B rit, med* J ,  1, 1508.
4. M cNicol. O .P . ,  Douglas, A.S* (1964)
The fib rino ly tic  enzyme system , in , R ecent Advances in
•w itjtm» mà
c lin ical pathology, s e r ie s  IV, C hurchill, London, p. 187.
5. M cNicol, G ,P . ,  Douglas, A .S . (1964)
U roldnase and non-enzym atic fibrinoly tic  agen ts,
Scand. J , Lab. clin. In v e s t., 16, supixl. 76, 34,
6. M cNicol, G .P , ,  Douglas, A .S . (1965)
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CHAPTER 1. 
INTRODUCTION.
In the past decade, s tim ulated  by the availability  o£ 
fibrino ly tic  agents su itable fo r use in m an in the trea tm en t 
of throm bo-em bolic v ascu la r occlusion, th e re  has been a 
g rea t in c re a se  in  in te re s t  in  the components and functions 
of the fib rino ly tic  enzyme or p lasm inogen-p lasm in  system . 
This th esis  rep o rts  studies with plasm inogen ac tiv a to rs , 
that is  substances which activate the pi a s mino g en- pi as m in 
sy stem  and so bring  about fib rino ly sis .
Throm bolytic therapy , which may be defined as the use 
of plasm inogen ac tiva to rs  o r o ther fibrinoly tic  substances to 
induce the ly s is  of p re fo rm ed  throm bi in vivo, has obvious 
conceptual a ttrac tions in  the m anagem ent of throm bo-em bolic 
v ascu la r occlusion com pared with conventional anticoagulant 
drugs; at best anticoagulants can only prevent extension of 
th rom bosis and re s to ra tio n  of v ascu la r patency depends on 
re la tive ly /
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re la tive ly  slow n a tu ra l p ro c e sse s , w hereas with 
throm bolytic therapy  speedy rem oval of throm bi 
m ight be able to re s to re  v ascu la r patency quickly 
before d ista l tissu e  n ec ro s is  has taken p lace .
In view of the encouraging re su lts  which have been 
obtained with throm bolytic enzym es in anim al and human 
experim en ts, and from  individual w ell-stud ied  patients 
with v ascu la r occlusion, in tensive efforts a re  needed 
to place th is approach to trea tm en t on a basis  from  which 
la rg e -s c a le , well designed clin ical t r ia ls  can be c a rr ie d  
out. With th is object in view , a lo n g -te rm  program m e of 
investigation  of the problem s involved in throm bolytic 
therapy  ie being c a rr ie d  out in the U niversity  D epartm ent 
of M edicine, Glasgow Royal In firm ary , and the studies 
p re sen ted  in th is th es is  w ere perfoim ied as p a r t of this 
p rog ram m e.
The th es is  begins with a b rie f  h is to rica l review  of the 
developm ent of ideas in  fib rino lysis  and an account of 
cu rren t concepts of the components and functions of the 
p lasm inogen-p lasm in  sy stem . T here follows an account 
oil
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oi the ap p ra isa l and developm ent of labo ra to ry  m ethods 
used  in th is th es is  in  the study of throm bolytic activity; 
th is  in tu rn  is  followed by chap ters on the biochem ical 
effects and advantages and disadvantages of a  v a rie ty  of 
plasm inogen activators*  Finally» a rep o rt is given of 
ce rta in  fa c to rs , p a rticu la rly  p la te le t and lip id  content, 
which influence the p a tte rn s of response of a rtif ic ia l 
throm bi to plasm inogen ac tiva to r in v itro , and which may 
have a  bearing  on the throm bolytic p rocess in vivo*
Plan of the th esis .
The thesis is  presented in two volumes; volume 1 
contains the text and references, and volume 2, figures 
and tables. The tables are in two parts; those in 
appendix 2 are those to which reference is  made in the 
text# and those in appendix 3 are detailed tables from  
which, as indicated in the legends, the figures were compiled.
,4.
CHAPTER 2.
THE PLASMINOGEN-PLASMIN SYSTEM.
sHm)rxfsraim
H isto rica l Introduction.
It has been known for m ore than a century that under 
ce rta in  c ircum stances clots in shed blood may undergo 
spontaneous ly s is , but it is  only in the past 10 o r 15 y ea rs  
that detailed knowledge of the enzyme system  responsib le 
fo r such fibrinoly tic  activ ity , the p lasm inogen-plasm in 
system  has accum ulated.
The f i r s t  observations on the solution of fib rin  clots 
appear to have been m ade in the middle of the 19th century 
by Denis (1838) and Z im m erm an (1846) who found that fib rin  
from  human and bovine blood dissolved under ce rta in  
c ircu m stan ces. D astre  (1893) suggested that th is phenomenon 
was not solution in the tru e  sense but was due to digestion of 
the fib rin , a  p ro cess  fo r which he suggested the te rm  
'fibrinolysis* . Denys and de M arbaix (1889) showed that 
p ro teo ly tic  activity could be found in  serum  afte r trea tm en t 
with chloroform , Delezenne and P o zersk i (1903) observed 
tha t/
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that chloroform -indueed  proteoly tic  activity d isappeared  
if un trea ted  serum  was added and suggested that the 
action of ch loroform  was to rem ove or destroy  inhib itors 
of proteolytic activ ity . He din (1904) showed the p resence
of a p ro teo ly tic  enzyme in  the globulin fraction  of human 
se ru m  which itse lf  had no dem onstrable proteoly tic  activity; 
the album in frac tion  obtained from  serum  on ammonium 
sulphate fractionation  inhibited  the proteolytic activity of
the globulins. In 1946 C hristensen  confirm ed the effect of
/
chloroform  on the inh ib ito rs of p ro teo lysis and p resen ted  
evidence that ch loroform  activation of se rum  is  an 
auto cataly tic activation of a  proenzym e,
A, m ajo r advance in  underslanding of p lasm a fibrinolytic 
activ ity , from  which m ost subsequent knowledge has a r ise n , 
was the observation  of T ille tt and G arner (1933) that the 
culture f iltra te  of ce rta in  s tra in s  of haem olytic strep tococci 
contained a fac to r which caused rap id  ly sis  of fib rin  from  
hum an p lasm a. M ilstone (1941) showed that purified  hum an 
fib rin  was re s is ta n t to the strex>tocDccal product, but if a sm all 
amount of the euglobulin frac tion  of human serum  was added, 
ly s is /
ly sis  ensued rap id ly . Kaplan (1944) and C hristensen  
(1945) showed that the s trep tococcal fac to r and the 
euglohulin frac tion  of se ru m  when mixed, together gave 
r is e  to a p ro teo ly tic  ensym e; th is was produced by 
conversion to an active fo rm  of a norm ally  in e r t ensym e 
p re c u rso r  in  the globulin frac tio n . A now and now 
generally  accepted nom enclature was proposed by 
C hristensen  and MacLieod (1945); the strep tococcal 
fac to r was nam ed s trep to k in ase , the in e r t globulin* 
plasm inogen and the active enzyme to which it is  converted, 
p lasm in; the enzym e sy stem  as a whole is  nam ed the 
p lasm inogen^plasm in o r fib rino ly tic  enzyme system .
Components and. Functions of the P lasm inogen"P lasm in  System .
Though of considerab le  com plexity, the p lasm inogen-p lasm in  
system  has four m ain components: plasm inogen, p lasm in, 
ac tiva to rs  and inh ib ito rs *
P lasm inogen, a p lasm a globulin inactive in its  native s ta te , 
is  converted by ac tiv a to rs  to p lasm in , a p ro teo ly tic  enzyme 
which/
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which under su itab le c ircum stances d igests fib rin  to give 
soluble products (figure 1),
It is  not known w here in  the body plasm inogen is
j
syn thesised . Using a fluo rescen t antibody technique,
B anhart and Riddle (1961) have produced evidence to  suggest 
tha t eosinophils m ay tra n sp o r t and possibly also  syn thesise  
plasm inogen. P u re  p rep ara tio n s  of plasm inogen have not 
yet been produced and accordingly  ch a rac te risa tio n  is  
inadequate* P lasm inogen  is  a beta  globulin and is 
concentrated  in Cohn frac tion  III (Cohn et a l . , 1946), Two 
m olecu lar weights have been suggested # 143,000 (Shulman 
et a l . ,  1958) and 83,000 (Davies and E ngelert, I960), 
P lasm inogen is  stab le  in  dilute m inera l acid and advantage 
is taken of th is p ro p erty  in  the m ost commonly used  m ethod 
of p rep ara tio n , tha t of Kline (1953), which u ses  Cohn frac tion  
III as s ta rtin g  m a te r ia l. Such acid*^fractionated plasm inogen 
is  very  poorly soluble at n eu tra l pK. Also s ta rtin g  with 
Cohn frac tion  III, A lk jaersig  (1964) using DEAE chrom atography 
with lysine o r epsilon  am inocaproic acid  (EACA) as s ta b ilis e rs  
and so lu b ilise rs , has p re p a red  a  p repara tion  which is  free ly  
Soluble/
"S'
soluble at pH 7* S im ila r p repara tions have been m ade 
by among o th e rs . De rech in  et a l, (1962), W allen and 
B erg stro m  (i960) and Cole and M ertz (1961), and a 
p rep ara tio n  of th is  type is  now com m ercially  available 
(A. B. Kabi, Stockholm ).
A ctivation of Plasm inogen# A ctivation of plasm inogen, 
that is  its  conversion  to p lasm in , is  a p ro teo ly tic  phenomenon. 
A lk jaersig  et a l. (1958) found that the p rocess is  analogous 
to the form ation  of o ther p ro teo ly tic  enzym es from  th e ir  
inactive p re c u rso rs  (e .g . try p sin , pepsin, throm bin). T hree 
fac to rs  a re  common to the activation p ro cess  (i) the activation 
is  itse lf  an enzym atic reaction ; (ii) it  is  ir re v e rs ib le ;  and 
(iii) i t  involves the splitting  of a lim ited  num ber of peptide bonds. 
P lasm inogen ac tiv a to rs  p o ssess  the p roperty  of s%:litting lysine 
and arg in ine e s te r s  and such e s te rs  act as com petitive inh ib ito rs 
of plasm inogen activation; it  would th e re fo re  appear probable 
that lysine and arg in ine bonds a re  sp lit during the activation 
p ro c e ss , A lk jaersig  et a l. (1958) also  studied the re le a se  of 
tr ic h lo ra c e tic  acid  (TCA) soluble m a te ria l a fte r spontaneous 
activation of plasm inogen in  g lycero l, and a fte r activation 
with/
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with strep tok inase  and u rok inase  (see below). A fter 
s trep tok inase  and urok inase  activation, TCA soluble 
m a te r ia l accounted for about 16 p e r cent of the p ro te in  
in  the o rig inal p lasm inogen p reparation ; a f te r  spontaneous 
activation the figure was about 25 p e r cent# Shulman et 
al# (1958) observed  a d ec rease  in m olecu lar weight a fte r 
activation  of p lasm inogen which was in accord  with above 
data#
At the p re sen t tim e , little  is  known about the in terac tions 
of ac tiva to rs  and plasm inogen but as the pro teins involved 
becom e available in  m ore purified  fo rm s, th e ir  p rec ise  
in te r-re la tio n sh ip s  a t a  m olecu lar level w ill no doubt becom e 
b e tte r  understood*
A ctivators of P lasm inogen ,
P lasm inogen activation can be brought about in  four m ain 
ways:
(1) By substances which activate plasm inogen d irec tly , e .g .  
u rok inase , tis su e  ac tiv a to r,
(2) By substances which convert a norm ally  in e r t  p ro ac tiva to r 
to /
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to ac tiv a to r, e.g* s trep tok inase , tissu e  lysok inase. 
P ro ac tiv a to r has only been dem onstrated  as an 
activ ity  and not as a m olecu lar identity; it  m ay be 
plasm inogen its e lf  (see chapter 5), and the need to 
postu late p roac tiv a to r activ ity  has probably a r ise n  
because of d ifferences in  species specific ity  of 
ac tiva to r (M acfarlane, 1964).
(3) By px’o ced u res , a, g, dilution o r addition of ch loroform , 
which can bring  about activation in v itro ,
(4) By adm in istra tion  of substances, not them selves plasm inogen 
ac tiv a to rs , which can bring  about the re le a se  of ac tiva to r
in  vivo e ,g ,  nicotinic acid , b ac te ria l pyrogen.
T issue  A ctivato r, P lasm inogen ac tiva to r activ ity  can be 
ex trac ted  from  alm ost a ll body tis su es  except liv e r  and p lacenta 
(A lbrecht8en, 1957). High concentrations a re  found in  the 
p ro s ta te , u te ru s , thy ro id , lungs, ovary, adrenals and lymph 
nodes. Red ce lls  a lso  contain a plasm inogen ac tivato r 
(Kunzer and H aberhausen , 1963),
A/
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A tis su e  ac tiva to r, which can easily  he ex trac ted  from  
pig h e a rt with 2 M olar po tassium  th iocyanate, has been 
shown to produce activation  of plasm inogen by a  slow, 
probably s to ich iom etric  reac tion  (Abe and A strup , I960), 
Bachm an and S h erry  (1964) have also  ex trac ted  and p a rtia lly  
purified  and c h a ra c te r ise d  a pig h e a rt ac tiva to r,
A strup  (1956) believes that tis su e s  contain lysok inases 
which like s trep to k in ase , req u ire  p roac tiva to r to produce 
plasm inogen activation ,
Back ( 1964) has found considerab le amounts of tissu e  
ac tiv a to r in  the lysosom al frac tio n  of tissu e  hom ogenates.
He suggests tha t anoxia m ay be an im portan t cause of re le a se  
of th is  ac tiva to r from  lyaosom es, and he also  specu lates that 
re le a se  of lyoaom al ac tiv a to r m ay be a  cause of the 
excessive  p lasm a fib rino ly tic  activ ity  found following local 
v asoconstric tion , ischaem ia# anoxia, anaphylaxis and 
sudden death,
Todd (1964) has p re sen ted  evidence to suggest that 
fib rino ly tic /
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fib rinoly tic  activ ity  in the tis su es  is  concentrated  round 
blood v e sse ls , p a r tic u la r ly  veins,
p la sm a  ac tiv a to r. P lasm inogen  ac tiva to r activ ity  p re sen t 
in  tra c e  quantities in  norm al p lasm a, is found in  in c reased  
am ounts a fte r e x e rc ise , em otional s t r e s s ,  adrenaline and 
n icotinic acid  in jection , e le c tr ic  shock and adm in istra tion  
of b ac te ria l pyrogen (Sawyer et al», 1960a). The low levels 
of plasm inogen ac tiva to r p re se n t in  shed blood a re  probably 
responsib le  fo r the clot ly s is  activ ity  seen in the dilute clot 
ly s is  technique of F ea rn ley  and Tweed (1953), Caution 
m ust be observed  in assum ing from  the dem onstration  of 
fib rino ly tic  activ ity  in  j^lasma sam ples in  v itro  that the sam e 
activ ity  was p re se n t in  vivo; the trau m a  of venepuncture o r 
m anipulation a fte r  the w ithdraw al, may have in itia ted  the 
activ ity  found in  the te s t- tu b e .
F ea rn ley  et a l, (1952) found that in  v itro  p lasm a ac tiva to r 
is  lab ile  at room  tem p era titre , le s s  lab ile  at 4 ^ 0 , and apparently  
s tab ilised  by fib rin  fo rm ation , F le tch e r et a l. (1964a) have 
shown/
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shown that p lasm a ac tiva to r activ ity  induced in vivo by 
nicotin ic acid in jection  has a ha lf-life  in the c ircu la tion  
of about 13 m inu tes.
Source of p lasm a ac tiv a to r. This is uncerta in . Kwaan
et a l. (1937) have shown that p lasm a ac tivato r levels r is e  
in  iso la ted  venous segm ents in  response to paravenous 
in jection  of sero ton in , acety l choline and adrenaline *
This response , and the appearance of ac tiva to r in  the venous 
blood of ischaem ic limbs* is  blocked by atrop ine, and Kwaan 
and his asso c ia te s  suggest that a cholinergic effector m echanism  
may be involved. Though they did not identify the effector 
c e lls , they concluded that c ircu la tion  through the vas a vaso rum  
has a significant ro le  in  the production of fib rino ly tic  activity  
w ithin veins. It is  an a ttrac tiv e  hypothesis that local ac tiva to r 
re le a se  from  the v e sse l w all m ay be a response to in trav asc u la r 
th rom bosis , with sero ton in  from  aggregating p la te le ts  as the 
tr ig g e r  (Kwaan e t a l . , 1958).
Support fo r the view that vein w alls a re  in  p a rt at le a s t 
the source  of p lasm a ac tiva to r has been provided by Todd (1958) 
who, using a h is tochem ical technique, found that plasm inogen 
ac tiva to r/
14'
ac tiva to r was concen trated  round veins, venules and 
pulm onary a r te r ie s ,  and appeared  to be closely re la ted  
to th e ir  endothelium . W arren  (1964), using a s im ila r  
h is to chem ical m ethod, found evidence of plasm inogen 
ac tiva to r round both a r te r ie s  and veins; the activity  
appeared  to a r is e  from  the endothelium , and f%*om vas a 
vasorum .
G hakrabarti et a l. (1963) also  found in experim ents 
on unobstructed  veins exposed at operation , that trau m a  to 
the vein wall re su lted  in  a re le a se  of fibrinoly tic  activ ity  into 
the lumen; non-fibrino ly tic  p lasm a in troduced into the lum en 
also  rapidly  developed considerab le fibrinoly tic  activ ity . The 
authors considered  that th e ir  re su lts  w ere best explained by 
the re le a se  of plasm inogen ac tiva to r from  the vein w alls . 
U rokinase . U rokinase, the physiological plasm inogen ac tiva to r 
p re sen t in norm al u r in e , is  considered  in chapter 6.
B ac te ria l A ctiv a to rs . S trep tokinase is considered  in chap ter 5. 
Staphylococci have also  been shown to produce an exotoxin nam ed 
s t aphylokinas e /
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staphyXokinase which is  a plasm inagen ac tiva to r (Gorheim  
at a ï . , 19
A utoeatalytic Activation* A lk jaersig  et a l. (1958) have 
dem onstrated  tha t if the reac tio n  is  s tab ilised  in  50 p ar cent 
g lycero l, p lasm in  itse lf  can produce activation of a c tiv a to r-fre e  
plasm inogen in a fi-rs t-o rd a r reaction* T here is  evidence, 
a lready  cited, that the p lasm in  so produced may differ from  
that a ris in g  from  s trep tok inase  and urokinase activation . As 
has a lready  been d iscussed , ch loroform  probably produces 
plasm inogen activation  in  v itro  by destruction  of inh ib ito rs , 
thus perm itting  au tocata ly tic  activation to occur.
T rypsin  can a lso  activate  plasminogen* the activation 
k inetics being those of a first"^order enzym atic reaction  
(A lkjaersig  et a l , ,  1958).
Hagem an F a c to r . T here  is  evidence to suggest tha t activation 
of H agem an fac to r (factor XII) m ay prom ote fib rino lysis  
(H iewiarowski and P ro u -W arte lle , 1959* la tr id is  and F erguson , 
1962).
N on-Enzym atic A gents. By a m echanism  which is  not
understood/
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understood , tolbutam ide and chlorpropam ide (F earn ley  
e t a l . , I960), te s to s te ro n e  and nandrolone (F earn ley  and 
G hakrabarti, 1963), phenform in (Fearn ley  and G hakrabarti,
1964) and co rtico s te ro id s  (G hakrabarti et al#* 1964) all 
in c re a se  p lasm a fib rino ly tic  activ ity  in vivo, though all a re  
fib rino ly tically  in e r t  in  v itro .
When in jected  in travenausly  nicotinic acid causes a 
sh a rp  but not susta ined  r is e  in p lasm a ac tiva to r lev e ls , an 
effect which is  sh a red  w ith o th er vaso -active  substances and 
which is  d iscussed  in  chap ter 8* B acteria l pyrogen when given 
in travenously  a lso  causes an in tense but tran s ien t r is e  in  p lasm a 
fib rino ly tic  activ ity ; re s is tan c e  to the effect develops rapidly 
(M eneghini, 1949)*
Von K aulla (1962) has studied in v itro  a  la rg e  num ber of 
com pounds, many of which a re  u re a  o r u rethane d eriva tives, 
and o thers  a re  hyd ro trop ic , e*g. 2 ,4-dim ethyl benzene sulphonate 
and p^iodobenzoic acid , sodium  sa lt, which when incubated in 
the p resen ce  of hum an p lasm a produce plasm inogen activation . 
Von K aulla has suggested  th a t, like chloroform , they m ay do 
so/
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SO by destroying an inhib itory  mechanism*
A ctivator in  Secretions* P lasm inogen ac tiva to r activ ity  
is p resen t in  m ilk , (A strup and S terndorff, 1953), te a rs  
(S torm , 1955), sa liva  (A lbrechtsen and Thaysen, 1955) and 
sem inal fluid (von K aulla and Shettles* 1953), 
p la sm in ,
P lasm in  is  the pro teo ly tic  enzyme which evolves from  
plasm inogen by the activation  p rocedures already  discussed*
As already  m entioned, d ifferent m ethods of activation m ay 
produce a v arie ty  of m o lecu lar species of p lasm in , P lasm in  
can d igest many p ro te in s including fibrinogen (figure Z) and 
fib rin . O ther su b s tra te s  include glucagon, AGTH and growth 
horm one (M irsky e t a l* , 1959)* fac to r V (Aîagille and Soulier, 
1956), antihaem ophilic globulin (Lewis et al*, 1949) m%d ce rta in  
components of com plem ent (p illem er et al*, 1952), In v itro , 
p lasm in  has equal affinity for fibrinogen as fo r fib rin  (Ratnoff, 
1953), P lasm in  may also  be involved in the production of 
physiologically  active polypeptides, e .g .  bradykinin (E isen , 1964), 
Inh ib ito rs of the P lasm in o g en -P lasm in  System ,
Inh ib ito rs/
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Inhibitor B o£ the p lasm inogen-p lasm in  system  are  
of two m ain types; those which inhibit plasm inogen 
activation (an tiac tiva to rs) and those which inliibit form ed 
plasm in  (an tip lasm ins),
P la sm a  A n tiac tiva to r, The evidence to support the existence 
of an tiac tiva to r in p lasm a is suggestive but not conclusive, 
as the m ethods used  have not fully distinguished between 
antip lasm in  and an tiac tiva to r activ ity  (Lewis and F erguson , 
1951; M ullertz , 1957; Jacobs sen , 1955; N ilsson  et a l , ,
196la; P a ra sk ev as  e t a l , ,  1962). F u rth e r  evidence to 
suggest the p resence  of an tiac tiva to r activ ity  in  p lasm a is 
p re sen ted  in chapter 6.
O ther A n tiac tiva to rs . A v arie ty  of aliphatic amino compounds
including lysine and orn ith ine (M ullerts, 1954) a re  com petitive 
inh ib ito rs of plasm inogen activation , the m ost potent being 
EACA (A lkjaersig  et a l , ,  1959a; Ablondi et a l . ,  1959). O ther 
anti ac tiva to r 8 include p-am inom ethylbenzoic acid (Lohmann 
et a i . , 1964) and am inom ethyl cyclohexane carboxylic acid 
(Okamoto and Okam oto, 1962), the antifibrinoly tic ally active 
iso m e r/
iso m er of which is  about 10 tim es mo re  potent than EACA 
as an an tiactivato r (Dubber et a l* , 1964).
T.rasylol, a polypeptide with a m olecu lar weight of 
6,200» com m ercially  p rep a red  from  bovine lung, and 
m ark e ted  as, a try p s in  inh ib ito r, also has an tiactivato r 
p ro p e rtie s  (Steichele and H ersch le in , 1961),
P lasm a  Antiplasmin* p la sm a  and serum  ex e rt a substan tia l 
inhib itory  action on plasmin* N orm an and H ill (1958) have 
shown that th e re  a re  at le a s t two antip lasm ins in  se ru m .
One in  the a lp h a -2 globulin frac tion  reac ts  quickly as a 
com petitive inh ib ito r of plasmin* The o ther, in  the a lp h a -1 
frac tio n  reac ts  m ore slowly but firm ly  with p lasm in to produce 
an inactive com plex. P la te le ts  also  show antip lasm in  activ ity  
(Johnson and S chneider, 1953).
F le tc h e r (i960) rep o rts  that th e re  is  in  p lasm a about 
60 p e r cent m ore an tip lasm in  activ ity  than plasm inogen, i . e .  
than potential p lasm in , but a.ccording to N orm an (I960) th e re  
is about 30 tim es m ore  antip lasm in than plasm inogen. The 
d iscrepancy  probably a r is e s  because of the d ifferent assay  
m ethods/
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m ethods used  by the two authors: an tip lasm in estim ations 
vary  g reatly  under differing experim ental conditions.
In any event th e re  is  ag reem ent that an tip lasm in  levels 
considerably  exceed potential p lasm in  levels*
O ther A ntip lasm ins. N um erous substances have been shown
■U Biiu  ■■ii» M^ii.n.ii|i-!np i ^nw»i>cwiHiiiB»niij tinin iiii I u'l , pu
to po ssess  an tip lasm in  activ ity  including EACA (A lkjaersig  
et a l . , 1959a), am inom ethyl cyclohexane carfooxylic acid 
(Dubber et a l . ,  l96Sa), T rasy lo l (Steichele and H ers chlein,
1961), basic  amino acids (M ullerts, 1954), soya-bean try p sin  
inhib itor (C hristensen  and M acLeod, 1945), heavy m etals (Kowalski 
and L at alio , 1956) and toxic phosphorus compounds (M ounter 
and Shipley, 1958).
The A ntifibrinolytic A ctivity of L ip ids. It would seem  probable 
tha t in som e c ircum stances  lip ids ex e rt an inhib itory  effect on 
fib rino lysis; the evidence, which is  conflicting and confused, has 
recen tly  been review ed by Howell (1964).
F ib rin o ly sis  in  vivo -  The S herry  Hypothesis *
S herry  and h is asso c ia te s  (Sherry e t a l . ,  1959a; F le tc h e r  
e t a l . , 1959; A lk jaersig  et a l* , 1959b; S herry  et a l . , 1959b) 
have/
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have proposed a dual-phase concept of plasm inogen activation 
which is  now widely accepted  as the probable m echanism  by 
which in vivo the re la tive ly  non-specific  p ro teo ly tic  enzyme 
p lasm in  is  la rg e ly  re s tr ic te d  to a single highly specific  action, 
tha t of fib rin  ly s is . The suggested m echanism  is schem atica lly  
il lu s tra te d  in  figure 3. A ccording to th is hypothesis, 
plasm inogen in a sy stem  including both p lasm a and clot ex is ts , 
in  a physical sen se , in  a  dual phase , plasm inogen in the p lasm a 
constituting the soluble phase and, in  the clot, the gel phase.
As a consequence of th is  physical d istribu tion , the re su lts  of 
plasm inogen activation  in  the two phases a re  en tire ly  d ifferen t. 
P lasm inogen activation  in  the soluble or p lasm a phase, provided 
that i t  is  not unduly rap id , produces no appreciable effect on 
susceptib le  su b s tra te s  in the p lasm a, fo r p lasm a antip lasm in 
rapidly inhibits p lasm in  as it  is  form ed (figure 3, le ft hand 
section). However rap id  p lasm a plasm inogen activation may 
by a tem p o rary  overwhelm ing of the antip lasm in  m echanism  
p erm it the appearance of fre e  p lasm in in the c ircu la tion  with 
d igestion of suscep tib le  su b s tra te s  including fibrinogen and 
o ther coagulation fa c to rs , and hence produce a haem orrhag ic  
s ta te /
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State (see below). P lasm inogen activation in the clot o r 
gel phase, w here effective antix>lasmin levels a re  said  to 
be re la tive ly  low (Sawyer et a l# , 1961), produces a  d ifferent 
re su lt  (figure 3, righ t hand section)» in th is  c ircum stance , 
because of the in tim ate sp a tia l re la tionsh ip  of plasm inogen 
and fib rin , fib rin  ly s is  p r th rom bolysis re su lts .
The S herry  hypothesis is  supported by the in v itro  
observations that using the plasm inogen enriched  rad ioactive 
clo t system  (see chap ter 4) ly s is  is  readily  produced by 
ac tiv a to r in  the surrounding m edium , ly tic  activ ity  being a 
function of clo t plasm inogen content* M oreover such clots 
a re  re s is ta n t to  ly s is  by p lasm in  in  the surrounding m edium  
(A lkjaersig  et a l , , 1959b), S h erry  et a l. (1959a) have 
suggested  that the m ain function of p lasm a plasm inogon is  to 
endow any clo ts which may fo rm  with the m eans to m ediate th e ir  
subsequent ly sis  when ac tiva to r diffuses into them* P lasm inogen 
is  known to have a strong  affinity fo r fibrinogen and fib rin  
(Blomback and Blom back, 1956) and indeed it is  difficult without
spec ific /
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specific  so lubilising agents fo r plasm inogen to p rep are  
p lasm inogen-free  fibrinogen (M osesson, 1962), A ctivator 
is  also  absorbed on fib rin  in the p rocess of clotting, and 
G ross (1963) has shown, using an autoradiographic technique, 
tha t isotopic ally labelled  strep tok inase  can pene tra te  deeply 
into throm bus w ithin a sh o rt tim e of contact*
A ccording to the S herry  hypothesis, the ideal approach to 
therapeu tic  th rom bolysis would be so to elevate p lasm a ac tiva to r 
levels as to produce rap id  activation of in trin s ic  throm bus 
plasm inogen, with so lub le-phase plasm inogen activation 
proceeding at a ra te  w ithin the capacity of the p lasm a antip lasm in 
m echanism  to keep pace with p lasm in  production; th is ideal can 
probably never be re a lise d .
System ic H yperp lasm inaem ic S ta tes,
The consequence of excessively  rap id  p lasm a plasm inogen 
activation is  tem p o rary  overwhelm ing of the antip lasm in 
m echanism  with the appearance of free  p lasm in  in the c ircu la tion  
hyperp lasm inaem ia . A m ajo r component of the haem ostatic  
defect which occurs following hyperp lasm inaem ia is  the p resence  
in  the c ircu la tion  of products of p ro teo lysis  of fibrinogen by 
p lasm in , /
- 2 3 -
plasm in . N orm ally in  the final stage of blood coagulation 
th rom bin , a highly specific  p ro teo ly tic  enzym e, converts 
fibrinogen to fib rin  m onom er by splitting off specific 
peptides (Scheraga and Laskow ski, 1957), A fter po lym erisation  
of fib rin  m onom er, the final v isib le  clot is  fo rm ed in a 
gelation step; in  the p resence  of fac to r XIII the final clot 
is  stable unless exposed to pro teo ly tic  enzym es. S herry  and 
h is asso c ia tes  (F le tch er et a l . , 1962a; A lk jaersig  et a l , ,
1962; Bang et a l . , 1962) have shown that in  the p resen ce  of 
fibrinogen breakdown p roducts, clot form ation  is  delayed and 
defective, due to a defect in fib rin  polym er form ation . On 
naked-eye exam ination, clots form ed in the p resence  of 
fibrinogen breakdown products a re  loose and friab le , and th e ir  
abnorm al s tru c tu re  has also  been dem onstrated  with the e lec tron  
m icroscope . The abnorm ality  is  due to incorporation  with 
fib rin  m onom er as it  po lym erises of breakdown products of 
fibrinogen p ro teo lysis  by p lasm in; the breakdown products lack  
the c o rre c t s tru c tu re  to fo rm  a sound polym er. The m ain 
brealcdown product responsib le  for the defect has been identified  
and/
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and characterised*  N iew iarow ski and L at alio (1957),
H iew iarow ski and Kowalski (1958) and TriaiUaphyllopoulos
(1958) have observed  an an ti-th rom bin  effect of the products 
of fibrinogen p ro teo ly sis ; A lk jaersig  et a l. (1962) who 
orig inally  challenged th is  view , a re  now said  to accept that 
under cei*tain c ircu m stan ces fibrinogen breakdown products 
m ay show an ti-th rom bin  p ro p e rtie s  (H irsch, 1965).
O ther fac to rs  in  the genesis of the haem ostatic  fa ilu re  
of hyperp lasm inaem ia a re  digestion of fac to r V and antihaem ophilic 
globulin, and acce le ra ted  ly s is  of such clots as do form*
C auses of H yperplasm inaem ic States* Plyperplasm inaem ic 
s ta te s  may occur when p lasm a ac tivato r levels a re  sufficiently 
high to cause p lasm a plasm inogen activation at a ra te  in  excess of 
the capacity of the an tip lasm in  m echanism  to n eu tra lise  the p lasm in 
so form ed. Such high p lasm a ac tiva to r levels may a r is e  when 
tissu es  rich  in ac tiv a to r have been handled o r  dam aged, e .g . 
during su rg ica l operation , especially  card iac  su rg e ry  with an 
ex traco rp o rea l c ircu la tio n  (von K aulla and Swan, 1958; Gans 
et a l . , 1962). H yperp lasm inaem ia m ay also  com plicate o b ste tric  
acciden ts/
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acciden ts, e ,g .  armniotic fhiid em bolism , accidental haem orrhage: 
in trau te rin e  death with a  re ta in ed  dead foetus (Schneider,
1959)* P ro teo ly tic  s ta te s  have a lso  been rep o rted  in 
p ro s ta tic  carcinom a, especia lly  if  m étas tasés  a re  p resen t 
(Tagnpn at a l* , 1952), pancrea tic  neoplasm  (Ratnoff, 1952), 
leukaem ia (M ikata e t a l# , 1959)# and c irrh o s is  of the liv e r 
(G rossi et a l# , 1961)* The genesis of na tu ra lly  occurring  
hyperp lasm inaem ic s ta te s  is  probably often ex trem ely  complex*
It m ay be in  som e cases  a t le a s t  tha t the in itia l event is  re le a se  
into the c ircu la tion  of th rom boplastic  substances, with 
in tra v a sc u la r  clo tting , and that hyperp laam inaem ia ensues 
as a  hom eostatic  response  which •overshoots* (F le tch er e t a l* , 
1962b; Sharp, 1964),
As w ill be seen  la te r  in  th is th e s is , som e degree of 
hyperp lasm inaem ia is probably inevitable in patients in  whom a
throm bolytic s ta te  has been induced fo r therapeu tic  purposes*
/
F ib rin o ly s is  and the H aem ostatic  Mechanism#
n m\  # t f  n  I w in ii j i t W i p m w h  » ....... .. . . . . .  iw ,) , ,  w
I t is  a ttrac tiv e  to  speculate tha t the p lasm inogen-p lasm in  
sy stem , which when fully ac tivated  in vivo by strex>tokinase is  
sufficiently  potent to produce to ta l digestion of c ircu lating  
fibrinogen/
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fibrinogen (chapter 5), may under jsliysiologlcal c ircum stances 
be in dynamic equilibrium  with the coagulation system  to 
m aintain  an in tact patent v asc u la r t r e e . This hypothesis, 
whose proponents have included Copley (1957), A strup  (1956) 
and F earn ley  (1961) would suggest that the coagulation system  
is  constantly active laying down a th in  lay e r of fib rin  on the 
endothelium  to sea l any deficiencies which m ay occur, and that 
in  o rd e r to m ain tain  v ascu la r patency the p lasm inogen-p lasm in  
sy stem  is  also  constantly  active to renaove such fib rin  deposits 
a f te r  they have se rv e d  th e ir  haem ostatic  function. It has also  
been proposed (Mole, 1948; Biggs and M acfardane, 1962a; 
N ilsson et a l , , 1961a; F le tc h e r  et a l , , 1962b) that a reduction 
in  p lasm a fib rinoly tic  activ ity  m ight p erm it accum ulation of 
fib rin  on the endothelium , thus form ing the basis  of an 
atherom atous plaque (Duguid, 1949),
Though th e re  can  be no doubt as  to  the  ab ility  of th e  
co a g u la tio n  S y stem  to  p ro d u ce  f ib r in  in  v ivo , the  p h y s io lo g ica l 
ro le  of th e  p la s m in o g e n -p la sm in  s y s te m  is  no t so  f irm ly  
e s ta b lis h e d , E v id en ce  to  su p p o rt th e  v iew  th a t i t  is  co n s tan tly  
a c tiv e /
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active in vivo includes the dem onstration  of fib rinoly tic  
activity  in  p lasm a obtained from  norm al subjects under 
physiological c ircum stances (Fearn ley  and Tweed, 1953;
Sawyer et a l , , I960 a). In d irec t support fo r a ro le  fo r the 
p lasm inogen-p lasm in  sy stem  in  vivo can be found in the 
observations that in  general p lasm a fibrinoly tic  activity  
appears to be som ewhat reduced  in patients suffering from, 
d iseases  assoc ia ted  with th rom bosis (Hume, 1958; L ackner 
and M orsky, I960; N este l, 1959). F u r th e r , u rokinase 
excretion  is reduced in  d iseases  in wMch throm botic episodes 
a re  com mon, e .g ,  ca rc in o m ato sis , though it  is in c re ased  after 
m yocard ia l in farc tion , a conflicting observation  (Sm yrniotis 
et a l , , 1959),
On the o ther hand if  a dynamic equilibrium  between clotting 
and ly sis  does obtain, then a change in  one of the components 
of the equilib rium  s ta te , fo r exam ple the im paired  coagulation 
in  ce rta in  haem orrhag ic  d iso rd e rs  m ight be expected to lead  to 
a com pensating dim inution in  the o ther component and hence to 
a d ec rease  in  p lasm a fib rino ly tic  activ ity . However, 
fib rino ly tic /
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fib rino ly tic  activ ity  in  patien ts with haem ophilia, C hristm as 
d isease  and von W illebrand*s d isease  has been rep o rted  as 
no rm al (Kamel et a l , , 1963), M oreover, 13ij labelled  
fibrinogen su rv ival is  no rm al in patients with haem ophilia 
(Rausen et a l , , 1961), and prolonged adm in istra tion  of EACA 
to a group of haem ophiliacs did not re su lt  in an in c re a se  in 
p lasm a fibrinogen leve ls  (Gordon et a l , , 1965),
Until m ore  conclusive observations have been m ade, 
the concept of a dynam ic equilibrium  between clotting and ly sis  
m ust rem ain  an a ttra c tiv e  but unproven hypothesis; at the p re se n t 
tim e all that can be sa id  with certa in ty  is  that each system  can 
in te ra c t with the activ ity  of the o ther at many lev e ls , e , g, both 
system s may be ac tivated  by activation of Hagem an facto r; 
p la te le ts  have an tip lasm in  activity; fibrinogen and fac to rs  V,
VIII and pro throm bin  a re  d igested  by plasm in; fibrinogen 
breakdown products, which may have an an ti-th rom bin  effect, 
inliibit fib rin  po lym erisation .
Throm bolytic T herapy ,
T here is  now good evidence that in trav ascu la r adm in istra tion  
of plasm inogen ac tiv a to rs  to in c re a se  levels of p lasm a 
throm boly tic/
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throm bolytic activ ity  can bring  about the ly s is  of p re fo rm ed  
throm bi in  m an and experim enta l an im als, Johnson and 
T ille tt (1952) found tha t th rom bi produced in the m arg inal e a r  
veins of rabb its could be ly sed  by a system ic infusion of 
s trep tok inase , and S h erry  et a l. (1954) showed that in  dogs 
s trep to ldnase  and a v a rie ty  of pro teoly tic enzymes could lyse 
p e rip h e ra l a r te r ia l  th rom bi. S im ila r observations in re la tion  
to urokinase have been m ade by Tsapogas and F lu te  (1964),
The key observations in m an a re  those of Johnson and M cC arty
(1959) who rep o rted  that it  was possib le to  lyse a rtific ia lly  
produced throm bi in  the fo re a rm  veins of hum an volunteers by 
system ic  infusion of strep tok inase; in  control subjects not given 
strep tok inase  the veins went on to f ib ro s is . The effectiveness 
of throm bolytic therapy  in  m an has also  been dem onstrated  in 
individual w ell-s tud ied  cases  of p e rip h e ra l v ascu la r occlusion 
tre a te d  by plasm inogen ac tiva to r infusion (V erstrea te  et a l , ,  1963; 
McNicol et a l , , 1963).
In  view of the conceptual a ttrac tio n s of throm bolytic 
therapy , and the in itia l clin ical su cc esse s , in tensive efforts a re  
needed to extend knowledge of the biochem ical effects of 
plasm inogen/
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plasm inogen ac tiv a to rs  and to im prove m ethods used  in th e ir  
study, in o rd e r to p lace th is approach to trea tm en t on a routine 
b as is  so that la rg e  w ell designed clin ical t r ia ls  may be c a rr ie d  
out to a sse ss  its  genera l applicability  in  the trea tm en t of th rom bo­
em bolic occlusive v ascu la r d isease .
The m ajo rity  of the investigations p resen ted  in  th is 
th es is  w ere c a rr ie d  out during therapeu tic  adm in istra tion  of 
plasm inogen ac tiv a to rs , A few of the studies w ere p rim arily  
pharm acological and w ere  perfo rm ed  to elucidate ce rta in  of the 
b iochem ical effects of throm bolytic activity in  vivo, and the 
rem ainder w ere concerned w ith methodology, o r with the response 
of th rom bi in  v itro  to plasm inogen ac tiv a to rs .
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CHAPTER 3,
LABORATORY METHODS,
It is the purpose of th is chap ter to give an account of 
the m ore im portan t lab o ra to ry  m ethods used  in th is th e s is .
In the study of the effects of plasm inogen ac tiva to rs  it 
is  n ec essa ry  to have assay  system s for plasm inogen ac tivato r 
activ ity  in  p lasm a and o ther flu ids; the m ethods which a re  
available a re  d iscussed  below* T est system s m ust a lso  be 
available to m easu re  the coagulation defect produced by p lasm in  
activity; in  m ost cases the throm bin clotting tim e o r the one-stage 
p ro throm bin  tim e a re  su itab le fo r th is purpose, though in  som e 
circum stances a whole blood clotting tim e , reca lc ifica tion  tim e 
o r assay  of specific  coagulation fac to rs  m ay also  be helpful. 
F ina lly , to give understanding of the m echanism s of production 
of fibrinoly tic  s ta tes  and the asso c ia ted  coagulation defect, 
plasm inogen and fib rinogen  m ust be assayed .
A ctivator A ssay s, No specific  a ssay  system  fo r ac tiva to r in
biological fluids is  availab le . The fib rin  plate te s t and the 13 Ij 
labelled  clot sy stem  m oasu re  the ability  of the p lasm a o r o ther 
fluid/
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fluid under te s t  to lyse  p re fo rm ed  fib rin , a propei*ty which 
is  la rge ly  dependent on the ac tiva to r content of the fluid under 
te s t ,  though both system s a re  p a rtia lly  sensitive  to p lasm in  
in  the fluid being assay ed . The radioactive clot system , which 
is  described  in  detail in chap ter 4, is  re la tive ly  in sensitive , 
and is  som ewhat com plex. The fib rin  plate te s t ,  in  which 
sensitiv ity  cmi be in c re a se d  by the use of re  suspended euglobulin 
p rec ip ita te s  in  place of native p lasm a, req u ires  overnight 
incubation and so is  not su itable fo r concurren t contro l of 
throm bolytic therapy . The euglobulin ly sis  technique is  p rim arily  
a m easu re  of p lasm a ac tiva to r content, but i t  a lso  depends on 
plasm inogen levels and probably also  on fibrinogen lev e ls . As 
d iscussed  in  chapter 5, when plasm inogen is low, euglobulin 
ly s is  tim es may be long even in  the p resence  of in c reased  
concentrations of ac tiv a to r.
In a group of 40 patien ts with renal d isease , euglobulin 
ly s is  re su lts  c o rre la te d  w ell with those of the fib rin  p late te s t  
(figure 4), but th e re  was no co rre la tio n  between euglobulin ly sis  
activ ity  and plasm inogen levels  (figure 5) o r fibrinogen levels 
(figure 6),
D escrip tion  of M ethods,/
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D escrip tion  of Méthode#
T' raiw#c.%g*, *fvt*tnKTVWtAWNf#Mm'K»k
F ib rin  P la te  Test* în  the fib rin  plate te s t , a fibrinogen 
solution, rich  in  p lasm inogen, is  clo tted  with th rom bin  in  a 
P e tr i  d ish . If a sm all amount of a solution containing ac tiva to r 
is  p laced on the su rface  of the p la te , the plate plasm inogen is  
converted  to p lasm in  and a fte r incubation the holes m ade in 
the plate w here üae fib rin  is  ly sed  a re  m easu red . A reas of ly sis  
a re  usually  ex p ressed  in  sq uare  m illim e tre s  as the product of 
two perpend icu lar d iam ete rs  of the a re a  of lysis* A reas of 
ly s is  a re  not lin ea rily  re la te d  to ac tivato r concentration  and 
w here the re su lts  a re  to be subjected  to s ta tis tic a l analysis a 
s tandard  curve should be run with each batch of p la te s , activ ity  
in  the te s t  sam ple being read  off the curve (Sm yrniotis et a l . , 
1959).
Such a fib rin  p late  is  p rim arily  sensitive  to ac tivato r but 
it  is  also  susceptib le to d igestion by p lasm in . Response to 
ac tiva to r can be e lim inated  by heating the plate to destroy  
plasm inogen (80°C, fo r 45 m inutes; L assen  (1932) ). B ecause 
of p a r tia l dénaturation  of the fib rin , response to p lasm in  in a 
heated  plate is about 30 p er cent of that found in a com parable 
unheated/
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mille ate d p late (Alfcjaersig e t al», I959à)»
A ssay technique* The method used  in th is th esis  was slightly 
m odified from  that of Nils son and Oiow (1962), The fibrinogen
tl M
was bovine fibrinogen, B lomback frac tion  1 - 0  (Blomback and
M
Blom back, 1956) kindly supplied by Dr* I, H# Grondîial, 
Stockholm* 2* 5 ml* of 0 ,1  p e r cent bovine fibrinogen in t r i s  
buffer, 0* 15 Molar? pH 7*8 w ere clotted with 0. 5 m l. throm bin ,
50 H .Î.H * u n its /m l. (P arke Davis throm bin  top ical), in  a perspex  
dish , in te rn a l d iam eter 11,5 em s. A fter application of sam ples 
(30|ii, of p lasm a o r  resuspended  euglobulin p rec ip ita te ), the 
p lates w ere incubated fo r 18-20 hours at 37®C, Re suspended 
euglobulin p rec ip ita te s  w ere prepax^ed by adding 0 .1  m l. p lasm a 
to 1 .9  m l, 0 ,014 p a r cant acetic  acid, pH 5*4, the m ix ture was 
kept a t 4°G , fo r 10 m inutes and then centrifuged at 500 g, fo r 10 
m inu tes. The p rec% ita ta  was d issolved  in 0 ,1  ml* c itra te  saline 
(3 ,8  p er cent sodium  c itra te  in 0, 9 p er cent sodium  chloride 
solution). R esuspended euglobulin p rec ip ita te s  produced la rg e r  
a re a s  of ly sis  than the native p lasm a from  which they w ere 
p rep ared .
Sam ples w ere kept a t 4®C, until assayed  and w ere applied
to /
to the p lates as soon as possiM e afte r withdrawal*
Euglobulin L ysis A ctivity , In th is technique the euglobulin 
frac tion  of p lasm a, which includes fibrinogen, plasm inogen 
and plasm inogen ac tiv a to r, is  p rec ip ita ted  at pH 5. 4 and 
low ionic strength* Thé supernatan t which contains an tip lasm in , 
is  d iscarded . A ccordingly ly s is  tim es of clo ts m ade from  the 
euglobulin p rec ip ita te  a re  much sh o rte r  than those found with 
native p lasm a.
The technique used  was tha t of N ilsson and Glow ■(1962),
To 9 .5  m l. of 0*014 p e r cent acetic  acid, pH 5 .4 , was added 
0, 5 m l. p lasm a. The m ix ture was kept at 4®C, fo r 10 m inutes 
and then centrifuged at 4^C, at 500 g, for 10 m inutes. The 
supc m atan t was dis carded  and the p rec ip ita te  dis s olved in  0 * 5 
m l, of 0* 1 M olar b a r bitone buffei*, pH 7 ,3  (sodium  diethyl 
barb itone, 11,75 gm; HGl* 0 ,1  N, 430 mis Na C l, 14* 67 gms 
d is tilled  w ate r to 1000 m l,) .  A fter clotting with throm bin , 0, 5 
ml* of a 2 N *I,H , u n it/m l, solutionr the clot was incubated at 
37^G, and the tim e n ec essa ry  fo r com plete clot ly s is  was recorded , 
S herry  and A lk jaersig  (1957) have shown that in  fib rinoly tic  
a s sa y s , activ ity  i s  p roportional to the recipx*ocal of the ly sis  
tim e /
lb-
tim e and accordingly a logarithm ic plot of ly sis  tim e against 
units of activ ity  shows a lin e a r  re la tionsh ip . Such a plot 
can be used  to ex p ress  observed  ly s is  tim es in  te rm s  of 
a rb itra ry  units of activ ity , as suggested by S herry  et al.
(1959b). Such units can be used  fo r s ta tis tic a l purposes in 
analysis of data. In  the p re se n t s tud ies, a ly sis  tim e of 300 
m inutes was assigned  1 unit of activ ity . O bserved ly s is  tim es 
can be converted  to units by dividing the ly sis  tim e in  m inutes 
into 300,
R adioactive Clot A ssay , The m ethod is  described  in chapter 4* 
Throm bin Clotting Time* The throm bin clotting tim e was used  
in th is th esis  p rim a rily  as an index of defective fib rin  po lym erisation , 
but it is  also prolonged by reduced fibrinogen concentrations 
(figure 7),
The m ethod used  was that of F le tch e r et a l, (1959), To 
0, 1 m l, p lasm a was added 0 ,3  m l. of the ’'throm bin titra tio n  
m ix tu re” of S eegers and Sm ith (1942), This was made up fre sh  
on each occasion  with 6 m l, sa line , 1 m l, t r i s  buffer, 0, 1 M olar, 
pH 7 ,5 , Z m l, 0 ,7  p e r cent calcium  chloride and Z m l. 15 per 
cent acac ia  solution. The clotting tim e of the p lasm a with ’’throm bin  
titra tio n /
37-
titra tio n  m ix tu re” was estim ated  at 37^C* aft ex' addition of 
0 ,1  m l. throm bin, 10 H .I .H . u n its /m l.
O ne-Stage Px'othrom bin T im es w ere estim ated  as described  by 
Douglas (1962),
P lasm inogen  A ssay . The m ethod used  was the caeeinolytic 
assay  of R em m ert and Cohen (1949) as m odified by A lk jaersig  
et a l. (1959b). A ntip lasm in is  f i r s t  destroyed  by incubating 
the p lasm a with ac id . The acid  is  n eu tra lised  with alkali and 
buffer, and s trep tok inase  is  then added to convert the plasm inogen 
to p lasm in . The p lasm in  so produced is  assayed  by a caseinoly tic 
technique, the am ount of ty ro sine  re leased  from  the casein  being 
a m easu re  of the amount of p lasm in  p re sen t. The casein  
solution used  was p rep a red  by boiling for 20 m inutes 25 gm, 
case in  (L, L ight and Co. L td .,  Colnbrook) in 500 m l. phosphate 
buffer, 0. 1 M olar, pH 7 .6  (see below). The solution was 
f ilte re d  while hot and a fte r cooling, the pH was read justed  to 
7 .6 . The solution was then dialysed overnight against a la rg e  
volume of constantly  s t i r r e d  phosphate buffer.
A ssay technique. To O.S m l, p lasm a was added 0 .5  m l. I / 6  N.
hydroch loric  acid . A fter standing for 15 m inutes at room  
t  empe r  a tu r e /
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tem pei'attire to destroy  an tip lasm in , 0 ,5  m i, i /6  N* sodium  
hydroxide was added, followed by 1.0 m l. phosphate buffer,
0*1 M olar, pH 7*6, 0 .5  m l. s trep tok inase  solution 2,000 
u n its /m l. (Y aridase L ederle) and 2 .0  m l. 5 p e r  cent casein  
solution. A fter addition of casein  and thorough m ixing, 
the assay  m ix ture was incubated at 37^C. fo r 62 m inu tes.
At 2 m inutes and 62 m inu tes, 2 m l. aliquots w ere taken and to 
each was added 2 m l. 10 p e r  cent tr ich lo rac e tic  acid. A fter 
centrifugation  (SOD g. fo r 10 m inutes) 1 m l, of the supernatan t 
was added to 5 m l, 0 .5  N. sodium  hydroxide and 1 ,5  m l. 5 p e r 
cent tr ic h lo ra c e tic  acid , followed by 1.5 m l. dilute (1:2) F o lin  
G iocalteu reagen t. A fter standing fo r 15 m inutes fo r colour 
developm ent, the optical density of the 62 m inute sam ple was 
read  at 650 mp with the 2 m inute sam ple as blank. T yrosine 
re le a se  was read  off a  s tandard  curve; 1 casein  unit equals 
180 pg. ty rosine  re le a se d  in  1 hour.
F ibrinogen  A ssay . The m ethod described  is  that of Ratnoff and 
M ensie (1951) as m odified by A lk jaersig  (i960). In th is assay  
fibrinogen is  clo tted  with throm bin; the fib rin  so form ed is 
hydrolysed/
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hydrolysed with sodium  hydroxide and the ty rosine re le a sed  
is  estim ated  co lo rim etrica lly , A constant px*oportion of 
ty rosine  in  the fibrinogen m olecule is  assum ed (1: 11.7).
A ssay technique. In a 15 m l. te s t  tube w ere p laced ”0 .2  m l. ” 
g lass beads (d iam eter 0 .15  m m .) , 6 .0  m l. sa lin e , 0. 1 m l, 
throm bin solution, 100 H.X.H. u n i ts /m l . ,  0 ,2  m l, 2 ,5  p er 
cent calcium  chloride and 0 ,2  m l, p lasm a. The tube was 
shaken but not inverted  and the fib rin  was caught u%> on the g lass 
beads. A fter standing fo r 1 hour at 4^C. the tube was shaken 
again and centrifuged fo r 10 m inutes at 500 g. The g lass 
beads and adheren t fib rin  w ere w ashed 3 tim es with sa line .
A fter final centrifugation  and décantation of the washing fluid,
0 ,4  m l, 10 p e r cent sodium  hydroxide solution was added and 
the tube boiled in  a w ate r bath fo r 20 m inu tes. A fter cooling to 
room  tem p era tu re  0 .6  m l. 5 p e r  cent tr ich lo rac e tic  acid, 2 m l.
0, 5 N. sodium  hydroxide and 0 ,6  m l. dilute (1:2) F o lin  G iocalteu 
reagen t w ere added. A fter standing fo r 15 m inutes for colour 
developm ent, optical density  at 650 mp was read  against a  reagent 
blank. Readings w ere converted to fibrinogen concentration , 
m g/ 100 m l . , from  a standard  ty rosine curve.
C ollection of blood sam p les . In a ll the studies rep o rted  in  this 
th e s is /
—4 0 '
th e s is , c itra ted  blood was used; 9 volum es of blood collected  
by clean venepuncture w ere m ixed with 1 volume of 3, S per 
cent sodium  c itra te  in  a graduated  centrifuge tube. P la sm a  
was obtained by centrifugation  at 500 g, fo r 10 m inutes, and 
in  expressing  re su lts  of p lasm a a ssa y s , no co rrec tio n  has 
been made fo r dilution by c itra te .
S tandard  phosphate buffer. The standard  phosphate buffer used  
in  this th es is  was a  buffer of 0 ,1  M olar, pH 7 .6 , m ade up as 
follows: N a H g P O ^ . ZH^O, 2 .028 gm . ; Na2 H FO4 , 2H2O, 14.964 
gm , ; 9 ,0  gm, Ha Cl; w ate r to 1000 m l.
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CHAPTER 4.
PREPARATION AND PROPERTIES OF
TAGGED FIBRINOGEN, AND ITS USE AS A 
SUBSTRATE IN A THROMBOLYTIC ASSAY SYSTEM.
This chapter describes a method of preparing fibrinogen 
tagged with radioactive iodine, some of the properties of this 
tagged fibrinogen, and Its use in the assay of thrombolytic 
activity. The method of fibrinogen-tagging, devised in 
collaboration with M iss W. E, Clement (Clement and McNicol, 
1959} has subsequently been modified as described by McNicol 
and Douglas ( 1964) *
M aterials,
Radioactive Iodine (^^^I) was obtained from the Radiochemical
Centre, Amer sham, as radioactive sodium iodide, in 0 ,1  m l, 
dilute sodium thioeulphate solution. At various tim es the 
quantity of radioactivity used varied from 1 to 6 m e.
Fibrinogen was prepared from expired bank plasma by a phosphate 
buffer method (Biggs and M acfarlane, 1962b)*
Thrombin. /
Throm bin, P a rk e  Davis throm bin  top ical.
Plasm inogen* The plasm inogen used  to m ake rad ioactive 
c lo ts , p rep ared  by the m ethod of Kline (1953), was kindly 
supplied by M iss M, M ackay, It was insoluble at n eu tra l
P lasm in  was p re p a red  by spontaneous activation of plasm inogen
tvA a#*
in  g lycero l according to the m ethod of A lk jaersig  et a l. (1958).
The plasm inogen fo r th is purpose, soluble at neu tra l pH, was 
supplied by A, B, K abi,
Ion Exchange R esin . A m berlite  IRA 400 Cl.
S trep tok inase . A highly purified  p repara tion  supplied by 
A, B. Kabi,
U rokinase , Leo urok inase was used  (Leo L ab o ra to rie s , Copenhagen), 
Methods*
Buffer fo r e lec tro p h o re s is . B ar bitone buffer 0 .1  M olar, pH 8 ,6
iBPiwin ji . m  Jill I #. ###, * i . uXt . i u h. i . n Mii k . i im h
(Flynn and de Mayo, 1951).
P ap e r e lec tro p h o resis  was c a rr ie d  out in a horizontal e lec tro p h o resis  
tank on W hatman No. 1 paper fo r 16 hours at 130 volts* S trip s 
w ere  sta ined  fo r p ro te in  with brom ophenol blue.
C ellu lose aceta te  e lec tro p h o res is  was c a rr ie d  out using oxoid
* ,«ntiwn:tiu»i*eiÉW«v<i6ei
ce llu lose/
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célUtlose acetate strips which were run for Z hours at 150 
volts in a Shandon horizontal electrophoresis tank. After 
staining with Ponceau S, strips were scanned in a recording 
densitom eter (Chromoscan, Joyce Loebl and C o ., Gateshead 
on Tyne).
Chromatography was carried out by ascending chromatography 
with butanol acetic acid as solvent. Strips were stained for 
amino acids with diazotiaed sulphanilic acid and 10 per cent 
potassium  carbonate, and with 1 per cent palladium chloride 
for iodide. Monoiodotyrosine, diiodotyrosine and potassium  
iodide were run as m arkers.
Scanning for radioactivity. E lectrophoresis strips and 
chromatograms were scanned for radioactivity by passing them  
between two G eiger-M uller tubes linked through a rate m eter to 
a recording m ilUam m eter,
Autoradiography* Kodak *Kodirex* film  was used*
T yrosine ^ s say was c a r r ie d  out using F olin  Giocalteu*s reagen t, 
optical density  at 650 mp being reco rd ed  and ty ro sine  content of 
unknown/
—4 4 —
xmtoowii solutions being re ad  off a  standard  ty ro sine  cu rve. 
P rep a ra tio n  of R adioactive Iodine Tagged F ib rinogen . To 
6 m e. of rad ioactive sodium  iodide in  0* 1 m l. dilute sodium  
thiosidphate solution w ere added 0.025 m l. of a  norm al 
solution of stab le  iodine in m ethanol, 0 .025 m l. 0 .01  N. 
su lphuric  acid  and 5 m l. of hum an fibrinogen in c itra te  sa line , 
concentration  4 m g ./m l .  A fter 5.m inutes incubation at room  
tem p era tu re  I the fibrinogen was passed  through an ion-exchange 
re s in  column w ith 5 m l. 0 .1  M olar phosphate buffer, pH 7 .6 . 
A fter addition of hep arin  ( 0 .1 m l, of a 1 m g . /m l. solution), 
the fibrinogen was stored in  sm all aliquots at -EO^C,
properties of Tagged Fibrinogen.
The quality of the tagged fibrinogen produced is  
dependent on the quality of the starting fibrinogen. Figure 8 
shows a paper electrophoresis strip of a tagged fibrinogen 
preparation, clottable radioactivity 94 per cent, with a control 
strip  of normal serum  run simultaneously* The figure also  
shows a scan for radioactivity, and it w ill be seen that all the 
radioactivity was with the fibrinogen. The hazard of a poor 
starting/
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starting fibrinogen is  illustrated in figure 9# which shows an 
electrophoresis strip  of tagged fibrinogen prepared from a 
fibrinogen solution which was contaminated with gamma 
globulin; only 58 per cent of the radioactivity was thrombin- 
clottable* In the studies presented in this thesis using 
radioactive iodine tagged fibrinogen, thrombin-clottable 
racRoactivity varied from 89 -  94 per cent, and tricM oracetic 
acid radioactivity was always greater than 97 per cent.
Figure 10 shows a cellu lose acetate electrophoresis strip  
of a normal plasm a to which a trace of tagged fibrinogen had been 
added. Above tlie electrophoresis strip is  shown a densitom eter 
tracing from  an optical scan of the stained strip , and below is  
shown an autoradiogram with radioactivity w ell localised  to the 
fibrinogen peak*
Figure 11 shows a chromatogram of the tagged fibrinogen 
scanned for radioactivity w h ich ^ as all at the origin; no iodide 
was washed out* Chromatography was repeated after trypsin  
hydrolysis; figure 12 shows radioactivity, 63 per cent of which was 
opposite I
•46'
opposite mon- and di-iodotyrosine m arkers.
D iscussion.
The method of tagging fibrinogen with radioactive 
iodine which has been described in this chapter was quickly 
and easily  carried out. If the initial fibrinogen was of good 
quality, thrombin-clottable radioactivity was up to 94 per cent, 
with at least 97 per cent precipitable by trichloracetic acid.
The specificity of the tag was demonstrated by electrophoresis 
and by chromatography. Chromatography after hydrolysis 
suggests that tagging was largely due to iodination of tyrosines.
The next section of this chapter presents the use of tagged 
fibrinogen in the plasminogen enriched clot assay system  for 
plasminogen activator.
Activator assay with Plasm inogen enriched labelled Clots.
The method described, slightly modified from that of 
Alkjaersig et al. (1959b) is  dependent on the release of radioactivity 
from plasm inogen-enriched I tagged fibrin clots when incubated 
in thç presence of a plasminogen activator. Plasm inogen  
enrichment is  intended to ensure that, after washing to reduce 
blank/
.47-
blank radioactivity, the clots retain sensitivity to activator. 
Expired bank plasm a trace labelled with tagged fibrinogen 
prepared as described above, and enriched with plasminogen, 
is  clotted with thrombin round stain less steel w ire sp ira ls.
After washing, the clots are incubated at 37®C* with the test 
plasm a. Radioactivity released  from the clot in a standard 
tim e is  a m easure of activator concentration in the test plasm a. 
Method.
To 0, 5 m l. of pooled bank plasm a trace labelled with 
tagged fibrinogen so that 1 m g. of fibrinogen gave approximately 
2500 counts, was added 0 .1  m l. plasminogen, 6 casein units/m l; 
this plasminogen being insoluble at neutral pH was not eluted 
during washing. The plasm a was clotted round a stain less stee l 
w ire spiral in a 75 x 8 mm. test tube by addition of 0 .1  m l, 
thrombin, 10 N .I .H . u n its/m l. The clots were incubated at 
37*^C. for 30 minutes to ensure complete clotting. Still on the 
wire sp ira ls, the clots were removed from the test tubes and 
washed at 37^C. in phosphate buffer, 0 .1  Molar, pH 7 ,6 . ,  to 
reduce blank radioactivity and remove serum  with its high 
antiplasmin/
*48“
antiplasmin content* Washing was always carried out for at 
least 1 hour and som etim es overnight. For any one experiment, 
the washing period for all the clots was constant.
Activator Assay*
The activator assay was carried out as follow s. The 
test solution (0 .5  ml#) was incubated with a preformed clot for 
30 m inutes. The clot was then removed on its  wire spiral and 
residual radioactivity counted in a well-type scintillation counter 
with a puls e-height analyser* Results were recorded after 
subtraction of (i) background and (ii) mean counts from two 
control clots incubated with saline. Results were som etim es 
expressed In term s of counts, and som etim es, knowing the 
specific radioactivity of the fibrin* in term s of m icrogram s of 
fibrin lysed  per m illilitre  of test solution per hour*
Reproducibility of the assay system , and correlation of radioactivity 
release with tyrosine release* Forty-two radioactive clots were
prepared as described above, and were incubated with a solution 
of streptokinase in saline, 50 units/ml# Seven clots were 
incubated for 10 m inutes, 1 for 20 minutes, 7 for 30 minutes, 7 
for/
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for 40 m inutes, 7 for 50 minutes and 7 for 60 m inutes, and 
radioactivity release was counted. Results are as shown 
in figure 13. The coefficient of variation is 14.5 per cent 
(calculated by Dr. R. A. Robb),
In this experiment tyrosine release from the radioactive 
clots was also estim ated. F igure 14 shows the excellent 
correlation found between tyrosine release and radioactivity 
re lease  (r = +0.954, p < 0 .001).
Effect of plasminogen content. As shown in figure 15, 
susceptibility to ly s is  by streptokinase and urokinase was 
dependent on clot plasminogen content.
Response to Exogenous Plasm in of plasminogen enriched tagged clots.
■ I I ,h., k . .   1 - I ■ ■ i r- Tn 1 Tir  • ' " i  r'i~rrrrrriir iiViiniFtrr    m i  paiiiiii t i f rn i  iiilni ~ri m r> i i lwili l r.  ^.ni.^iiin n n . ,  i in i ■ i i w nw i ii ^ n  , wi wil lHii.
The response of the tagged clots to ly s is  by exogenous plasmin  
was also studied. An activator free plasmin solution, 7 casein  
u n its /m l., was compared in the radioactive clot assay system  
with varying concentrations of urokinase. The plasm in solution  
was assayed in quadruplicate and gave results of 183, 194, 216,
229 (mean = 206) pg. fibrin lysed/m l* test solution/hour. The 
results with a urokinase dilution curve are shown in figure 16. 
Interpolating into the dilution curve gives a thrombolytic potency 
for/
for the p lasm in  solution similan: to that of a 10 u n it/m l, 
nro ld iiase solution; i , e ,  the assay  system  was re la tive ly  
m ore  sensitive  to ac tiva to r than to p lasm in , 7 un it8 /ml* of 
%)lasmin being about tw ice the m ajdm um  p lasm in  activ ity  
which can be induced by activation  of p lasm a plasminogeiu, 
w hereas 10 u n its /m l, of u rok inase  rep re sen ts  a  re la tive ly  low 
ac tiva to r leve l. F ro m  the dilution curve it w ill be seen  that 
quantitative aspec ts  of the a ssay  system  w ere not sa tis fac to ry  
w ith concentrations of u rok inase  below 20 u n its /m l.
D iscussion ,
The plasm inogen en riched  radioactive iodine labelled  clot 
has definite advantages as a  su b stra te  fo r assay  of throm bolytic 
activ ity . I t m easu re s  the p roperty  which throm bolytic therapy 
is  designed to induce in  p lasm a, that is  the ability  to  lyse  
p re fo rm ed  hum an fibrin* A re su lt  is  obtained re la tive ly  quickly, 
the system  is  m ore sensitive  to ac tiva to r than to p lasm in  (see 
a lso  chapter 7) and th e re  is  good co rre la tio n  between rad ioactiv ity  
re le a se  and ty ro sine  re le a se . On the o ther hand the m ethod 
req u ires  re la tive ly  com plex appara tu s, quantitative aspects a re  
som ew hat/
<fc> >"ï I  w
som ewhat disappointing (coefficient of varia tion  14,5 p er cent), 
and the m ethod is poor w ith low levels of activ ity .
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CHAPTER. 5.
IN VIVO STUDIES WITH STREPTOKINASE.
I I  . . . . . . . . . . .
Streptoîânase was the first activator of the fibrinolytic 
enzyme system  to become available for investigative purposes 
in man and it is  s till the only fibrinolytic agent com m ercially  
available in this country for intravascular administration, 
it  is  a bacterial protein with a m olecular weight of about 50,000, 
which is  produced by certain strains of streptococci: in recent
years m ost streptokinase preparations have been produced by 
streptococci of type Ç (H 46 A) (von Kaulla, 1963a). The 
toxicity of ea rly  preparations of streptokinase prevented their 
intr avascular administration but Fletcher and Johnson (1957) 
described a method of purification which made possible com m ercial 
production of streptokinase preparations suitable for intr avascular 
administration, which if given with corticosteroids are largely  
devoid of toxicity.
There is marked species variability in response to 
streptokinase. Human plasminogen is readily activated, the 
m echanism /
53'
mechanism of activation being discussed below, but rabbit and 
dog plasminogens are more resistant to activation by streptokinase 
and bovine plasminogen is  virtually totally resistant (Cliffton and 
Downie, 1950).
The only known biochemical effect of streptokinase is  
to bring about the conversion of plasminogen to plasm in. A 
two-phase reaction is  involved. Streptokinase first reacts 
rapidly and stoichiom etrically with a proactivator in plasma  
(Troll and Sherry, 1955) to form activator which brings about 
the enzymatic conversion of plasminogen to plasm in by splitting 
off nitrogen containing m aterial (Alkjaersig et a l , , 1958). There 
is  controversy as to the nature of proactivator, some (e .g . de 
Renzo, I960) believing it to be plasminogen itse lf, while others 
interpret the evidence as suggesting that plasminogen and 
proactivator are separate entities (e .g . L assen, I960).
Streptokinase shares with other streptococcal proteins 
the ability to act as an antigen in man and antibodies to 
streptokinase are distributed through the population, varying very  
widely in concentration; in streptokinase therapy enough 
streptokinase must be given to bind circulating antibody and 
other/
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other non-specific inhibitors before the specific effect on the 
fibrinolytic enzyme system  is  seen (e .g . F letcher et al. * 1958). 
These authors have shown that the streptokinase-antibody complex 
is  cleared rapidly from the circulation at two rates; a very fast 
rate (50 per cent plasm a clearance time -  18 minutes) and a 
somewhat slow er rate (50 per cent plasma clearance time -  83 
m inutes). Surprisingly enough immediate deleterious effects 
due to the immunological consequences of streptokinase infusion 
have not been reported, possibly because of the rapidity with which 
the streptokinase-antibody complex is  removed from the 
circulation.
In this chapter an account is  given of the biochem ical effects 
of streptokinase given intravascularly to six  patients with thrombo­
embolic occlusive vascular d isease.
M aterials and Methods.
Streptokinase. A highly purified preparation, suitable for
intr avascular administration, was provided by A. B. Kabi. Vials 
of streptokinase were reconstituted with saline immediately 
before use. All patients except number 6 were given streptokinase 
by/
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by intravenous infusion using a constant rate infusion pump 
(B, Braun*. Melsungen,; West Germany) delivering a concentrated 
stroptokiViase solution into a freely  running intravenous drip; 
patient 6 was given streptokinase intra*arteriadly.
Streptokinase sensitiv ity  te st . This test was designed to find a 
concentration of streptokinase which would neutralise circulating 
antibody and other inhibitors and leave over enough free  
streptokinase to produce a plasm a*clot ly s is  tim e of about 20 
minutes (Johnson et a l. ,  1957)• To 0, 2 m l. aliquots of the 
plasm a in a ser ie s  of te s t  tubes was added reopectively 2, 4, 6*
8^  16, 24* 32, 46 and 80 m icrplitres of streptokinase solution,
500 u n its/m l. After clotting with thrombin* 0 .1  n il. of a 
20 N ,I.H *u nits/m l. solution, the tubes were incubated at 37®C. 
and the tim es for com plete clot ly s is  measured* For each 
patient, plasm a volume was estim ated from body weight (39 m l. / kg. ) 
and an initial dose of streptokinase calculated on the basis of 
plasm a volume and the concentration of streptokinase, estim ated  
as described above* which produced a ly s is  tim e of 16 * 20 m inutes. 
Re calcification tim es were m easured by the method of Biggs and 
M acfarlane/
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Macfarlane (1962c).
Antihaemophiiic-globulin assays and Christmas factor assays were
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carried out by P rofessor A* S. Douglas by a one-stage method 
(Douglas, 1965) which depends on the clotting time of recalcified  
plasm a from patients with severe haemophilia (or Christmas 
disease) which has been "contact activated" by kaolin. Cephalin, 
as prepared by B ell and Alton (1954) was added to the substrate 
system .
Factor V was assayed by P rofessor Douglas by the technique 
described by Douglas and Biggs (1953) but the readings were taken 
only 5 and 6 minutes after the start of the incubation. Results are 
expressed as a percentage of the pre-infusion value.
Prothrombin assays were carried out using toeyl arginine methyl 
ester  (TAMe) by the technique of Glueck and Sherry (1954). 
Radioactive clot activator assays were carried out as described  
in chapter 4.
Fibrin plate tests  were carried out as described in chapter 3, 
using bovine fibrinogen, No "proactivator", apart from that 
present in the test plasm as, was added*
Other assays were carried out as described in chapter 3*
R esults. /
j i tigimw rr
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R esults.
The biochem ical effects of streptokinase administration  
to 6 patients are described. In each case an initial fibrinolysis 
inducing dose of streptokinase was given calculated as described  
above from the streptokinase sensitivity te st. Details of 
estim ated plasm a volum es, streptokinase concentrations and 
initial dosages are shown in table 1.
patient 1, Results are shown in figure 17 and table 2, After 
infusion of an in itial dose of 155,000 units over 20 m inutes, 
administration was continued with 45* 000 units over the succeeding  
40 m inutes. The in itial dose produced no activity in the radioactive 
clot te st , and the changes recorded in plasminogen and fibrinogen 
are within the lim its of experimental error. At the end of the 
infusion there was marked activity in the radioactive clot test, 
and whole clot ly s is  and euglobulin ly s is  were much accelerated. 
There was a fall in plasminogen to 0. 9 u n its /m l., with a level of 
1 .2  units 3 hours after the infusion and 3*2 units at 24 hours. 
Fibrinogen fe ll from 250 m g. 1 100 ml* to 140 mg, / 100 m l, and had 
not fully returned to its pre-infusion level at 24 hours. The 
thrombin/
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thrombin clotting tim e, 10 seconds before streptokinase was 
given, was 19 seconds at the end of the infusion and 16 seconds 
3 hours la ter . At 24 hours it was again 10 seconds.
Patient 2. Results are shown in figure 18. The initial dose in 
this patient was large -  750,000 units. When 500,000 units had 
been given, no evidence of fibrinolytic activity was seen, but when 
the full initial dose had been given, high levels of circulating 
activator were found and plasminogen was depressed to near zero. 
The initial dose of streptokinase was followed by infusion of
50,000 units/hour for 5 hours * During this period activator levels  
remained high and plasminogen depressed. Fibrinogen levels  
slowly fe ll and at the same tim e the thrombin clotting time increased  
from  12 to 19 seconds. Four hours after the end of the infusion, 
plasminogen, fibrinogen and thrombin tim es were s till abnormal, 
but had all returned to normal the next day.
Patient 3. An Initial dose of 80,000 units was followed by 80,000 
units/hour for 5 hours: results are shown in figure 19. The 
initial dose produced a slight increase in activator activity in 
the radioactive clot te st, and minor changes in plasminogen and 
fibrinogen. Prothrombin tim e, re calcification tim e, prothrombin, 
factor/
factor Y, anUhaemophiîic globulin and Christmas factor were 
unaffected. As the infusion continued, activator levels quickly 
rose and plasminogen fe ll to zero where it remained throughout 
the infusion; plasminogen had not returned to pre-infusion levels  
23 hours after the infusion ended. Early in the infusion fibrinogen 
fe ll to zero, but thereafter it climbed to about 100 m g. /100 m l, 
where it remained while streptokinase was being given.
The prothrombin tim e, 14*5 seconds before infusion, 
increased  to 60 seconds, and the re calcification tim e, 206 seconds 
before infusion, to over 800 seconds* Prothrombin fe ll to 36 
per cent of its pre-infusion leve l, factor V to 25 per cent of the 
pre-infusion level and antihaemophilic globulin to zero. Christmas 
factor was unaffected.
Patient 4* An initial dose of 460,000 units was given over the 
first hour, followed by 50,000 units/hour for a further two hours 
(figure 20), In this patient the initiad dose produced a r ise  in 
activator assay in the radioactive clot system  and a fall in 
plasminogen from 3 .0  to 1 ,5  units/m l; there was also a fall 
in fibrinogen from 244 to 151 mg. / 100 m l. The initial dose 
produced a slight r ise  in prothrombin tim e and thrombin tim e, 
and/
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and a fall in antihaemophilic globulin, prothx*ombin and factor 
V assays. During the following 2 hours there was a further fall 
in plasminogen, fibrinogen, antihaemophilic globulin, prothrombin 
and factor V. An hour after the end of the infusion no 
plasminogen was detectable. At this point also fibrinogen 
levels were m ost depressed and the greatest abnormality was seen  
in the thrombin clotting time and the prothrombin tim e . Euglobulin 
ly s is  tim e, 360 minutes before infusion, fell to 13 minutes after 
the initial dose had been given* had risen to 240 minutes at the 
end of the infusion, presumably because of plasminogen depletion.
As in patient 3, antihaemophilic globulin, factor V and prothrombin 
were reduced but Christmas factor was unaffected*
Patient 5* After an initial dose of 250,000 units given over 1 hour, 
therapy was continued for a further 21;| hours with an infusion of
75,000 units of streptokinase/hour. Results are shown in figure 21, 
where it w ill be seen that there w^ as a short accidental break in the 
infusion at 16 hours, due to blood clot in the infusion tubing. This 
clot, resulting from back flow of blood during a change of tubing, 
persisted  unlysed in the 1000 unit/ml* solution of streptokinase 
which was being given to the patient, failure of ly sis  being 
presumably/
presumably due to plasminogen depletion. In the radioactive clot 
assay system , large amounts of thrombolytic activity were 
present in the plasm a throughout the infusion, a finding 
confirmed in the fibrin plate te st . Euglobulin ly sis  on the other 
hand was not accelerated and euglobulin ly sis  tim es were in 
excess of 3 days for the greater part of the infusion. During 
the break in infusion at 16 hours when a little plasminogen was 
present in the plasm a, slight euglobulin ly sis  activity was seen, 
though at other tim es (e .g . 4. 5 and 5. 5 hours) when a little  
plasminogen was also assayed, euglobulin ly sis  was grossly  
prolonged. Fibrinogen fe ll to 125 mg. / 100 m l, at 8 hours and 
remained at about that level for the duration of the infusion and 
for 16 hours after it: 40 hours after the end of infusion, 
fibrinogen had risen  to 238 mg, / 100 m l. Thrombin clotting 
tim e climbed slowly during the infusion and reached a maximum  
value, 8 seconds above the pre-infusion level, at the time of the 
break in infusion; thereafter it fe ll slowly and had returned to 
pre-infusion levels at 16 hours after the end of infusion.
Patient 6. Streptokinase was given by intra-arte rial perfusion  
using a constant-rate infusion pump. An initial dose of 350,000  
units/
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uîiits was given over 5-^  hours followed by 12, 500 units/hour 
for the remaining hours (figure 22). Thrombolytic 
activity in venous blood as demonstrated in the euglobulin 
ly s is  time and the fibrin plate te st , was induced by the initial 
dose and was maintained for the duration of the perfusion* 
Plasm inogen was rapidly depleted and was zero at 16 and 
26 hours: it had not returned to the pro-infusion value 30 
hours after the end of infusion. Fibrinogen fe ll from  a 
pre-infusion level of 276 m g ./ 100 ml* to 112 m g . /100 m l, 
at 8 hours ; thereafter it slowly increased, being 148 mg. / 100 m l. 
at 26 hours* The thrombin clotting time showed the same 
pattern, the maximum abnormality being at 8 hours, with 
thereafter gradual improvement*
D iscussion.
Since T illet and his associa tes (1955) first administered  
streptokinase intravenously to man, it has been given to animals 
and man by numerous investigators, and from its use has em erged  
much of our current knowledge of the fibrinolytic enzyme system .
As streptokinase is  s till the only fibrinolytic activator com m ercially  
available/
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available for intravascular administration, detailed knowledge 
of its effects is  clearly important*
The studies reported in this chaptex' confirm that by 
intravascular administration of appropriate amounts of 
streptokinase intense thrombolytic activity can be imparted to 
the plasm a. In all the patients, the ability of the plasm a to 
dissolve preformed fibrin clots was investigated and found to 
be present either in the radioactive clot test or the fibrin plate 
te st .
The present experim ents also confirm the observation first  
made by Johnson et al. (1957) that in plasma the specific biochem ical 
effect of streptokinase as an activator of plasminogen is  only seen  
when enough streptokinase has been administered to neutralise 
circulating antibody and other Inhibitors. In patient 2 for 
example the initial dose ( i .e .  the amount of streptokinase to 
neutralise circulating antibody and then induce a brisk lytic state) 
was calculated as 750,000 units ; 500,000 units produced a barely 
detectable effect. In patient 3 on the other hand the total dose 
of streptokinase given was 480,000 units and this served not only 
to neutralise antibody but to maintain for 5 hours intense 
fibrinolytic/
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fibrinolytic activity with a major coagulation defect* It 
is  clear that administration of a suitable initial dose, 
individually calculated for each patient, is  an essen tia l 
preliminary to rational use of streptokinase*
The coagulation defect. As has already been d iscussed  in
,  o u r , V I ,* ,I* , I * I * # , 'i f  I * . . m o  * i m m v a * ** # w m w w
chapter 2, the coagulation defect induced by streptokinase 
administration has been studied in detail by Sherry and his 
associa tes, who have shown that a major component is  
defective fibrin polym erisation caused by the digestion of 
circulating fibrinogen by free plasmin (Alkjaersig et a l . , 1962; 
Bang et a l . , 1962; F letcher et a l . , 1962a). Fibrinogen  
breakdown products become incorporated with fibrin monomer 
as it polym erises and as a result fibrin polym erisation and clot 
structure are strikingly defective. F ree plasmin appears in the 
circulation (hyperplasminaemia) when after the infusion of large 
amounts of activator, sudden m assive plasmin production 
temporarily overwhelms the physiological antiplasmin mechanism- 
The defect in fibrin polym erisation is  reflected in the 
prolongation of the thrombin clotting time seen in all the 
present/
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present patients and also contributes to the prolongation of 
the prothrombin tim e and the re calcification tim e. The 
thrombin clotting tim e as illustrated in figure 7, is  also  
prolonged by hypofibrinogenaemia per se .
Other iactors are involved in the genesis of the 
coagulation defect. Factor V is particularly susceptible  
to digestion by plasm in (Lewis et a l . , 1949; A lagille arid 
Soulier, 1956; F letcher et a l . , 1959; Donaldson, I960;
N ilsson and Olow, 1962) and reduced levels of antihaemophilic 
globulin in the presence of increased fibrinolytic activity have 
cilso been reported (Lewis et a l . , 1949; A lagille and Soulier, 
1956; Niewiarowski and Latallo, 1957; Donaldson, I960). Low 
leve ls  of Christmas factor have been found le s s  often (Alagille 
and Soulier, 1956; Donaldson, I960). In the present patients 
fibrinogen was depleted in all and depletion of prothrombin, 
factor V and antihaemophilic globulin was found in all the 
patients in whom these factors were assayed. The factor V 
assays may have been affected by the presence of breakdown 
products which may have exaggerated the fall in factor V 
lev e ls /
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levels Been, but the fall in prothrombin was almost certainly  
real as a synthetic substrate (TAMe) was used for its assay, 
there being no dependence for an end-point on clot formation 
which might be interfered with by fibrinogen breakdown products. 
The reduced leve ls  of antihaemophilic globulin assayed were 
also probably real, as in the same plasma sam ples, and 
employing an identical technique, (apart from the use of 
plasm a from a patient with Christmas d isease instead of a 
patient with haem ophilia,) Christmas factor assayed at 100 
per cent.
Duration of the lytic state and coagulation defect after cessation
I............................................................................................................................................................................................................................................... ........................................................................................................ .
of therapy. Activator leve ls  in the plasma were found to 
decline very rapidly after the Infusion of streptokinase was 
stopped. For exam ple, in patients 1, 3 and 4, activator levels  
were high in sam ples taken off just before the infusions were 
stopped, but 1 hour la ter , virtually no activator was found. This 
observation is  in agreement with the very short half-life  (15 
minutes) of n icotin ic-acid  induced plasma activator found by 
Fletcher et al. (I964a),
The/
-67
The .tibrinogen breakdown products responsible for 
defective fibrin polym erisation have a half-life in the 
circulation of about 9 hours (Fletcher et a l . , 1962a), and 
this is  reflected in tlie duration of elevation of the thrombin 
tim e or re calcification tim e found in the present ser ie s  of 
patients after the cessation  of streptokinase therapy. For 
example in patient 1, tiie thrombin tim e was still abnormal 
3 hours after the end of infusion but was normal at 24 hours: 
in patient 2 the thrombin time was abnormal 4 i  hours after 
the end of infusion but was normal at 24 hours; and in patient 
3 re calcification tim e was abnormal 7 hours after the end of 
infusion, but was normal 16 hours after the infusion stopped.
The return to normal of plasminogen, fibrinogen, 
prothrombin, factor V and antihaemophilic globulin presumably 
occurs as these factors are synthesised and released into the 
circulation. In patient 1, neither plasminogen nor fibrinogen 
had returned to pre-infusion levels at 24 hours; and in patient 
6a both plasminogen and fibrinogen were essentially normal at 
30 hours after the end of the streptokinase infusion* In each of 
the remaining patients in the final sample studied plasminogen was 
s t i l l /
still depleted but fibrinogen was normal, suggesting a slower rate 
oil Synthesis of plasminogen than fibrinogen* In patients 3 and 
4 antiha.emophiiic globulin, prothrombin and factor V returned 
to pre-infusion leve ls  m.ore rapidly than did fibrinogen. 
Streptokinase Dosage Schedules.
There is  general agreement as to the need for initiation  
of streptoldnaae therapy with an individually calculated antibody 
nsvitralisiiag dose. It would also seem  clear that thereafter in 
order to restore vascular patency as rapidly as jjossible the 
plasm a surrounding a thrombus in vivo should have imparted to 
it as high a level of thrombolytic activity as is  compatible with a 
tolerable coagulation defect * Opinions differ as to how this 
objective can best be achieved. The manufacturers of 
streptokinase preparation used in these studies advise that after 
administration of an Initial dose, treatment should be continued 
with one third to one half of this initial dose given each hour, It 
would seem  px+obable that a dosage schedule of this sort w ill 
with some patients result in overdosage* for example in patient 
2, where the initial dose was 750,000 units, 250,000 units/hour 
would, according to the manufacturers suggestion be indicated  
for/
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for maintaining therapy, whereas in fact 50,000 units/houi’ 
maintained a brisk fibrinolytic state.
The theoretical effects of three other possible dosage 
schedules are illustrated schem atically in figure 23: low 
dosage therapy, interm ediate and high dosage. In the 
hypothetical low dosage regimen (figure 23, left hand section), 
an antibody neutralising dose is  followed by an infusion rate which 
produces only a slight fall in plasminogen, and a negligible 
coagulation defect: plasm a thrombolytic activity is  also low, 
McNicoi et al* (1963) have suggested in patients with arterial 
obstruction the use of a low dosage schedule of this type, given  
by intra-arterial perfusion, with a catheter tip near the thrombus, 
in  the hope that sm all amounts of streptokinase which may produce 
a negligible system ic fibrinolytic state, might induce intense 
thrombolytic activity round the catheter tip at the site of vascular  
occlusion. However, Hume (1964) stated as a result of 
experim ents in dogs, that local perfusion is  no m ore effective in 
producing throm bolysis in arteries than the same dosage of 
streptokinase given intravenously.
With/
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With interm ediate dosage schedules (figure 23, centre 
section), plasminogen is  partially but not completely depleted, 
and a constant state of hyperplasminaemia is  produced together 
with a serious and sustained coagulation defect. Johnson and 
McCarty (1959) found that this biochemical state, with both 
streptokinase and plasm in in the circulation, was highly effective  
in producing the ly s is  of artificial thrombi induced in the forearm  
veins of human volunteers. Patients 2 and 4 show findings 
approximating to those anticipated in this hypothetical state, 
though in both patients plasminogen levels tended to drift down 
during the infusion, and as the plasminogen levels fe ll, the 
coagulation defect became more marked, presumably because of 
increasing plasmin production.
The third schedule of streptokinase administration, a 
high dosage or "plasminogen depletion" regimen, is  also illustrated  
schem atically in figure 23 (right hand section), and V erstreate  
and his associates (1964) have suggested that this is  the m ost 
satisfactory method of streptokinase administration. According 
to this scheme of treatm ent, after giving an initial antibody 
neutralising dose of streptokinase, therapy is  maintained with 
large/
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large doses of streptokinase designed to bring about rapidly 
and thereafter to maintain com plete, or alm ost complete 
plasminogen depletion. It is  suggested that there w ill be an 
initial transient phase of hyperplasm inaemia, and in consequence 
a coagulation defect as plasminogen is falling, but when complete 
plasminogen depletion has been achieved, as newly synthesised  
plasminogen is  released  into the circulation it is  converted to 
plasm in, the rate of plasm in production being within the capacity 
of the antiplasmin m echanism  to bring about alm ost immediate 
neutralisation. Accordingly the deleterious effects of the 
in itial transient hyperplasm inaemia w ill pass off as the infusion  
continues.
Patients 3 and 6 illustrate that plasminogen depletion is  
attended in practice by the sequence of events postulated above.
In both patients plasminogen leve ls  fe ll to zero early in the 
infusion and remained at zero levels for the remainder of the 
infusion. Fibrinogen leve ls  were low est, and the coagulation 
defect m ost marked at the beginning of the infusion, but thereafter 
a progressive improvement in both fibrinogen levels and the 
coagulation defect was observed.
Hazards of plasminogen depletion, Johnson and McCarty (1959) 
have/
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have pointed out that when plasminogen depletion has been 
induced, fibrin which form s w ill lack plasminogen and hence 
w ill be resistant to subsequent ly s is . This circum stance is  
illustrated in patient 5, in whom the infusion tubing became 
obstructed by unlysable clot. Johnson and McCarty (1959) 
have also suggested that in their human volunteers clot ly sis  
is  more readily produced with interm ediate dosage of 
streptokinase when both activator and plasm in are present in 
the circulation than with high dosage streptokinase when only 
activator is  present*
The evidence suggests that when total plasminogen depletion  
has been produced, conventional anticoagulants should be given 
as soon as streptokinase administration stops to prevent laying 
down of unlysable fibrin in the blood v esse ls  during the relatively  
long period of plasminogen regeneration.
Patient 5 also illustrates that in the presence of plasminogen  
depletion the euglobulin ly s is  tim e is  not a satisfactory index of 
plasm a thrombolytic activity* In this patient euglobulin ly sis  
tim es were prolonged despite high levels  of activator in the 
circulation: euglobulin ly s is  activity was only seen when there 
w as/
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was a short accidental break in streptokinase infusion and 
though activator leve ls  fe ll, a little  plasminogen was detected  
in the plasm a (figure 21).
Conclusions.
Intravascular administration of streptokinase in appropriate 
dosage readily produces and maintains an intense thrombolytic 
state in the plasm a. A degree of hyperplasminaemia appears 
to be an inevitable concomitant of intense plasm a thrombolytic 
activity, with in consequence a coagulation defect due in part to 
defective fibrin polym erisation resulting from the presence in 
the circulation of products of proteolysis of fibrinogen by plasm in, 
and in part to digestion of coagulation factors. Various possible  
streptokinase dosage schedules have been d iscussed, but the 
m ost satisfactory method of streptokinase administration to induce 
a maximum thrombolytic effect with minimum hazard to the patient, 
remains to be established by further clinical and laboratory 
investigation*
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CHAPTER 6
m  VITRO AND IN VIVO STUDIES OF A 
PREPARATION OF UROKINASE.
It has been known for many years that urine can digest 
blood clots (Sahli, 1880), an action clue to its content of a 
plasminogen activator named urokinase (W illiam s, 1951;
Astrup and Sterndorff, 1952; Sobol et a l , , 1952)# Urokinase, 
itse lf  a proteolytic enzym e, activates plasminogen by first order 
kinetics, probably by splitting lysine and/or arginine bonds 
(Kjeldgaard and Ploug, 1957; A lkjaersig et a l . , 1958). It is  
a colourless protein with a high degree of stability over a wide 
pH range (Ploug and Kjeldgaard, 1957).
Bjerrehous (1952) has shown that urokinase concentrations 
are sim ilar in bladder urine and urine obtained from  the renal 
p elv is. Colander and Guest (I960) demonstrated that there are at 
lea st two urinary proteins with urokinase activity and von Kaulla 
and Swan (1958) and Smyrniotis et al# (1959) have produced evidence 
to suggest that urokinase may represent in part at least excreted  
plasm a plasminogen activator. There is  also evidence to support 
the/
7 5 -
th e  concept that it has a physiological role in maintaining the 
patency o£ the urinary tract by promoting the ly s is  of fibrinous 
deposits (McNicoi et a l , , 1961)*
Because o i  its human origin, it has been hoped that 
urokinase might have many advantages, including freedom from  
toxicity and antigenicity, as a therapeutic fibrinolytic substance. 
Interest in the use of urokinase was stimulated by its isolation  
and purification by Ploug and Kjeldgaard (1957). There are 
reports in the literature of the use of urokinase activated plasm in  
(e*g. Sokal et a l« , 1958; Suss man and Fitch, 1958)* Hansen 
et al. (1961) also report On the infusion of urokinase to ZZ subjects, 
though they present no data on the biochemical effects induced, 
and Fletcher et al* (1964b) report in an abstract on the administration  
of high doses of urokinase to a group of 34 patients.
The present chapter gives an account of the study in vitro  
and in vivo of a com m ercial preparation of urokinase.
M aterials and M ethods.
Urokinase* A purified preparation, isolated from the urine of 
normal m ales was made available by Leo Laboratories* The 
preparation, /
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preparation, supplied ae sterile  yellowish-wM te pellets, was 
freely soluble in  0 .9  per cent sodium chloride. The 
manufacturers state that potency iix arbitrary units (Ploug 
and Kjeldgaard, 1957) v a ïie s  from  batch to batch from 5000 to 
12000 units/m g. The m aterials used in this study had a potency 
of 7100 unite/mg* Calcium content of a 10,000 unit/m l, solution  
was le ss  than 0 .2  m E q ./litre  (assay carried out by M iss M. Gray) 
Recalcification tim es were estim ated as described by Biggs and
Macfarlane (1962c)* In som e of the experiments the plasm a was 
low-spun, and in others where it was high spun, cephalin (Bell 
and Alton, 1954) was added to the system  in place of saline* In 
ail cases EACA was pi'esent in a concentration of lO'*^  Molar to 
inhibit ly s is .
Thromboplastin generation tests were carried out as described by 
Biggs and Douglas (1953) with the following modifications * The 
volumes of plasm a, serum , platelet $ysponsion, M olar/40 
calcium chloride and urokinase (10,000 units/m l, solution) were 
0 .3  ml* In each case saline was added to give a constant volume 
of 1. 5 m l. and EACA was present in a concentration of 10“  ^ Molar 
to/
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to inîübit ly s is .
Antihaem ophilic globulin, C h ris tm as fac to r and fac to r V assays w ere 
c a rr ie d  out as described  in chapter 5#
Electrophorer?ls* Oxoicl cellu lose acetate  s tr ip s  w ere  used  for
e lec trophoresis*  S trip s w ere run  fo r two hours at 150 volts in  a 
Shandon horizon tal e lec tro p h o res is  tank with the barbitone buffer 
of F lynn and de Mayo,(1951). A fter stain ing , s tr ip s  w ere  scanned 
in  a Chl’Omoacan record ing  densitom eter*
E ste ro ly tic  a ssay s i using tosy l arg in ine m ethyl e s te r  (TAMe) w ere
c a rr ie d  out by the m ethod of T ro ll ê t a l, (1954)# W here serum  
was used  in the assays i t  was dialysed with constant s tir r in g  
overnight at 4^C, against a la rg e  volume of 0 ,9  p er cent saline# 
Optim um  urokinase concentration  was found to be 200 units/m l#  and 
incubation was fo r 30 minutes*
U rokinase sensitiv ity  te s ts .  To 0#2 m l. of c ftra ted  p lasm a w ere 
added, using a m ic ro -b u re tte , 80 ,^1# of urokinase solution, 500 
u n its /m l* , and th rom bin ,0* 1 ml* of a HO H .I.H # unit/m l# solution. 
The p lasm a was incubated at 37^C# and the tim e fo r com plete clot 
ly s is  m easu red ,
Throm bin. P a rk e  Davis th rom bin  topical.
Plasminogen* /
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Plasm inogen. A preparation of human plasminogen, soluble 
at neutral pH, was made available by A. B. Kabi.
Radioactive clot assays were carried out as described in 
chapter 4,
Other assays were carried out as described in chapter 3.
Results of In Vitro Studies*
Fibrinolytic activity in purified system s.
In purified system s, the urokinase preparation was found 
to be a potent activator of plasminogen.
(i) Fibrin plate te st . In a concentration of 10 u n its/m l. the 
urokinase preparation tested  in triplicate gave zones of 
ly s is  of 400, 440 and 380 sq. mm. No ly sis  was seen with 
the sam e concentration in another plate containing EACA at a 
concentration of 5 x 10"**^  Molar, a concentration adequate to 
inhibit plasminogen activation but not to inhibit plasm in  
(Alkjaersig et a l* , 1959a).
(ii) Radioactive clot assay . Tested in triplicate in the radioactive 
clot assay, a urokinase solution, 10 un its/m l. gave 162, 181 
and 147 pg. fibrin ly s e d/ml* teat solution/hour.
Este roly tic activity. As has been reported by Sherry et al. (1959a) 
urokinase/
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x ivdkm àB Q  p o ssesses  este roly tic activity against TAMe. The 
present preparation demonstrated th is, I mg. of the urokinase 
preparation producing ly s is  of l 6 l -  23 pM TAMe in 30 minutes 
(Table 2).
Natural Inhibitors of Urokinase,
It was observed that in system s containing serum  or plasma, 
also in vivo (see below), the activity of urokinase was much le ss  
than that seen with sim ilar amounts of urokinase in purified 
sy stem s.
Fibrin Plate test. Figure 24 shows the effects of plasm a in 
inîiibiting urokinase in the fibrin plate test. Mean values and 
standard deviations from observations on 18 plasm as are shown. 
Complete inhibition of 1 unit of urokinase was observed when 
40 |jJ,. or more of plasm a was added to the urokinase preparation 
before assay.
Radioactive clot system s. Sim ilar results were found in the 
radioactive d o t system  where in each of 25 experiments inliibition 
was complete with 50 pi. of plasm a per unit of urokinase; with 
10 pi, of plasma per unit of urokinase, inhibition was 22- 10 per 
cent/
BO
cent (Table 3),
Electrpphoyeeig étudiés. To identify the protein fraction  
roaponsibie for tliis inhibitory effect, electrophoresis of 10 jal* 
of eernm was carried out on cellu lose acetate. After 
electrophoresis the wet cellu lose acetate paper was divided longi­
tudinally, that is ,  at right angles to the origin. One half of the 
paper was stained with Ponceau Sî the other half was cut, 
parallel with the origin, into strips 0 ,5  cm, wide. Ten pi, of 
urokinase solution, 20 u n its/m l, was evenly applied as a streak  
along the long axis of each strip , which was then placed, 
urokinase side down, on a fibrin plate. After incubation for 
IB hours at 37^C# the strips were lifted from the surface of the 
plate and the area of ly s is  associated with each strip was m easured. 
Using as control the area of ly s is  produced by urokinase which had 
been applied to a strip cut w ell away from the serum  pattern, 
iniiibition of urokinase activity produced by each serum  band was 
measured* Results are shown in figure 25, where it can be seen  
that inlnibitory activity is  largely concentrated in the alpha-i and 
alpha-2 globulin bands,
Gaseinolytic assays. As the action of urokinase in the fibrin plate 
and/
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anti radioactive clot assays is  mediated through its ability 
to convert plasminogen to plasm in, and as it is  the plasmin so 
produced which brings about the ly sis  observed in the assay  
system s, the inhibitory effects seen may be due in  part at 
least to the antiplasmin content of the plasma or serum . In 
Order to demonstrate an ”antiurokinase’* as opposed to an 
antiplasmin effect in serum , the following experiment was 
carried out using a caseinolytic assay. Urokinase (0*25 ml* 
of a 25 unit/m l. solution) was incubated at 37^C. for one hour 
with O.S ml* plasminogen solution, 7 casein units/ml* After 
addition of 0* 5 m l, of serum  the easeinolytic activity induced 
was measured^ The assay  was also carried Out adding the serum  
first and incubating the serum  at 37^C. for one hour with the 
urokinase before adding the plasminogen solution. Twenty-five 
sera  were examined in this way. Results are shown in figure 
26, where it w ill be seen that in 20 of the 25 experim ents, 
caseinolytic activity was greater when plasminogen was added 
first than when serum  was added first. Mean caseinolytic  
activity (expressed as optical density readings) when serum  was 
added first was 0* 16Î 0 .0 4 , and when plasminogen was added first  
w as/
was 0. IB- 0 ,05 . The difference is  highly significant 
(t r, 3 .905, p<0.001).
E otero ly tic  system . S erum  was also  found to inhibit the 
e s te ro ly tic  activ ity  of u rok inase  on TAM a* The re su lts  
a re  shown in tab le  2* M ean eo tero ly tic  activ ity  of 1 mg. 
u rok inase  (7100 units) in  8 experim ents was 161- 23 pM.
TAMe lyoéd in  30 minutes* When se ru m , 20 p i ./u n it  of 
u rok inase , was added* m ean eo tero ly tic  activ ity  p e r m g, 
u rok inase  was in  8 experim ents l i l t  pM, TAMe, The 
difference is signficant (t := 2,292# p<0,05).
T hrom boplastic  o r Coagulative Activity of tjro ld n ase .
Since hum an u rine  is  known to contain th roniboplastic  
ac tiv ity , it was decided to study the coagulative p ro p e rtie s  of 
the urokinase prepai^ation. U rokinase in  increasing  concentrations 
was substitu ted  fo r sa line  in a reca lc ifica tion  tim e a ssay , using 
fre sh  norm al p lasm a as su b stra te  and incorporating  EACA at 
a concentration  of 10*^ M olar to inhibit ly s is , A p ro g ress iv e  
reduction  in  the reca lc ifica tio n  time# linearly  re la ted  to  urokinase 
concentration  in  a sem ilogarithm lc  plot# was found and is  shown 
in  figure 27,
Substituted/
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Substituted for brain, extract in the one-stage px-othrombin 
time# it was found that the urokinase preparation in a concentration 
of 10,000 u n its/m l, had a sim ilar potency to a 1:750 dilution of 
the brain extract in use in the laboratory at that tim e.
The coagulative property of the urokinase was readily 
demonstrated in plasm a collected and clotted in silicone tubes.
Xn such an experiment the addition of urokinase at a concentration 
of 1500 u n its/m l. reduced the I'ecalcification time from 450 to 
175 seconds. In an experiment using Hagentan plasma 
reductions in recalcification tim es were very readily observed  
when sm all concentrations of the urokinase preparation were 
present in the system . The figures obtained are shown in table 
4* where it can be seen  that urokinase in a concentration of Z 
u nits/m l, shortened the x*ecalcification time from 025 to 585 
seconds *
Table 5 shows the effect of urokinase in the thromboplastin 
generation test in partially correcting for antihaermophillc globulin 
deficiency* Christmas factor deficiency and platelet 
deficiency. Urokinase was found to substitute partially for 
Chxdstmas factor and antihaemophilic globulin. In the test for 
substitution/
sübstition of urokmaée lor platelets no correction was 
seen when the plasm a or serum  was tested at the standard 
dilution, hut when plasm a and serum  were further diluted 
1:4 slight correction of the abnormality resulting from platelet
lack  was seen ,
Electrophoretic Studies* To attempt separation of fibrinolytic
»i top^W N pepm i !«
from  coagulative activity the urokinase preparation was studied 
after electrophoresis. Acetate buffer, pH 4 .5 , 0 ,1  Molar, was 
found to give the best separation. After electrophoresis of 20 pi. 
of urokinase solution, 10,000 unitiw/ml,, on cellu lose acetate, 
each paper was divided, at right angles to the origin* into three 
equal portions* One portion was stained with nigrosinv the other 
two were cut parallel with the origin into strips 1 cm* wide.
Each strip from the second portion of the paper was applied to 
the surface of a fibrin plate and the extent of ly s is  after overnight 
incubation was assessed* To each strip from the third portion 
of the paper was added, in a 12 x 75 mm. test tube* 0, 2 m l, of 
saline. Each strip was pounded with a glass rod for several 
m inutesÎ the strips did not disintegrate. Thirty minutes later  
the ability of 0 . 1 m l, of the eluting fluid to shorten the 
recalcification/
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re calcification time of normal plasm a was m easured. Results 
are shown in figure 28# In this buffer system  urokinase 
separated into at least 4 components. The fibrinolytic activity 
was largely associated with slow moving components, whereas 
the coagulative property was more uniformly distributed*
EESÜETB OF m  VIVO STUDIES,
The results of intravenous infusion of the urokinase 
preparation in 4 adult subjects w ill be described*
Subject 1. 40,000 units of urokinase were infused over 1 hour*
if  II »  mm  II w vi'w  w m i
Results are shown in figure 29 and table 6, At the end of the 
infusion the radioactive clot te st, the fibrin plate test and the 
euglobulin ly s is  test all showed evidence of activator in the 
circulation* There was a slight fall in plasminogen, but no 
significant changes occurred in prothrombin tim e, thrombin tim e, 
fibrinogen, recalcification tim e, antihaemophilic globulin and 
Christmas factor assays*
Subject 2 was given 40,000 units/hour for two hours* The 
effects of the infusion are presented in figure 30 and table 7* At 
the end of 1 hour activator activity was seen in the radioactive 
clot assay and euglobulin ly s is  was accelerated, no 
activity/
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activity was seen in the fibrin plate test. At two hours 
there was a 50 per cent fall in plasminogen, and the radioactive 
clot assay showed increased activity^ lytic activity was also  
seen  in the fibrin plate te st . There were no significant 
changes in thrombin tim e, prothrombin time and fibrinogen  
lev e ls . In an AHG assay clotting tim es fe ll from 171 seconds 
before infusion to 160 seconds at the end of infusion* Clotting 
tim e in the Christmas factor assay fell from 149 seconds before 
infusion to 105 seconds at the end of infusion.
Subject 3 was given 80,000 units in 1 hour. The effects of the 
infusion are presented in figure 31 and table 8. The infusion 
produced activity in the fibrin plate test and acceleration of 
euglobulin ly s is . There were no significant changes in thrombin 
tim e, prothrombin tim e, plasminogen or fibrinogen. Re calcification  
time (cephalin added) fe ll from 82 to 27 seconds. The changes in 
AHG assay, Christmas factor assay and factor V assay are set 
out in table 8. In AHG and Christmas assays, apparent AHG and 
Christmas activities w ere increased -  that i s ,  clotting tim es were 
shortened. There was also a sharp fall in factor V activity.
Subject 4/
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Subject 4 had an infusion of 60,000 units over 30 minutes 
(figure 32 and table 9). The radioactive clot assay , the fibrin  
plate test and the euglobulin ly sis  tim e all showed a marked 
increase in activator activity* Peak activity in  the radioactive 
clot assay was 970 counts/ 100 seconds* A urokinase solution 
20 units/ml* gave 6800 cou n ts/100 seconds; 20 units/ml* is  
approximately the concentration which should have been induced 
in the plasma by rapid infusion of 60,000 units.
Urokinase Sensitivity T ests , These were carried out before and 
again 10 days after Infusion* Results are shown in table 10, 
where it can be seen that urokinase sensitivity had not been 
significantly altered by the infusions.
Antigenicity, Another subject was given an intravenous infusion 
of 30,000 units urokinase. One week later a challenging dose 
of 1 mg, was injected intravenously and one further week later  
intradermal injection of 10 jxg, produced no skin reaction. Serum  
obtained at the tim e of the intradermal test was examined by 
Dr* Robert Goudie for precipitating antibody, using double 
diffusion in an agar^gel plate. The serum  was used undiluted 
and the antigen, urokinase, was tested at 1 and 0* 1 m g ,/m l.
No/
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No prooipitins were found after seven days diffusion at ZO^C.
D iscussion.
In vitro testing of the uroMnaae preparation demonstrated
that it was an effective activator of the plasm inogen-plasm in
system . In the fibrin plate test no activity was seen in the
-3presence of EAGA at a concentration of 5 x 10 Molar which
inhibits plasminogen activation (Alkjaorsig et al.# 1959a).
Este roly tic activity against a synthetic substrate was shown by 
the present preparation, 1 m g. of which lysod 161- 22 pM, TAMe 
in 30 minutes*
The inhibitory action of plasm a and serum on urokinase, 
previously reported by Hansen et al* (1961) and Paraskevas et al* 
(1962) can readily be demonstrated in the fibrin plate test and the 
radioactive clot te st. As all activator assays at present 
available m easure the plasm in produced by plasminogen 
activation, inhibition can be due either to antiplasmin activity 
or to antiactivator activity; and the inhibitory effect here 
reported appears to be largely localised  in the alpha'll and alpha-2 
globulin fractions to which Norman and Hill (1958) have 
demonstrated/
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demonstrated that the antiplaemins belong. The caseinolytic  
assays in which with sera  from m ost subjects, le s s  casein is  
digested when urokinase and serum  are incubated together 
before addition of further purified plasminogen than when 
serum  is added after plasminogen# suggest that the inhibitory 
effect is  due, in part at least# to direct inhibition of plasminogen 
activation. The finding in the este roly tic assays that some sera  
inhibit the action of urokinase on TAMe reinforces the view that 
som e sera contain antiactivator activity. However as sera  
also contain plasminogen and antiplasmin# the results must be 
regarded only as strongly suggestive of the existence of 
antiurokinase activity in  plasm a or serum .
Thromboplastic or Coagulative Activity.
As shown in figure 28# the preparation is  not a homogeneous 
protein; there can be no doubt from the experiments that the 
preparation can be separated into components with much lytic  
activity and others with le s s  or none. There is  suggestive but 
not final evidence that the coagulative activity may be separated  
from  the lytic activity.
Whole normal urine is  known to contain thromboplastic 
activity/
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activity (Tocantins and Lindquist, 1947), Though the 
thromboplastic activity seen in vitro in the re calcification  
tim e and the thromboplastin generation test with a solution  
of 10,000 u n its/m l. is  not potent (equivalent to a 1:750 solution  
of brain extract in the prothrombin tim e), definite evidence of 
coagulative activity was seen  in vivo in subjects Z and 3 where 
plasm a concentrations of urokinase can have been at m ost 
25 units/ m l. In these subjects infusion of urokinase was 
followed by shortening of re calcification tim e and an apparent 
r ise  in AHG and Christmas factor lev e ls , probably by distortion  
of the assay system  by the non-specific coagulative activity 
of the urokinase* The fall in factor V activity in subject 3 
may perhpas be m ost readily explained on the basis of factor V 
consumption due to som e m easure of intravascular coagulation.
latrid is et al. (I960) found that a urokinase preparation 
had a *Hageman-like’ effect. In term s of current knowledge 
there would seem  to be two possible explanations of the 
coagulative phenomena observed in the experiments presented  
in this chapter -  either inadequate removal of the thromboplastic 
component of urine or a Hageman^like effect of the urokinase 
m olecule/
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m olecule itse lf . Since th e re  can be no doubt that the p rep ara tio n  
used  in  these  experim en ts was not a  homogeneous p ro te in , it 
m ight w ell be possib le  to  sep a ra te  the p rep ara tio n  into its  
sev e ra l com ponents on a la rg e  scales the fraction^ obtained 
could then be te s ted  fo r coagulative activ ity  and ly tic  activ ity  
to  determ ine w hether a product can be obtained which has ly tic  
activ ity  but no coagulative properties*
It is  perhaps su rp ris in g  that with the dosage used in  the 
p re sen t experim ents in vivo it  was possib le  to dem onstrate  a 
coagulative effect* The generation  of throm bin  from  pro throm bin  
is  auto Catalytic I and th e re fo re  pro throm bin  conversion , once 
tr ig g e re d  by the effect dem onstra ted  in  v itro , m ay have been 
perpetuated  by the au tocata ly tlc  reaction  in vivo#
F ib rino ly tic  Effects in vivo.
In the u rok inase  sensitiv ity  te s ts  it  was found that 
in  v itro  a  concentration  of 200 units/m l#  of p lasm a gave a m ean 
ly s is  tim e of 12 m inutes* In fib rino ly tic  therapy  with 
strep tok inase  it is  usually  thought d esirab le  to  induce in the 
p lasm a a b r isk  fib rino ly tic  s ta te  and in itia l doses of strep tok inase  
a re  calcu la ted  to produce p lasm a clot ly s is  tim es of 15 to 20 
m inu tes/
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m inutes (see chap ter S). On the basis  of the u rok inase  
sensitiv ity  te s ts ,  and assum ing à plasma, volume of 3 litres»  
a dose of about 600,000 units would foe n ec essa ry  to produce 
such activ ity , H ansen et a l, (1961) found that at le a s t 250,000 
units of urokm as e had to bê adm in iste red  to produce whole ^ p lasm a 
clot ly sis  tim es of le s s  than th ree  hours and F le tc h e r at al# (1964b) 
gave 180oi 400 units/Ifo* foody w eight/hour of another com m ercia l 
p rep ara tio n  ( i .e .  about 250,000 un its/hour) to induce b r isk  p lasm a 
fib rinoly tic  activity . It is  not th e re fo re  su rp ris in g  that in  the 
p re sen t study only alight o r m oderate fib rino ly tic  activ ity , 
substan tially  le s s  than tha t induced in  healthy subjects by strenuous 
ex e rc ise  (table 21) was seen  a fte r infusion of 40 -  80,000 units 
of urokinase* In view of the coagulative activ ity  seen  in  vivo 
in  subjects Z and 3 th e re  m ust be som e doubt about the w isdom  
of adm in istering  doses of the p rep ara tio n  studied adequate to 
produce b r isk  fib rino ly tic  activ ity . I t may foe how ever that with 
la rg e r  doses of u rok inase  any fib rin  deposited would be so rapidly 
lysed i that no untow ard c lin ica l effects w ill be produced. This 
view is  supported by the rep o rt of F le tch e r et a l, (1964b), using 
la rg o /
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la rgo  closes of another commeareial p repara tion  of urokinase 
which is  also  coagulative in  v itro  (Dubber e t a i. » 1965b), that 
no significant evidence of coagulative activity  in  vivo was found* 
F u r th e r  w ork is  n ec essa ry  to produce good clin ical and 
lab o ra to ry  evidence on th is im portan t point.
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CHAPTER 7*
EXPERIMENTS WITH ’‘PLASMIN” PREPARATIONS *
For som e years there has been controversy as to whether 
the best approach to thrombolytic therapy is  with plasminogen  
activator or with preformed plasm in, but there now appears to 
be general agreement that the use of activators is  to be preferred* 
There are superficial attractions in the use of plasm in, the 
en^ayme which actually brings about the ly s is  of fibrin# but for 
reasons to be presented and d iscussed  in this chapter, plasminogen 
activators are not only more effective in bringing about the ly s is  
of preformed fibrin but also are le s s  liable to produce a coagulation 
defect. Experiments with A ctase, a com m ercial “plasm in” 
preparation which w ill be shown to consist largely of streptokinase, 
are also described. '
M aterials and Methods.
Activater"^free plasm in was prepared by the method of Alkjaersig  
et al. (1958) by spontaneous activation in glycerol of a preparation 
of human plasminogen soluble at neutral pH (supplied by A. B. Kabi) 
The/
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T he p re p a ra t io n  w as  d ia ly s e d o v e rn ig h t before, use*
A ctase , a com m erc ia l p rep ara tio n  described  by the m anufactu rers  
as Immah p lasm in , was supplied by Ortho P harm aceiitica l Ltd, 
O ther m a te ria ls  and m eth o d s  a re  described  in chap ters 3# 4, 5 
and 6.
R esults.
Comparison of Streptokinase, Urokinase and p lasm in in Fibrinolytic  
and Coagulation System s,
* , WK I III ,  I . IL III lit  L I I L I III . ' I I  « I II ii. ■!■■ iw t .n  «
Table II shows the results of an experiment in which mixtures 
of normal plasma with saline, streptokinase, urokinase and plasmin 
were a ssessed  for fibrinolytic activity and defective coagulation.
It w ill be seen that in assays where the thrombolytic activity was 
m easured against preformed fibrin, i . e .  the fibrin plate test and 
the radioactive clot te st , plasmin was no more effective than saline, 
but caused major defects in the one^stage protlirombin tim e and 
thrombin clotting tim e. Streptokinase and urokinase on the other 
hand imparted to the plasm a marked lytic activity against preformed  
fibrin without causing a coagulation defect. Euglobulin ly sis  
activity was le s s  intense with plasmin than with the activators.
In Vitro Studies with A ctase, /
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lu V itro  Studies with A*ctase.
(i) G aseiuolytic activ ity  o£ Actase* One v ial of A ctase was 
reconstitu ted  with 10 m i, d is tilled  w ater and 0# S mi* aliquots
w ere assayed  in the caseino ly tic  sy stem  for plasm inogen (chapter 3). 
The assays w ere c a rr ie d  out in  trip lic a te : iden tical re su lts  w ere 
obtained w ith (1 .3 , 1.3 and 1.2 u n its /m l. ) and without (1*2, 1*3,
1 * 4 units /m l* ) s trep tok inase .
(ii) A ctivity in  the F ib rin  P la te  T ost. R ésulté of assay
of A ctase reconstitu ted  as desc rib ed  in  the preceding paragraph , 
a re  set out in  table 12, which a lso  shows re su lts  from  a  dilution 
curve of a  s tandard  strep tok inase  solution, 10 u n its /m l* , with 
a c tiv a to r-fre e  p lasm in , 1*3 u n its /m i* , added to sim ulate  the 
p lasm in  content of A ctase . The negligible ly tic  effect of the 
a c tiv a to r-fre e  p lasm in  alone is  also  shown* In th is  sy stem  the 
strep tok inase  content of a  v ia l of A ctase appeared  to be about 
65,000 units.
A ctase Infusions*
Two subjects received  A ctase by Intravenous Infusion*
Subject 1 had a calcu lated  p lasm a volume of 2BS0 m l. An IB 
m inute/
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minute lysie  time in the stro-ptoldnase sensitivity test was given 
by a concentration of 40 m iits/m l# , giving a total initial “fibrinolysis* 
inducing” dose of 115,200 unite of streptokinase. Results of 
infusion of the contents of I vial of Actase over 1 hour are shown 
in figure 33, where it w ill be seen  that there was a trivial increase  
in plasm a activator leve ls  and a slight drop i n  plasm a plasminogen  
following infusion. Fibrinogen levels and thrombin clotting tim es 
were unchanged (table 13#)
Subject Z had a calculated plasm a volume of 3000 m l. A 20 minute 
ly s is  tim e in the streptokinase sensitivity test was given by a 
concentration of ZOO u n its /m l., indicating a total initial “fibrinolysis 
inducing” dose of streptokinase of 600,000 units. Results of 
infusion of the contents of 2 v ials of Actase over I hour are shown 
in  table 14, where it w ill be seen  that there was a slight increase  
in plasm a activator lev e ls  as m easured by the euglobulin ly s is  tim e 
and radioactive clot te st , and there was a slight drop in plasma 
plasminogen le v e ls# There were no changes in the fibrin plate 
te st, fibrinogen lev e ls  or thrombin clotting tim e.
D iscussion.
In the controversy as to whether the best approach to 
thrombolytic/
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thrombolytic therapy is  with activator or plasm in, évidence to 
support the use of activator has been provided largely by the 
work of Sherry and his associates (see reviews by Sherry and 
F letcher, I960, and Sawyer et a l , , 1961). Sherry's group 
(Alkjaersig et al#, 1959b) first showed that preformed thrombi 
are relatively resistant to plasm in in the surrounding medium, but 
are sensitive to activator. The results presented in table 11 
confirm that streptokinase and urokinase are much m ore effective  
than activator-free plasmin in imparting thrombolytic activity to 
human plasma# Under the specific conditions of this particular 
in vitro experim ent, the activators induced plasm a thrombolytic 
activity without the serious coagulation defect produced by a 
thrombolyticaily inert concentration of plasmin, which was however 
able to reduce plasm a fibrinogen levels and accelerate euglobulin 
ly s is  activity. The disparity in assay of plasm a-plasm in m ixtures 
between the euglobulin ly s is  results on the one hand and the fibrin  
plate tests and radioactive clot tests on the other, presumably rests  
on the incorporation of plasm in within the clot and in close proximity 
to fibrin in the euglobulin te sts , but its  presence in the surrounding 
medium/
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medium only and not incorporated with the fibrin# In the 
other teste . This experiment supports the concept that 
ly s is  results m ore readily from activation of intrinsic clot 
plasminogen than from surface action of plasmin# Furtherm ore, 
as pointed out by Alkjaersig et al, (1959b), if such a mechanism  
were operative, the rate of ly sis  of thrombus would not only be 
a function of the concentration of activator surrounding the 
thrombus, but also as shown by Alkjaersig et al, (1959b) and 
supported by the observations displayed in figure 15, a function 
of plasminogen concentration within the clot.
On the basis of the postulated physiological mechanism  
for fibrinolysis (chapter Z) a sm all amount of plasm in w ill on 
infusion be neutralised by antiplasmin, and it might be expected  
that to produce with plasm in a thrombolytic effect in the plasm a  
surrounding a thrombus, sufficient plasm in must be infused to 
neutralise circulating antiplasmin; that is ,  it w ill be necessary  
to induce a hyperplasminaemic state with all its deleterious 
consequences. Arguments in favour of plasmin as a therapeutic 
weapon have been put by, among others, Gliffton (1957), Moser 
(1959) Ambrus and his group (Sokal et al*, 1958) and Am ris and 
his associates (Amris and A m ris, 1963; Am ris et a l , , 1963). 
The/
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The Ambrus group (Ambrus and Markus, I960) claim s that = 
the piasmin-*antiplasxnin complex formed on infusion of plasmin  
is  readily dissociable and constitutes a I'eservolr of plasmin  
which may be released  at the site of a thrombus, but no good 
evidence has been produced to support the relevance of this 
concept to thrombolytic therapy in man* Most claim s of clinical 
benefit with plasmin therapy relate to the use of Actase (e .g ,
M oser, 1959) which as d iscussed  below, owes the greater part 
of its activity to its  streptokinase content, and Johnson (1964) 
has found that activator-free plasm in, when infused in doses 
sufficient to produce a serious coagulation defect, is  ineffective  
in producing in vivo in man the ly s is  of experimental thrombi 
which are readily lyaed with streptokinase and urokinase.
The preparation of A ctase used in the experiments described  
in the present chapter had a plasm in content of about 13 u n its/v ia l, 
and a streptokinase content of about 65,000 units/ v ia l. In the 
fibrin plate test, its activity appeared to be almost entirely due 
to its content of streptokinase, since an activater-free plasmin  
preparation tested  in the same concentration as the plasm in content 
of/
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of A ctase solution produced negligible lysis* The total content
of plasm in present in the Actase vial might have been expected to 
have been produced from about 1 m l. of normal plasm a, and to 
have been neutralised by the antiplasmin content of 3 or 4 m l, of 
normal plasma; accordingly for practical purposes Actase should 
be regarded as a streptokinase preparation.
The dosage of Actase suggested by the xnanufacturers 
was one or two vials infused over 1 hour on any one day. Subject 
1, who was given 1 vial of A ctase, had an initial dose level for 
streptokinase calculated at 115,200 units, significantly in excess  
of the streptokinase content of the 1 vial of Actase which he was 
given, and subject 2 had an initial dose level for streptokinase 
calculated at 600,000, much in excess of the streptokinase 
content of the two vials of Actase* As might have been anticipated 
in the circum stances, tr iv ial and barely detectable leve ls  of 
fibrinolytic activity were found in the plasmas of these two subjects 
after Actase infusion, F letcher et al, (I960) examined an Actase 
preparation available in the United States at that tim e, and found 
a much lower concentration of streptokinase, about 6500 units/v ia l 
than/
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than that i n  the preparation used in the present stud ies. These 
authors found that infusion of the American preparation, also in 
the m anufacturers' recommended dosage, did not produce any 
fibrinolytic response#
Despite extensive publication Of clin ical results obtained 
with A ctase, in which it was regarded as a plasm in preparation, 
(e#g* Symposium, Angiology, 1959# M oser, 1958; Suss man and 
Fitch , 1958) it is  clear that Actase must be regarded for all 
practical purposes as a preparation of streptokinase and 
that all the problems associated with streptokinase, especially  
the need for initial dosage calculation# are present with A ctase.
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CHAPTER 8.
u        I ! ■
IN VIVO STUDIES WITH COMPLAMIN* A NICOTINIC ACID
THEOPHYLLINE ESTER, AS A FIBRINOLYTIC AGENT.
!lüï£IW «K W |t
Though the feasib ility  of thrombolytic therapy with fibrinolytic 
enzym es has been demonstrated (see chapter Z for a brief review  
of the literature), the expense involved in the preparation of 
suitable enèiymes and the difficulties in laboratory control of 
enzyme therapy have stimulated a search for non-enzymatic 
agents which when adm inistered might stimulate production or 
release of fibrinolytic enzym es in the body. One such substance 
is  nicotinic acid, which, fibrinolytically inert in vitro, was 
discovered by Meneghini and F iccin ini (1958) and Weiner et al.
(1958) to have the property of inducing intense but transient 
fibrinolytic activity when injected intravenously in man. Because 
of the short duration of the fibrinolytic response and the rapid develop* 
ment of resistance, attempts have been made to provide modified  
preparations of nicotinic acid with enhanced activity, and it is  the 
purpose/
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purpose of this chapter to describe studies with one such 
preparation -  3 -(methyloxyethylamino) -2-oxypropyl
theophylline nicotinate -  Complamin*
Nicotinic acid owes its fibrinolytic activity to its  ability 
to increase plasm a activator levels (Sawyer et a l , , 1960a) though 
the mechanism by which it does so is  not known. In the present 
assessm ent of Complamin as a fibrinolytic agent, factors studied 
after its administration included plasm a fibrinolytic activity; 
plasminogen and fibrinogen levels; and thrombin clotting tim e 
and one-stage prothrombin tim e.
M aterials and methods,
Complaxmn was made available by Edinburgh Pharm aceutical 
Industries, as ampoules containing 300 m g, in Z m l.,and  ISO mg, 
tablets. The minimum dosage of the intravenous preparation 
suggested by the manufacturera is  300 m g, t#i,d; and of the tablets 
ISO m g, t , i ,d .
The laboratory methods used are described in chapters 3 and 4,
R esults,
Single intravenous injections. Seven subjects (healthy colleagues) 
w ere/
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were given a single intravenous injection of Complaniin# I ml* 
of solution (i*e* ISO m g.) diluted in 10 ml* of saline, being 
injected over 60 seconds, The response in euglobulin ly s is  
activity is  shown In figure 34 where it w ill be seen  that S minutes 
after injection there was a r ise  in euglobulin ly s is  activity from  
a mean pro ^ infusion level of 1*2 units to a mean level of 7. 9 units* 
Euglobulin ly s is  activity was alm ost back to normal at 30 minutes* 
There was a slight drop in mean fibrinogen and plasminogen levels  
(tables 15 and l6) but there were no changes in thrombin clotting 
tim es or prothrombin times* The response of the sam e subjects 
on another day to exercise  (5 minutes skipping with a heavy rubber 
tube) is  also shown in figure 34, where a sim ilar pattern of euglobulin 
ly s is  activity is  seen# The peak rise is  somewhat le s s  than that seen  
with Gomplamin but the general pattern of r ise  and fall of activity 
is  closely  parallel* With ex erc ise , there were no changes in 
plasminogen or fibrinogen leve ls  and thrombin and prothrombin 
tim es (tables 17 and 18).
Repeated intravenous injections * The response in a healthy colleague
  I i r w i 1 i p < i , # 4 , rui . i'W w i M a f w m v #•«*>wm*w
to three intravenous injections of 150 mg* Gomplamin given at 
hourly intervals is  shown in figure 35, where it w ill be seen  that 
there/
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there was a progressive reduction in euglobulin ly sis  activity  
induced by the second and third injections, Another healthy 
subject was given a daily intravenous injection of Complamin 
for five days, The eiiglobulm ly s is  response is  shown in figure 
36, where again a progressive reduction in response was seen* 
Intravenous Infusions# An intravenous infusion o£ Gomplamin was 
given to two subjects with very sim ilar results* The effects of tlio 
infusion in one of the subjects are shown in figure 37* Over the 
first 30 minutes 150 mg* was infused, over the next 30 minutes 
300 mgj and over the la st 30 minutes 600 mg* As detected by 
the radioactive clot method, euglobulin ly sis  and fibrin plate 
tost, infusion produced a marked, but transient increase in plasma  
thrombolytic activity, which fe ll off rapidly despite progressive  
doubling of the infusion rate* There were no significant changes 
in plasminogen, fibrinogen, thrombin tim e or prothrombin tim e.
The data for second subject are presented in table 19. In a third 
subject, 150 mg* of Gomplanain infused over I hour produced a 
r ise  in euglobulin ly s is  activity from 0. B units before infusion to 
1* 6 units after 30 minutes and 1,2 units at the end of the infusion*
One hour later the euglobulin ly s is  activity was 1* 1 units.
Oral Administration/
ïor
Oral Administration,
Gomplamin tablets were given to 4 normal adult male 
subjects. One subject was given Z tablets only, the others wore 
given Z tablets on one day and 4 tablets several days later. The 
results are shown in table 20, where it w ill be seen that with Z 
tablets there was a minor increase in euglobulin ly s is  activity 
in  subjects 1 and 3, but no change in subjects Z and 4* With 
four tablets, subject 2 showed no change. Euglobulin ly s is  activity  
doubled in subject 4 and showed a significant increase in subject 3* 
With 2 tablets, where a rise  in euglobulin ly sis  activity was seen, 
it was noted in the 30^minute sam ples but had subsided at 60 
m inutes, With 4 tablets the effect seem ed to be somewhat longer 
lasting, being noted in both subjects 2 and 4 at 120 m inutes. 
Gomplamin and E xercise .
In order to study the in terrela tion sh ip s between the 
fibrinolytic responses to Gomplamin and to exerc ise , two healthy 
subjects participated in the following experim ents, each experiment 
being carried out separated from the others by an interval of several 
days.
(a) 5 minutes exerc ise , followed in 30 minutes 
by 5 minutes exercise
(b)/
(b) 5 m inutes e x e rc ise , followed in 30 m inutes 
by ISO mg* Gomplamin Intravenously.
(c) 150 mg. Gomplamin intravenously, followed 
in 30 minutes by ISO mg* Gomplamin 
intravenously.
(d) ISO m g, Gomplamin intravenously, followed  
in 30 minutes by S minutes exercise .
Response of euglobulin ly s is  activity is  shown for experiments 
(a) and (b) in figure 38 and lor experiments (c) and (d) in figure 
39#
It w ill be seen  that for both subjects, if exercise  was 
followed by exerc ise , or Gomplamin by Gomplamin, the second  
stimulus provoked a much reduced euglobulin ly s is  response, 
whereas if  exercise  was followed by Gomplamin, or Gomplamin 
by exerc ise , a full response was observed. It may be that the 
reduced response on the second occasion to repeated exercise  is  
due to fatigue and a le s s  vigorous performance of the exercise .
Discussion.
The results presented in this chapter demonstrate that 
Gomplamin/
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Gomplamin, like nicotinic acid, when given rapidly intravenously, 
produces a marked but transient rise  in plasma fibrinolytic 
activity, comparable in duration (not more than 30 minutes) 
and intensity to that produced by five minutes strenuous exercise*
The fibrinolytic response fa lls off rapidly With injections repeated 
at hourly intervals and at 24-hour intervals* The response was 
also transient when Gomplamin was given by intravenous infusion, 
contrary to the observations of Amery et al* (1962) who found a 
response for an hour or more when Gomplamin was given in this 
way. Given by mouth, Gomplamin either, in soma subjects, 
failed to produce a fibrinolytic response or, in other subjects, 
produced à triv ia l effect.
The mechanism by which Gomplamin produces increased  
leve ls  of fibrinolytic activity in the circulation is not clear, though 
it is  shared by som e other vaso-active drugs, e .g .  adrenaline and 
p itressin  (von Kaulla, 1963b)* Histam ine, however, which 
produces yaso-dilation, does not cause increased plasma 
fibrinolytic activity (Weiner et à l . , 1959), and there is  no 
correlation between the intensity of the flush produced by Gomplamin 
and the degree of fibrinolytic activity induced, Kwaan et al* (1958) 
have/
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have shown that fib rino ly tic  p rincip les can be re le a sed  from  
the v e sse l w all in  response  to paravenous in jection  of adrenaline , 
sero ton in  and acetyl choline in the sam e and in  the opposite a rm , 
and it  m ay be that a n eu ra l pathway, stim ulated  by Gomplamin and 
o ther substances, can bring  about plasm inogen ac tiv a to r re le a se  
into the c ircu la tion .
The sh o rt duration  of the fib rinoly tic  response  to Gomplamin 
is  due in  p a r t to the rap id  c lea rance  of fib rinoly tic  ac tiva to r from  
the c ircu la tion  by the liv e r  (F le tch er et a l* , 1964a) and a lso  to  the 
rap id  developm ent of a  re fra c to ry  sta te  to the drug. The experim ents 
in  which Gom plam in given a f te r  e x e rc ise , o r ex e rc ise  taken a fte r 
Gom plam in, produce a  full fib rino ly tic  re sponse , suggest that the 
fa ilu re  to produce a repeated  o r sustained  response to Gomplamin 
is  not due to exhaustion of the body’s fibrino ly tic  re so u rc e s , but 
to  re s is tan c e  to the action of the drug. The experim ents suggest 
tha t it  m ay be possib le  to  find a drug to produce a susta ined  re le a se  
of plasm inogen ac tiv a to r into the c ircu la tion .
The fa ilu re  in  the p re se n t experim ents to see significant 
changes in plasminogen* fibrinogen, th rom bin  clotting tim e and 
o n e s ta g e  p ro throm bin  tim e is  probably due to the sh o rt duration 
of/
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of the increase in activator levels produced in healthy sizhjects 
by Cmiiplamin injection* F letcher et al* (1964a), who gave 
m cotinic acid by intravenous injection.to patienta with oirrhosis 
of the l iv e r , . in whom there is. impaired clearance of plasminogen 
activator from  .the circulation, and hence a persistence of high 
lev e ls  of activator for much longer than In normal subjects, . 
found evidence of hyperj>lasminaemia,including a drop in plasminogen 
and fibrinogen values and a rise  in the thrombin clotting tim e and in 
one-atage .prothrombin time# ..
Conclusions. In thrombolytic therapy with streptokinase, where 
intense fibrinolytic activity (e .g . activity at lea st as great as the 
maximum response seen to Gomplamin in any subject) can readily 
be achieved and maintained, therapy may need to be continued for 
40 hours or m ore (é. g. Johnson and McCarty, 1959* Y erstreate 
et a l* , 1963; McNicol et a l* , 1963) to remove thrombus and 
restore vascular patency# It would therefore appear m ost improbable 
that therapy with Gomplamin would be of benefit i n  the treatment of 
acute thromboembolic occlusive vascular disease# On the other hand, 
as the present studies demonstrate, Gomplamin clearly does not 
exploit the full fibrinolytic resources of the body and a search for 
further/
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further modifications of nicotinic acid or other pharmacological 
substances which would produce a sustained fibrinoiytio response, 
would seem  worthwhile, In particular* a non-toxic substance 
active when given by mouth# might by long term  administration  
to increase physiological fibrinolytic activity, have an important 
role in the prevention of vascular throm bosis,
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CHAPTER 9.
PLASMINOGEH-PLASMIN SYSTEM ACTIVITY
TH SURGICAL OPERATIONS#
Fibrinolytic activity in the blood arising in association  
witîi surgical operations was first noted by Macfarlane (1937) 
and has since been frequently studied# The increased fibrinolytic 
activity may be partly a physiological non-specific response to 
s tr e ss , and anxiety with adrenalin release may also play a part 
(Iiatner, 1947), Other possible factors include division of 
adhesions and handling of lung, with release of tissu e activator 
into the circulation (Marchai et a l* , I960), reduced pH and 
hypoxaemia (von Kaulla and Swan, 1958) and the effects of 
anaesthesia (von Kaulla, 1947),
Sudden death is  often followed by intense fibrinolytic 
activity (Berg, 1950) and Schneck and von Kaulla (1961) have 
observed increased plasm a fibrinolytic activity associated with 
syncope or collapse during procedures such as pneumoencephalography; 
it may be that hypotension and cardiac arrest predispose to the 
development/
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development of pathological plasminogen^^plasmin system  
activity*
In view of the obvious potential use of tissu e or other 
endogenous activators as therapeutic agents, an account is given 
in the present chapter of the activity of the fibrinolytic enzyme 
system  in 10 patients before, during and after a major abdominal 
operation, and the biochem ical features found in two patients 
with a severe haemorrhagic state associated with increased  
plasm a fibrinolytic activity are also described.
M aterials and methods.
Whole clot ly s is  tim es were estim ated as described by McNicol
and Douglas (1964)*
Whole blood clotting tim es were determined by the method of Lee 
and White (1913).
Other methods were as described in chapters 3 and 4*
R esu lts.
1 * F ib rinolytic Activity in a Group of Patients Undergoing Excision  
of the Rectum* In a group of 10 patients in whom combined 
abdomino-perineal excision  of the rectum was performed (surgeon -  
Mr. M. K* Browne), blood sam ples were obtained immediately 
before/
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before the administration of the anaesthetic# during the 
operation at a time when much tissue dissection was taking 
place, and again as soon as the operation had been completed.
In no case was there a clin ical haemostatic defect. For each 
sam ple, a fibrin plate te st, euglobulin ly s is  tim e, plasminogen 
assay , fibrinogen assay and thrombin clotting tim e were carried  
out. Results are shown in figure 40# where it w ill be seen that 
during surgery there was a marked increase in activator activity  
as m easured in the fibrin plate test and the euglobulin ly s is  time; 
pre-operative levels had largely been regained in the sam ples 
obtained after surgery. There were also minor fa lls in 
plasminogen and fibrinogen lev e ls , and a slight r ise  in the thrombin 
tim e,
2, Individual Patients with a Fibrinolytic Coagulation Defect during 
Surgery,
Patient 11, During excision of the rectum in a 30 year old woman
with ulcerative colitis (surgeon -  Mr, A , A, Bonar), oozing of
blood was noted to be excessive and bleeding from the perineal wound
continued after operation despite repacking. Seven hours after
surgery the patient had a cardiac arrest. Resuscitation was by 
open heart m assage and bleeding in the chest and from the perineal
wound/
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wound in c reased  despite fibidnogen infusion (figure 41), At
th is  tim e the blood was appax^ently incoagulable, but clotting
o cc u rred  witli throm bin  in 93 seconds# Whole clot ly s is  tim e
w as 30 minutes* P lasm inogen  was assayed  as ze ro  and fibrinogen
40 m g. / 100 m l. The fib rino ly tic  inhibitox* epsilon am inocaproic
acid  (EACA) was given in travenously  as shown in  figure 41;
a fte r a  loading dose of 5 gm *, I gm* / hour was given fo r 5 h o u rs ,
then 0*5 gm . / hour fo r a fu rth e r 5 hours* T ransfusion  requ irem en ts
from  the beginning of operation  until EACA was given w ere 30 p in ts .
W ithin 5 m inutes of giving EACA bleeding ceased  and did not re c u r ,
and the pa tien t’s course  th e re a f te r  was uneventful. The
p ro g re ss iv e  im provem ent in  the labo ra to ry  te s ts  can be seen  in  figure 41
P a tien t 12, Im m ediately  a fte r sp leno -rena l anastom osis and
splenectom y fo r haem atem esis  due to hepatic c ir rh o s is  aiid po rta l 
hypertension  (surgeon « P ro fe s s o r  w *  A* Mackey) th is patien t, 
a  52 y e a r  old woman, was found to have a haem orrhag ic  s ta te  with 
incoagulable blood. L abo ra to ry  study a t th is tim e (figure 42) 
showed in c re a sed  throm bolytic activ ity  in  the fib rin  p late te s t  
but euglobulin ly s is  was normal# p resum ably  because of 
p lasm inogen depletion which w as a lso  found# The whole blood 
clotting/
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clotting tim e was infinite* After treatment witii EACA 
(10 gm, i*V.) the haemorrhagic state was corrected alm ost 
im m ediately. The improvement in the laboratory findings can 
be seen in figure 42,
Discussion*
The findings presented in figure 40 confirm that increased  
plasminogen^plasmin system  activity occurs during a major 
surgical operation. In the present ser ies  of patients, studied 
in association with abdomino-perineal excision of the rectum, 
a procedure involving much tissu e trauma, increased levels of 
plasminogen activator in the circulation were associated with 
a slight fall in mean plasminogen and fibrinogen leve ls  and a 
trivial coagulation defects this had corrected itse lf  by the end 
of operation. As none of the patients had a clin ically manifest 
defect of haem ostasis, it would seem  probable tiiat the fibrinolytic 
activity seen was a physiological response to the s tre sse s  of 
operation, pre-operative anxiety and the administration of an 
anaesthetic, though the release of activator from damaged tissu es  
may also have contributed*
In/
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In patient 11 on o ther hand, in associa tion  with the 
sam e operation  th e re  developed a profound and c lea ily  
pathological lib rin o ly tlc  s ta te , witîi a lif© -threatening haem ostatic  
defect* Although plasm inogen was assayed  as ze ro  in the 
caBcinplytic technique, a  li tt le  plasm inogen was presum ably  
p re se n t to give the very  rap id  whole clot ly sis  tim e of 30 minutes* 
As p lasm a fibrinogen was only 40 m g. / 100 n d * , t ra c e  quantities 
of plasm inogen could p resum ably  bring  about its  rap id  ly s is  in  the 
p resen ce  of la rg e  am ounts of activator* A lternatively , the rap id  
clo t ly s is  m ay have been due to  f re e  p lasm in  which had becom e 
bound to an tip lasm in  before the assay  was c a rr ie d  out* The 
strik ing  clin ical response to EAGA therapy  confirm s the role of 
pathological fib rino ly tic  activ ity  in the genesis of the haem orrhag ic  
s ta te .
In patient 12, also  w ith a haem orrhag ic  s ta te  asso c ia ted  
with in c re a se d  fib rino ly tic  activ ity  and rapidly contro lled  by EACA 
therapy , la rg e  am ounts of activato?; w ere found in  the fib rin  plate 
te s t ,  but because of the low plasm inogen level, with a  re la tive ly  
n o rm al fibrinogen, euglobidin ly s is  activ ity  was not acce le ra ted .
Tablé 21 su m m arises  b iochem ical data from  o ther chap ters
in /
-1 1 9 -
in this thesis relating to selected  subjects in whom fibrinolytic 
activity was induced in vivo by streptokinase, urokinase,
Compiamin or ex erc ise , together with some of the findings from  
the present chapter* It w ill be seen  that urokinase, Gomplamin, 
ex erc ise , and surgery in m ost subjects, can produce increased  
fibrinolytic activity without significant abnormalities in 
plasminogen, fibrinogen or thrombin tim e, whereas operation 
in som e patients, and streptokinase probably always produce 
fibrinolytic activity associated  with reduction in plasminogen and 
fibrinogen and a significant coagulation defect. The duration 
of the rise  in plasm a activator levels  may be a factor in the 
differing responses seen; o* g# the urokinase infusion was only 
for 30 m inutes, and the fibrinolytic responses to Gomplamin and 
exercise  were transient* The duration of the fibrinolytic response 
in the 10 subjects shown in figure 40 was not determined. On the 
otimr hand, Sawyer et al. (1960b), comparing the fibrinolytic with 
the fibrinogenolytic properties of activators, have shown that for 
a given rate of fibrinolysis, a le s se r  fall of plasma plasminogen and 
le s s  fibrinogenolysis is  produced by urokinase than by streptokinase, 
and there may be important differences of this type between the 
action/
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action of p lasm a ac tiv a to r and tis su e  ac tiv a to r. In any event, 
i t  is  c le a r  from  patien ts 11 and 12 that endogenous ac tiva to r 
can  produce fib rinoly tic  activ ity  assoc ia ted  with a sev e re  
haem orrhag ic  .sta te , and tha t purified  tissu e  ac tiva to r cannot 
be expected, if m ade available fo r therapeu tic  u se , to be 
fre e  from  r is k  of haem osta tic  failure*
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CHAPTER 10.
THROMBOLYSIS STUDIED IN AN ARTIFICIAL CIRCULATION,
WITH THROMBI PREPARED IN VITRO IN A CHANDLER'S TUBE.
In the investigation of the plasm inogen-plasm in system , the 
human substrates m ost commonly employed hdve been whole 
blood clo ts, plasm a clots and euglobulin clots and while from  
these system s has em erged m ost of the present knowledge of 
fibrinolysis, it is  c lear that such test tube clots are very different 
in structure and composition from the pathological thrombi which 
are the in vivo target of thrombolytic agents •
The structural differences between clot and thrombus 
have recently been reviewed by Poole (1964a), who pointed out 
that a clot has a uniform structure, with the formed elem ents 
distributed at random in the fibrin network, whereas a thrombus 
consiste of two types of material; white thrombus, consisting  
largely of agglutinated p latelets, and red thrombus, consisting  
of fibrin and red blood cells# Chandler (1953) demonstrated that 
it was possible to produce artificia l thrombi in vitro by making 
blood/
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Mood flow round and x’ound a  cloBed c irc u la r  loop of p lastic  
tubing; when so lid ification  occu rs  in th is system# a throm bus 
is  fo rm ed  with a p la te le t head and a fib rin  ta il  (figure 43); 
h isto log ica lly  C handler th rom bi voxy closely  resem b le  pathological 
th rom bi (figure 44).
The object of th rom bolytic  therapy  is  to  incxease p lasm a 
throm boly tic  activ ity  by W u sio n  of plasm inogen ac tiv a to rs  and 
so to  accelex'ate the physiological p ro cess  of th rom bo lysis . It 
is  the purpose of th is  chap ter to d esc rib e  experim en ts in which 
fac to rs  affecting the p ro c ess  of th rom bolysis in  v itro  w ere  studied  
using Ghaxrdler-type th rom bi as substrate# In the belief th a t the 
re su lts  obtained m ay have m ore  re levance to the in  vivo situation  
than  experim ents with blood clots* Thrombi# tra c e  labelled  
with rad ioactive iod ine-tagged  fibrin# w ere m ade in a C handler’s 
tube and tra n s fe r re d  to  an a r tif ic ia l c ircu la tion  w here they w ere 
p erfu sed  w ith streptokinase# p a tte rn s  of rad ioactiv ity  d istribu tion  
during perfxision w ere  studied .
M ate ria ls  and metho<^*
S trep tok inase . A highly purified  p rep ara tio n  was supplied by A. B, 
K abi./
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Kabi*
ürokitiase. Leo urokinase was used.
H on-asterified fatty acids were estim ated by the method of Dole
( 1956), Values above 100 p. e q ,/l itr e  were regarded as elevated. 
T riglycerides were m easured by a modification of the method of 
van Handel and Zilverem it (1957). Values above 200 m g ./ 100 m l,
were regarded as abnormal.
Cholesterol was m easured by the method of Zlatkis et al.
(1953)* The upper lim it of normal was accepted as 275 mg* / 100 ml, 
Lipid assays were performed by Dr. B. M. Rifkind*
Preparation of artificial thrombi. A rtificial thrombi were made by 
a modification of the method of Chandler (1958). Whole blood was 
used, 20 m l. being collected  with a plastic syringe and immediately  
transferred to a ’Chandler’s tube’ made with 27*5 inches of 
transparent vinyl p lastic tubing, internal diameter 12,5 mm* 
(Portland P la stic s , L td ., Kent). At the sam e tim e a trace of 
tagged fibrinogen was added (usually about 0 .1  m l. to give 
1000 counts/second) and the tubing, made into a continuous loop 
with a nylon adaptor, was placed on the turntable of a blood cell 
suspension m ixer revolving at 28 .5  r .p .m . The tube was left 
to revolve for one hour at room temperature when the resulting 
thrombus/
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thrombus was decanted and washed three tim es with saline#
The radioactivity of the thrombus was then counted and it was 
transferred to the perfusion circulation.
Perfusion circulation* The perfusion circulation (figure 46), 
devised by Mr. W. H. Bain, was made up with ’Tygon* plastic  
tubing, internal diameter 0. 26 inch, with a length of narrow  
tubing, internal diameter 0 .0626 inch as a collateral bypassing 
the site of insertion of the thrombus. A sigm am otor pump 
(Sigmamotor Pump C o ., Middleport, K .Y .) was used at a flow  
rate of 140 m l.7 minute, giving a mean upstream  pressure of 
80 mm. of m ercury. The perfusion fluid was 0 .9  per cent saline, 
the total volume being 200 m l* , and perfusion was carried out at 
a temperature of about 28®C. Thrombi were inserted into the 
circulation through à break in the tubing to sit on a stain less steel 
gauze basket (mesh s ize  120). Until ly s is  had taken place, 
occlusion by the thrombus of the main channel of the circulation  
was usually alm ost or quite complete and m ost of the flow was 
deviated through the collateral circulation, but as ly s is  occurred, 
the flow through the main channel progressively  increased.
Other methods /
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other methods used are described in chapters 3 and 4.
R esults,
In each case  the throm bus was perfused  fo r 24 hours 
and 1 m l. sam ples w ere taken from  the c ircu la tion  at 0, 4# 8,
12» 20 and 24 h o u rs . A fter centrifugation for 10 m inutes at 
1000 g* » rad ioactiv ity  in  0 .5  m l. of supernatan t was counted.
At the conclusion of the experim ent, the w ire  gauze basket with 
any throm bus s till  rem aining in  i t  was cut out and rad ioactiv ity  
counted. The perfusing  fluid was filte red  and non-filterub le  
rad ioactiv ity  counted. R adioactivity  in  solution, at the s ite  of 
throm bus in se rtio n  and non -filte rab le  ( i .e .  in  fragm ents) was 
ex p ressed  in  each case a f te r  co rrec tio n  for radioactiv ity  decay, 
as a  percentage of in itia l throm bus rad ioactiv ity .
’Normal* T hrom bi, Throm bi w ore made from  seven healthy 
co lleagues, aged 2 1 - 4 2  years# who all had norm al fibrinogen 
and plasm inogen assay s {table 22). F ig u re  46 shows the white 
head and fib rin  ta il of a throm bus p rep ared  in this way from  a 
■patient with hyperXipidaemia (patient 3a, table 27), and figure 47 
il lu s tra te s  the s trik ing  d ifferences between h isto logical s tru c tu ré  
of head and ta il in a thrombus prepared from a normal subject. 
Autor adiog raphy /
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Autoradiography of the platelet head was carried out and while 
radioactivity was associated  with platelet clumps, resolution  
was not adequate to determine whether the radioactivity was 
present in the spaces between individual platelets (histological 
preparations made and reported by Dr* F . Walker)*
The pattern o f  release of radioactivity into solution during 
perfusion with streptokinase is  shown in figure 48, and table 23 
shows mean values and standard deviations for percentage 
radioactivity in solution, in fragments and at the site of insertion  
after perfusion for 24 hours* It w ill be seen that the rate of release  
of radioactivity had fallen off after 12 hours and that only a mean of 62 
per cent of the radioactivity was in solution at 24 hours, when rather 
m ore than 25 per cent was present as non-filterable fragments*
A proportion of the fragments appeared to be fibrin, but the 
majority (figure 49) were yellowish-white m illet seed  sized  granules 
the histological appearances of which, shown in figures 50 and 51, 
are compatible with an origin from platelet aggregates* Tables 23 
and 24 and figure 48 also show that in the absence of streptokinase 
in the perfusing fluid, thrombi showed le ss  than 10 per cent ly s is  
in 24 hours*
Effect of EACA* This is  shown in figure 52 and table 23 where it 
w ill/
w ill fee soon than when EACA wâo praoont Ut the c ircu la tion  in 
m concentration 10^  ^ Molar, the cloto wore as cthble as when 
no atroptoMnUéo was pro sent in the aireulatian# there being 
only 1 -  8 por cent eoïnhle radioactivity after povfusion for 
24 hours *
Effect QÎ Piariminogom Enrichm ent# Plaorninogon onrlehod throm bi 
w ore m ade from  two no rm al aubjocte w ith p lasm a placmiinogon 
lovele of 3*4 and 2*6 oaeoln unitis/ml, liy adding to the Chandler’a 
tulïo with the Mood and tagged fibrinogen# roapectlvoly  44 
and 48 unite of lûmmimgon  In saline# to  give p lasm a pimemlnogom 
lovela about thxroo times- nox^màl* E esu lts  of perfusion  with 
s trop tok lnase  o£ the two plaSxmii%Ogen enriched th rom bi at© shown 
in  tab le0 33 and 34,and lign ro  53 shows the re su lts  from  one of the 
oxperimentà* Plasminogen enrichment re su lted  in very  rapid and 
alm ost com plete lysis* In  both experim en ts, a f te r  only 4 hours 
perfusion  with etroptolcinaèe, over 90 p e r cent of the rad ioactiv ity  
w as In so lu tion  and only 4 ami 7 pov cent I'ospoctivoly was prescm t 
In fragm ents in  the circtdation*
E ffe c t of P la te le t  Count on S u S o ep tib ility  to  L ysis*  T h ro m b i w o re
r-iSiS»
m ade/
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made frorç two patients with a low platelet eount (patient (a), 
refractory anaemia, platelet count 12, 500 /c*mm*, and patient 
(b)# idiopathic thrombocytopenic purpura, platelet count 
37, 500 /c .m m .) and from two patients with thrombocythaemia 
(patient (c), platelet count 1, 2 5 0 ,0 0 0 /c* mm. and patient (d), 
platelet count 1, 150 ,000 /c,mm*)* Results of perfusion with 
streptokinase are shown in tables 24 and 26 and for patients 
(a) and (c) patterns of release of soluble radioactivity are shown 
in figure 53* With the thrombocytopenic thrombi, ly s is  was much 
more complete than with ’normal* thrombi, and le s s  radioactivity 
was present in fragments* For both patients (a) and (b), the 
percentage of radioactivity in solution after perfusion for 24 hours 
was more than 2 standard deviations above the mean value for the 
’normal* thrombi, and the percentage of radioactivity in fragments 
was more than 2 standard deviations below the mean of the normals* 
Figure 54 shows the histological appearance of the head of the 
thrombus prepared on another occasion from patient (a) at a time 
when the platelet count was 2 2 ,0 0 0 /c. mm* The appearances 
resem ble those of a sim ple blood clot and are in striking contrast 
to those seen in figure 47 which illustrates the appearance of a 
’normal*/
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’normal* platelet head, the head of the thrombocytoiuemc thrombus 
lacking the normal coral-like platelet aggregates and having a 
much more loose , open structure*
Both the thrombocythaemic thrombi were found to be 
resistant to ly s is . The percentage of radioactivity in solution 
at 24 hours was more than 2 standard deviations below the mean 
’normal* value, and the percentage radioactivity in fragments was 
m ore than 2 standard deviations above mean ’normal* values, 
Hyperlipidaemic Thrombi* Thrombi were made from 4 patients 
with elevated blood lipid le v e ls . Details of the lipid abnormalities 
present and of conventional fibrinolytic studies, are shown in table 
27, Patient 1, a man aged 30 years, had idiopathic hype r choies ter o l-  
aemia* Patient 2# a man aged B6 years, also had idiopathic 
hypercholestarolaem ia with xanthomatosis. Patient 3, a girl 
of 15 years, had severe diabetes m ellitus and Hashimoto*s thyroiditis. 
When sample 3a was taken, she was in ketoacidosis* Sample 3b 
was taken 14 days later when her diabetic state was under control 
and non-esterifiad fatty acid, cholesterol and triglyceride levels  
had fallen substantially, though cholesterol and triglyceride levels  
were s t ill above normal* Thé diagnosis of Hashimoto’s thyroiditis 
w as/
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Was only confirmed after sam ple 3b had been taken» and the 
patient was not receiving thyroxine at the time of study* Patient 
4, a man of years» had a nephrotic syndrome. It w ill be 
noted (table 27) that all four patients had normal plasminogen  
a ssa y s. Patients 2 and 3 a lso  had euglobulin ly s is  tim es within 
normal» but patients 1 and 4 had a marked réduction in euglobulin 
ly s is  activity. A ll four patients » including the two with euglobulin 
ly s is  tim es within the normal range» yielded thrombi which were 
much more resistant to ly s is  than those prepared from normal 
subjects (figure B5 and table 28). The percentage of soluble 
radioactivity at 24 hours with all the hyperlipidaemic thrombi was 
m ore than 3 standard deviations below the mean value obtained 
with ’normaV thrombi.
Stability of Streptokinase.
During perfusion» tliere was a definite fall in plasminogen 
activator activity in the perfusing fluid. For example» in one 
experim ent (carried out by Dr. B . Sweet) in which the perfusing 
fluid was assayed for activator activity in a clot ly s is  system  
incorporating purified fibrinogen and plasminogen» ly s is  tim es  
rose from 3 minutes with fluid removed at the beginning of the 
perfusion/
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•perfusion» to 9 minutes with fluid removed after 24 hours» 
indicating a marked lo ss  of streptokinase activity in the 
perfusion fluid. However» failure to obtain complete ly s is  of 
the Chandler thrombi cannot be attributed to this decline in the 
lytic activity of the perfusing fluid, for as shown in tablé 29, 
addition to the perfusing fluid of further streptokinase, 200 u n its/m l, » 
or urokinase 200 u n its/m l. after 24 hours perfusion produced no 
increm ent in soluble radioactivity*
D iscussion.
The data presented indicate that perfusion with streptokinase
of artificia l thrombi with a histological structure sim ilar to that
of pathological thrombi, results in substantial but not complete
throm bolysis. About two-thirds of the radioactivity of thrombi
131trace-labelled  with I fibrin was found in solution after about 24 
hours in the artificial circulation, and only 10 per cent of the 
radioactivity remained at the site of insertion of thrombi into the 
circulation. About 30 per cent of the radioactivity was found in 
the circulation after perfusion as particulate m atter, many of the 
fragments having a h istological structure suggesting their 
com position/
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composition to b© from platelet aggregates. Support for the 
contention that the unlysed particulate radioactivity in the 
circulation was associated with platelet aggregates is  obtained 
from the experiment with blood from patients with low platelet 
counts in which ly sis  was much more complete and little  
radioactivity was present in fragm ents, and blood from patients 
with high platelet counts in which ly sis  was much le s s  complete 
and much more radioactivity was present in fragm ents.
The nature of the substance which is  responsible for 
maintaining platelet aggrogation is  unknown (Poole, 1946b), but 
the experiments described in this chapter can be interpreted as 
suggesting that fibrin may contribute to the maintenance of platelet 
aggregation. With the plasminogen enriched thrombi, ly s is  was 
rapid and sdmost complete# Little radioactivity was present as 
particles in the circulation. P latelets are known to contain 
significant amounts of antiplasmin (Johnson and Schneider, 1953), 
which may neutralise plasmin and protect fibrin in the immediate 
vicinity, and plasminogen enrichment of thrombi may provide enough 
plasm in to swamp the antiplasmin mechanism and make available 
free plasm in to lyse  the fibrin holding platelets aggregated, hence 
the I
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the smaU amount of rad ioactiv ity  p re sen t in  p a rtic le s  a fte r 
Btx’eptokinase perfusion  of plasm inogen enriched  th ro m b i.
In view of the s tru c tu ra l resem blance of the th rom bi used  
in  these  experim ents to pathological th rom bi, i t  would appear 
possib le  that a s im ila r  p a tte rn  of throm bolysis with re le ase  Of 
p la te le t- r ic h  p a rtic le s  into the c ircu la tion , m ay %)ertain during 
th rom bolysis in  vivo. While re le a se  of p la te le t em boli may not 
be significantly  dele terious in  the trea tm en t of p e rip h e ra l v ascu la r 
occlusion , such a phenomenon would be assoc ia ted  with obvious 
and im portan t haïsards in the c e re b ra l circulation* This potential 
danger lends w eight to  the p re sen t re luctance, based  on the r isk  
of converting iachaem ic to  haem orrhag ic  in fa rc ts , to use throm bolytic 
agents in the trea tm en t of c e re b ra l throm bosis o r c e re b ra l embolism*
N ilsson  et àl# (1961b) have suggested that EACA, a potent 
com petitive inh ib itor of plasm inogen activation# can be given with 
s trep tok inase  in throm bolytic  therapy# with elim ination of p lasm a 
pro teo ly tic  activ ity , but un im paired  throm bolytic ac tiv ity . The 
re su lts  of the experim ents w ith EACA p resen ted  h e re  would suggest 
that it  is  highly probable that EACA if given w ith s trep tok inase  would 
inh ib it/
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inhibit thrombolytic activity in vivo*
The utility of this approach to the study of thrombolysis 
is  also illustrated by the experiments with hyperlipidaemic blood. 
As might be expected from  the present confusion as to the role 
of lipids as inhibitors of fibrinolysis (Howell, 1964), in two 
of the hyperlipidaemic patients plasm a fibrinolytic activity as 
assessed  by the euglobulin ly s is  method was normal and in two 
patients was much reduced, a finding which may possibly be 
related in part to elevated fibrinogen levels* However blood 
from all four yielded thrombi which were resistant to streptokinase 
and it is  possible that the present technique can highlight 
abnormalities in response to lytic agents which are poorly or 
inconsistently reflected in other test systems*
Conclusions*
The technique described in this chapter of studying factors 
affecting throm bolysis, by perfusing with streptokinase in an 
artificial circulation thrombi with a histological structure closely  
resembling that of pathological thrombi, produced in vitro in a 
Chandler's tube, may have more relevance to in vivo response to 
thrombolytic agents than in vitro experiments with blood clots •
The/
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T he r e s u l t s  p re s e n te d  su g g e s t th a t w hen th ro m b i a r e  ex p o sed  
to  s tre p to k in a s e  th e  f ib r in  com ponen t m ay  be la rg e ly  d is so lv e d , 
b u t p la te le t  e m b o li, p o ss ib ly  ce m en ted  by f ib r in  p ro te c te d  f ro m  ly sis  
by p la te le t  a n tip la sm in  co n ten t, m ay  be r e le a s e d  in to  the circu la tion . 
T he g e n e ra l  a p p lic a b ility  of th e  tech n iq u e  in  th e  study  of throm bolytic 
m echa^ iism s h a s  a lso  b een  i l lu s t r a te d  by i ts  u se  to  d e m o n s tra te  
th e  in h ib ito ry  e ffec ts  of c irc u la tin g  EACA and of h y p e r lip ld a e m ia  
on th ro m b o ly tic  a c tiv ity ,
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CHAPTER 11.
SUMMARY AND CONCLUSIONS •
Over the past ten years, with the demonstration of the 
feasibility of treatment of thrombo-embolic occlusive vascular 
disease with fibrinolytic enzym es, there has been intensive study 
of the components and functions of the fibrinolytic enssyme, or 
plasm inogen-plasm in system . The studies reported in this 
thesis were carried out in an effort to increase understanding 
of the plasm inogen-plasm in system , and of the consequences of 
plasminogen activation, with a view if possible to the eventual 
routine use of fibrinolytic enscymes in the treatment of patients 
with vascular occlusion.
The P lasm inogen-Plasm in System .
The plasm inogen-plasm in system  may have a function in 
vivo complementary to the coagulation system  in maintaining an 
intact patent vascular tree . According to this hypothesis, the 
coagulation system  sea ls with a haemostatic fibrin plug any 
deficiencies which may appear in the vascular endothelium and 
the/
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the fibrinolytic m echanism  rem oves such fibrin deposits after 
they have served their haem ostatic function and endothelial 
repair has occurred.
The main components of the plasm inogen-plasm in system  
are plasminogen* plasmin* activators and inhibitors. Plasminogen* 
a normally inert plasm a globulin* is  converted by activators to 
plasmin* a proteolytic en»yme which can digest many proteins 
including fibrin* fibrinogen* factor V, prothrombin and 
antihaemophilic globulin. Activators of plasminogen include 
tissu e activators I a plasm a activator; a urinary activator named 
urokinase which may represent in part at least excreted plasm a 
activator* bacterial activator, e , g ,  streptokinase which is  
produced by certain strains of haemolytic streptococci; and 
substances* fibrinolytic ally inert in vitro* which when injected  
intravenously produce an increase in plasma activator levels*  
e*g,  bacterial pyrogen and nicotinic acid.
According to Sherry et al, (1959a) under physiological 
conditions inhibitory m echanism s restrict plasmin to digestion  
of fibrin* In plasma there is more antiplasmin than plasminogen, 
that is  than potential plasm in, and if plasminogen activation takes
138
place re la tive ly  slowly* then as p lasm in  is  produced, it  is  
neutralised, by antiplasm in* and so p lasm a p ro teins a re  p ro tec ted  
from  digestion. In  th rom bi On tlie o ther hand* w here plasm inogen 
concentrations a re  re la tiv e ly  high and effective antip lasm in 
concentrations a re  sa id  to  be re la tive ly  low, ac tiva to r diffusing 
into throm bus ac tivates plasm inogen in close proxim ity  to the 
fib rin  which is  d igested  -  the p ro cess  of th rom bolysis.
The necessity  fo r the an tip lasm in  m echanism , which in  vivo 
norm ally  confers su b s tra te  specific ity  on p lasm in  and p ro tec ts  
p lasm a p ro teins from  digestion can be apprecia ted  if the effects 
of f re e  p lasm in  in  the c ircu la tion  -  hyperp lasm inaem ia -  a re  
considered , H yperp lasm inaem ia re su lts  in  a  grave coagulation 
defect, due in  p a r t to depletion of coagulation fac to rs  -  for 
exam ple, fibrinogen, fac to r V, antihaem ophilic globulin -  and 
in  p a r t to defective fib rin  po lym erisation  resu lting  from  the 
p resen ce  in  the c ircu la tio n  of polypeptides a ris ing  from  the 
digestion of fibrinogen by p lasm in; these  in te rfe re  with the norm al 
conversion of fib rin  m onom er to fib rin  polym er, A cce lera ted  
ly s is  of Such clo ts as do fo rm  in c re a se s  the haem ostatic  defect* 
F u ll p lasm in -an tip lasm in  union takes place re la tively  slowly and 
a/
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a temporary overwhelming of the antiplasmin mechanism may 
occur when the sudden arrival of large amounts of plasminogen activator 
brings about quick and m assive conversion of plasminogen to 
plasm in, with the appearance of free plasmin in the circulation*
Large amounts of plasminogen activator may appear in the circulation  
in spontaneous pathological fibrinolytic states, and in thrombolytic 
therapy.
Owing to the defect in fibrin polymerisation, the whole 
blood clotting tim e is  prolonged, as are the thrombin clotting 
tim e and the one-stage prothrombin tim e, Plasm inogen, fibrinogen, 
factor V, prothrombin and antihaemophilic globulin assays show 
low values.
It is  believed that physiological plasma fibrinolytic activity  
may be due to trace quantities of activator in the plasm a and it is  
now generally accepted that the object of fibrinolytic or thrombolytic 
therapy is  to increase plasm a activator levels and so accelerate  
the process of thrombolysis «. The ideal is  to produce rapid 
digestion of thrombi without significant hyperplasminaemia; in 
practice this ideal is  probably im possible to achieve*
Studies with Plasm inogen A ctivators.
Human/
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Human and anim al experim ents in the l i te ra tu re  have 
suggested  that ac tiv a to rs  of the p lasm inogen-p lasm in  system  
m ay he successfu lly  used  in the trea tm en t of th rom bo-em bolic 
v ascu la r occlusion , and the w ork p resen ted  in th is th es is  was 
c a rr ie d  out as p a r t of a lo n g -te rm  clin ical and labo ra to ry  
p rogram m e of investigation  of the problem s involved in 
th rom bolytic  therapy .
After two chapters devoted to methods, including an original 
method of preparing fibrinogen tagged with radioactive iodine, 
an account is  given of in vitro and in vivo studies with a variety  
Of plasminogen activators -  streptokinase, urokinase, a 
com m ercial plasmin preparation which owes the greater part of 
its  thrombolytic activity to its  content of streptokinase, and a 
nicotinic acid compound* In view of the possible use of tissue  
or other endogenous activators in therapy, an account is  given 
of biochem ical findings in patients with increased levels of 
plasminogen activator in the plasm a during surgical operations, 
which may perhaps be due to re lease into the circulation of tissu e  
activator* Finally an account is  given of some factors, 
particularly platelet and lipid content, affecting the in vitro  
response/
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response to streptokinase of artificial thrombi.
Laboratory methods. The methods are not original, though 
some have been modified in minor ways for the present studies. 
Methods described include assays for plasminogen activator 
activity, plasminogen, fibrinogen, and the hyperplasminaemic 
coagulation defect. Activator assay techniques described  
include the euglobulin ly s is  method* which is  sim ple and speedy, 
but can give m isleading results if plasma plasminogen leve ls  are 
low, and the fibrin plate te st , which m easures plasm a thrombolytic 
activity, but takes many hours to carry out. Evidence is  
presented that in a large group of te sts , there was good correlation  
between results with euglobulin ly s is  and with the fibrin plate 
te st . An account is  then given of a casainolytic technique for 
plasminogen assay, and a standard method of fibrinogen assay.
There follows a description of the thrombin clotting tim e, which 
was used as a combined index of defective fibrin polym erisation  
and hypofibrinogenaemia*
Fibrinogen tagged with radioactive iodine* The next chapter 
(chapter 4) gives an account of a simple original method of preparing 
fibrinogen tagged with radioactive iodine. The method was quick 
and/
142
and easy to p e rfo rm , and produced a tagged fibrinogen in
which throm bin clot tab le  rad ioactiv ity  v aried  from  89 to 96
j>er cent, tr ic h lo ra c e tic  acid  p rec ip itab le  rad ioactiv ity  always
being g re a te r  than 97 p e r cent. The e lec trophore tic  and
chrom atographic p ro p e rtie s  of th is  tagged fibrinogen a re
desc rib ed , and an account is  given of its  use in  a m odified
131v ersio n  of the p laem inogen-onriched  I fib rin  labelled  clot 
sy stem  of ac tiv a to r a ssay  o rig inally  described  by A lk jaersig  
et al, (1959b), Though a good co rre la tio n  was dem onstra ted  
betw een rad ioactiv ity  re le a se  and ty ro sine  re le a se , quantitative 
aspects of the m ethod w ere  som ewhat disappointing (coefficient 
of variation* 14*5 p er cent)» Though the clots w ere p rim arily  
sensitive  to activator» they a lso  showed som e response  to p lasm in  
in  the te s t  solution* they appeared  to m easu re  the p ro p erty  which 
throm bolytic therapy  is  intended to im p art to the p lasm a, that is  
the ability  to d isso lve p re fo rm ed  hum an fibrin*
S trep tok inase . The th e s is  then goes on (chapter 5) to give an 
account of the biochem ical effect of in trav asc u la r adm in istra tion  
of a highly purified  p rep a ra tio n  of strep tok inase  to 6 su b jec ts . 
S trep tokinase is  the only plasm inogen ac tiva to r com m ercia lly  
availab le/
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available at the p re sen t tim e in th is  country for in trav ascu la r 
adm in istra tion . It is  a s trep tococcal antigen and antibodies 
to strep tok inase  a re  d is tribu ted  through the populcition, varying 
widely in concentration . A ccordingly each subject was given 
an in itia l doae of streptokinase* individually calculated  from  an 
in v itro  sensitiv ity  te s t ,  to n eu tra lise  circu la ting  antibody to 
strep tok inase  and leave over enough free  strep tok inase  to induce 
a  b risk  throm bolytic sta te  in the p lasm a. S treptokinase 
adm in istra tion  was continued th e re a fte r  fo r a  period  varying in 
d ifferen t subjects from  40 m inutes to 26 hou rs, the dosage ra te  
of the continuing infusion being from  12,500 to 80,000 units p er 
hour. In all cases  xnarked plasm inogen ac tiva to r activ ity  was 
im parted  to the p lasm a by strep tok inase  adm in istra tion . The 
n ecessity  fo r individual in itia l dosage calculation is  illu s tra te d  
by the findings in  two of the subjects; in one, an in itia l dose of 
500,000 units produced a b a re ly  detectable effect, w hereas in the 
o ther a to tal dose of 480,000 units produced and m aintained fo r 
five hours high levels of throm bolytic activity  in  the c ircu la tion .
In  assoc ia tion  with the throm bolytic s ta te , a ll the patients showed 
evidence of hyperp lasm inaem ia , with low plasm inogen and fibrinogen 
lev e ls , /
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lev e ls , and prolongation of the th rom bin  clotting tim e and one- 
stage prothrom bin  tim e . In the patients in whom the assays w ere 
c a rr ie d  out, p ro throm bin , fac to r V and antihaem ophilic globulin 
w ere  also  reduced. A fter strep tok inase  adm in istra tion  ceased , 
throm bolytic activ ity  in  the p lasm a declined very  rapidly; in 
the patients in whom sam ples w ere taken one hour la te r , 
v irtua lly  no activ ity  was found. On the o ther hand, the 
duration  of the s trep tok inase  induced coagulation defect was 
many hours *
S evera l d ifferen t approaches to the problem  of choice of 
dosage schedule of s trep tok inase  a re  d iscussed . T here is 
suggestive but by no m eans com plete evidence that the m ost 
p ra c tic a l, though possibly  not the m ost effective, m ethod of 
s trep tok inase  adm in istra tion  m ay be by the 'p lasm inogen depletion* 
technique, in  which a fte r adm in istra tion  of a suitable in itia l antibody 
n eu tra lis ing  dose, therapy  is m aintained with la rg e  amounts of 
strep tok inase  designed to produce rapidly and th e re a f te r  to 
m aintain  to ta l, o r alm ost to ta l, plasm inogen depletion. In this 
c ircum stance  the coagulation defect is m ost m arked  n ea r the onset 
o i l
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of the infusion hut the re  a lte r  gradually  im proves, p lasm in  
being produced only at the ra te  m ade possiM e by the appearance 
of new plasm inogen in  the c ircu la tion  as it  is  synthesised; 
the ra te  of p lasm in  production in th is c ircum stance appears 
to bo w ithin the capacity  of the an tip lasm in  m echanism  to bring  
about rap id  n eu tra lisa tio n . Much m ore work is  needed to 
determ ine the b est m ethod of strep tok inase  adm in istra tion  in 
routine c lin ical c irc u m sta n c e s .
U rokinase, C hapter 6 gives a re p o rt of in v itro  and in  vivo 
studies with a com m erc ia l p rep ara tio n  of u rok inase , the 
physiological p lasm inogen ac tiv a to r p resen t in  no rm al u rin e .
The p rep ara tio n  was found to be a potent ac tiva to r of plasm inogen 
in  purified  sy s tem s, and also  to po ssess  esto roly  tic  activ ity  against 
to sy l arginine m ethyl e s te r .  S erum  was found to inhibit the 
plasm inogen ac tiv a to r and the es te ro ly tic  activ ity  of the u rok inase , 
the inhib itory  effect being located  in  the a lp h a -1 and alpha-2 globulin 
frac tions of the se ru m , to which the antipXasmins belong. However 
in  a easeinoly tic  assay  sy stem , w ith purified  plasm inogen as 
su b s tra te , se ru m  appeared  to ex e rt a  d is tinc t an tiac tiv a to r, as 
opposed to an an tip lasm in , effect.
S ince/
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S ince  hu m an  u r in e  is  know n to  co n ta in  t h r o m b o a s t i c  
a c tiv ity , th e  u ro k in a s e  p r e p a ra t io n  w as ex am in ed  fo r  co ag u la tiv e  
p r o p e r t i e s . I t  w as found to  s h o r te n  the  r e  c a lc if ic a t io n  t im e  of 
n o rm a l and H ag em an  fa c to r  d e f ic ie n t p la s m a , to  s u b s t itu te  fo r  
b3*ain e x t r a c t  in  th e  o n e -s ta g e  p ro th ro m b in  t im e , and to  su b s titu te  
p a r t ia l ly  fo r  a n tih a e m o p h ilic  g lo b u lin , C h r is tm a s  fa c to r  and 
p la te le ts  in  th e  th ro m b o p la s tin  g e n e ra tio n  t e s t .  O n e le c t ro p h o re s is  
on c e llu lo se  a c e ta te  th e  u ro k in a s e  p re p a ra t io n  s e p a ra te d  in to  a t 
l e a s t  f our  conq^onents and i t  a p p e a re d  to  be p o s s ib le  by e le c t ro p h o re s is  
to  ach iev e  a  p a r t ia l  s e p a ra t io n  of p la sm in o g e n  a c t iv a to r  from , th e  
co ag u la tiv e  a c tiv ity .
T he u ro k in a s e  p r e p a ra t io n  w as g iven  by in tra v e n o u s  in fu s io n  
to  fo u r  p a t ie n ts ;  in  e a c h  s lig h t th ro m b o ly tic  a c tiv ity  w as p ro d u ced  
in  the  p la s m a , and in  tw o of th e  s u b je c ts ,  d e fin ite  la b o ra to ry  bu t 
no t c l in ic a l ev id en ce  of eo a g u la tiv e  a c tiv ity  in  v ivo  w as found. 
U ro k in a se  Is know n to  h av e  *H agem an-like* e f fe c ts , w h ich  m ay  be 
due to  an  in t r in s ic  a c tio n  of th e  u ro k in a se  m o le c u le , o r  to  
in a d eq u a te  re m o v a l of th e  th ro m b o p la s tic  com ponen t of th e  u r in e .  
A lthough  i t  i s  p o s s ib le  th a t  in  v ivo  a t a  c l in ic a l le v e l the  eo ag u la tiv e  
p r o p e r t ie s  d e te c te d  in  th e  p r e s e n t  p re p a ra t io n  m ay  be o v e rsh a d o w ed  
b y /
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by the fibrinolytic effects of the preparation, which may possibly  
be devoid of haaard of producing intravascular clotting, it would 
seem  worth while for the manufacturers to attempt to produce 
a preparation free from  eoagulative properties.
In one patient in whom antibodies to urokinase were looked for 
after an Infusion and a subsequent intradermal challenging dose, 
there was no evidence of antigenicity, and in all four patients the 
response to urokinase in vitro was the same before and 10 days 
after the infusions, again suggesting that urokinase Is not antigenic. 
Activator or plasmin? There has been much controversy in the 
literature as to whether activator or plasmin offers the best 
approach to thrombolytic therapy, but the case for the use of 
activator seem s to have been established. Evidence to support the 
use of activator includes the observation already cited that 
preformed thrombi are relatively resistant to plasmin in the 
surrounding medium, but are sensitive to activator. Further, 
on the basis of the postulated physiological mechanism for 
throm bolysis, a sm all amount of plasmin w ill on infusion be 
neutralised by antiplasmin. To produce with plasmin a fibrinolytic 
effect in the plasma surrounding a thrombus, sufficient plasmin  
m ust/
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must be infused to neutralise circulating antiplasmin; that is ,  
it w ill be necessary to induce a hyperplaeminaemic state with 
all its deleterious consequences. Those who argue in favour 
of plasm in as a therpeutic weapon claim  that the plasm in- 
antiplasmin complex formed on infusion of plasm in is readily 
dissociable and constitutes a reservoir of plasmin which may 
be released  at the site  of a thrombus, but they have produced 
no good evidence to support the relevance of this concept to 
thrombolytic therapy in man (Ambrus and Markus, I960), 
Studies with plasm in preparation. Chapter 7 begins with a
description of in  vitro experim ents in which a comparison is  
made of streptokinase, urokinase and activât or-free plasm in  
as regards thrombolytic activity and ability to produce a 
coagulation defect. When m ixed with plasma the activators 
endowed it with marked thrombolytic activity but in the 
concentrations used, a coagulation defect was not produced, 
whereas plasm in, when mixed with plasm a in a concentration 
which did not cause detectable thrombolytic activity, produced 
a striking coagulation defect. In vivo and in vitro studies were 
also made with A ctase, a com m ercial ''plasmin" preparation, 
which/
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which was shown to owe the greater par-t of its thrombolytic 
activity to its content of streptokinase. When infused 
intravenously in the manufacturer's lecommended dosage 
to two subjects with streptokinase antibody levels in excess  
of the streptokinase content of the Actase administered, 
negligible plasma thrombolytic activity was produced. Clearly 
com m ercial "plasmin" preparations of this type must be used  
with the same criteria  for individual dosage calculation as 
apply to streptokinase.
Gomplamin, a nicotinic acid-theophylUne ester* was selected  
for study (chapter 8) as representative of a group of substances, 
them selves fibrinolytic ally inert, which when injected intravenously 
induce increased leve ls  of plasm a plasminogen activator activity; 
the mechanism responsible for the activator release is  not known. 
Evidence is  presented that* as with its parent substance nicotinic 
acid, the plasminogen activator activity induced in vivo by 
intravenous injection of Gomplamin is  intense but transient; a 
refractory state soon develops in which the response to further 
Gomplamin injections is  lo st. The response to a single Gomplamin 
injection was comparable in duration and degree to that observed  
after/
-150
after 5 minutes strenuous exercise  in the same subjects* Some 
subjects showed trivial increases in plasminogen activator 
activity after taking Gomplamin by mouth*
When two Gomplamin injections were given at an interval 
of 30 minutes* there was a much reduced response to tho second  
injection; sim ilarly when exercise  was taken twice at an interval 
of 30 m inutes, there was a diminished response to the exercise  
on the second occasion* However, when exercise  was followed  
by Gomplamin, or Gomplamin by exercise , a full plasminogen 
activator response to the second stimulus in each case, as w ell 
as to the first was seen* The findings suggest that the failure 
of response to repeated injections of Gomplamin was due to 
resistance to the drug and not to exhaustion of the body's reserve  
of plasminogen activator; accordingly it might be possible to 
find a pharmacological agent to produce a sustained rise  in 
plasminogen activator levels  in the plasma*
Fibrinolytic activity during surgical operation* In view of the
obvious possibility that endogenous plasminogen activator extracted  
from the tissu es or the plasm a might be of therapeutic use, the 
activity/
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activity of the plasm inogen-piasm in eystem  in patients undergoing 
surgical operations was studied (chapter 9)* one of the causes 
of the increased fibrinolytic activity found in such patients is  
thought to be release of tissu e activator into the circulation.
Ten patients were studied before, during and after excision  of 
the rectum, a procedure in which there is  much tissu e trauma. 
Although in no patient was there a clinical haem ostatic defect, 
each showed a marked increase in plasma activator levels  
accompanied by a slight fall in plasminogen and fibrinogen assays  
and a r ise  in the thrombin clotting tim e. Two patients with 
a serious haem ostatic defect associated with increased plasm inogen- 
plasm in system  activity were investigated. In each, increased  
leve ls  of plasminogen activator in the circulation w ere accompanied 
by depletion of plasminogen and fibrinogen, and a severe coagulation 
defect. It is  clear from the findings that endogenous plasminogen  
activator, perhaps of tissu e origin, can produce plasm a fibrinolytic 
activity associated with severe hyperplasminaemia, and that 
purified endogenous activator cannot be expected, if  made 
available for therapeutic use, to be free from risk of inducing 
haem ostatic/
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haem ostatic failure.
Studies with artificia l thrombi. The concluding chapter in the
th esis (chapter 10) describes in vitro experim ents using
artificial thrombi in which a number of factors affecting the
response of such thrombi to perfusion with plasminogen activator
w ere studied. Thrombi, trace-labelled  with tagged fibrin,
w ere prepared by allowing whole blood* mixed with a sm all 
131amount of I tagged fibrinogen, to clot in a closed  loop of 
rotating plastic tubing. Chandler (1958) showed that in such 
circum stances thrombi were produced which closely  resem bled  
pathological in vivo thrombi, with a white platelet rich head and 
a red tail with fibrin, red ce lls  and white c e lls . Radioactive 
thrombi made in this way w ere transferred after washing to a 
perfusion circulation com prising a pump, plastic tubing and a 
reservoir , where for 24 hours they were perfused with a solution 
of streptokinase in sa line. The thrombi were inserted into a wire 
basket in one branch of the perfusion circulation* the site of 
occlusion thus produced was by-passed by a length of narrower 
tubing simulating a collateral v e sse l in vivo. Patterns of 
radioactivity release during 24 hours perfusion with streptokinase, 
200 u n its /m l., /
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200 u n its /m l., were studied.
With thrombi produced from normal blood, after perfusion  
for 24 hours, about 60 per cent of the total radioactivity was in 
solution, 10 per cent was still attached to the basket into which 
the thrombus had been inserted, and 30 per cent was in fragments 
in the circulation. The fragments had a histological appearance 
suggesting their origin to be largely from platelet aggregates.
In the absence of streptokinase, or with the fibrinolytic inhibitor 
epsilon aminocaproic acid in the circulation, the thrombi were more 
than 90 per cent stable for 24 hours.
Thrombi made from  blood which had been artificially enriched 
with plasminogen were also perfused with streptokinase; ly s is  
was very rapid and alm ost com plete. When thrombi were made 
from  thrombocytopenic blood* ly s is  was also more rapid and complete 
than with thrombi from  normal blood* and thrombi from  
thrombocythaemic blood showed increased resistance to ly sis  
compared with norm al. The findings suggest that when thrombi 
are subjected to ly s is , the fibrin component d issolves but the platelet 
rich head breaks up into m acroscopic plat.elet clum ps. The 
experim ents/
-154.
experim ents with plasm inogen-enriched thrombi suggest that 
the platelets in these clumps may be held together by fibrin  
which is  protected from  ly s is  by the antiplasmin content of the 
platelets. In thrombolytic therapy, formation of such ly s is -res is ta n t  
platelet emboli would represent an important hazard in the 
cerebral circulation. Thrombi were also made from 4 patients 
with hyperlipldaemia, two of whom had normal euglobulin ly s is  
tim es and two had prolonged ly s is  times* The thrombi from all 
four were resistant to ly s is  in the artificial circulation and it may 
be that this technique can highlight abnormalities which are poorly 
or inconsistently reflected in other methods of assessin g  substrate 
responsiveness to the activity of the plasm inogen-plasm in system . 
Conclusion* Despite intensive investigative efforts in many 
laboratories over the past 10 years# the goal of routine thrombolytic 
therapy with plasminogen activators has not been achieved. 
Outstanding problems include the lack of suitable plasminogen 
activators, and the sid e-effects of those which are available; lack  
of suitable sim ple assay system s for control of therapy; 
uncertainty as to the best approach to selection  of dosage schedules
155-
and control o î  therapy; and ignorance of the effects of 
plasminogen activators on pathological thrombi in vivo. In 
the work presented in this th es is> a variety of plasminogen 
activators was used to investigate some of these problems in 
vitro and in vivo. While there is  still much to be learned  
before plasminogen activators can be used as a routine in the 
treatment of thrombo**embolic vascular occlusion, the problems 
are a challenge to the clin ical investigator# and from the attempts 
made to solve them should em erge more understanding of the 
components and functions in health and disease of the fibrinolytic 
enzyme system .
• - 156-
a c k n o w l e d g e m e n t s  .
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Figure Z shows i n  the upper portion an electrophoresis strip  
of a normal plasm a and in the lower portion an electrophoresis 
strip of the same plasma after addition of streptokinase,
100 u n its/m l. As can he seen from the strips, and the 
densitometer tracings made from them, the plasmin produced 
by the streptokinase has resulted in very substantial digestion  
of fibrinogen, The cellu lose acetate electrophoresis strips 
were run, stained and scanned as described in chapter 4.
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Figure 5 shows lack of correlation between euglobulin ly sis  
activity and plasminogen levels in 40 patients with renal 
disease (r = +0. l60, p > 0* 1), The figure is  prepared from  
table 30*
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6 s h o w B  lack of correlation between euglobulin ly^ie 
activity and fibrinogen leve ls  in 40 patients with renal disease  
(r = -0 ,2 3 2 , p > 0 , 1), The figure ia prepared from table 30,
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Figure 10 shows a cellu lose acetate electrophoresis strip of 
a normal plasm a to which a trace of fibrinogen tagged with 
radioactive iodine had been added. Also shown are an optical 
scan of the stained strip and an autoradiogram prepared from  
the strip.
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Figure 15. The effect of increasing concentrations 
of plasminogen on susceptibility to ly s is  in the 
plasminogen enriched radioactive clot system* The 
figure is prepared from table 34.
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Figure 17. Effects of streptokinase infusion in patient 1, 
chapter S. An initial dose of 155,000 units was given in 
the period shown with hatching and the infusion was continued 
with a further 45,000 units. The figure is  prepared from  
table 36.
I  1000
STREPTOKINASE INFUSION 
_______ 50,000 units/hr
A CTIV A TO R_L
EV)
§
I PLASMINOGEN
300
FIBRINOGEN
_ I _
THROMBIN TIME
TIM E, HOURS
Figure 18, Effects of streptokinase infusion in patient Z,  
chapter 5. An initial dose of 750,000 units was given in 
the period shown with hatching* The figure is prepared 
from table 37*
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Figure 19. Effects of streptokinase infusion in patient 3, 
chapter 5* An initial dose of 80*000 units was given in the 
period shown with hatching. The figure is  prepared from  
tahle 38,
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Figure 20. Effect8 of streptokinase infusion in patient 4, 
chapter A n  initial dose of 460,000 units was given over 
the first hour. The figure is  prepared from table 39.
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Figure Z l*  Effect© of streptokinase infusion in patient 5* 
chapter An initial dose of 2S0»000 units v/as given in the 
period shown in hlack* The figure is  prepared from table 40
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UROKINASE BY PLASMA.
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Figure 24, Effect of pWema in inMbiting urokinase in the 
fibrin pXate test. Mean values and standard deviations from  
observations on 18 plasm as are shown* The figure is  
prepared from table 42 «
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Figtiye 25* Effect of various serum  fractious, obtained 
by eiectropkoresis on cellu lose acetate, in inhibiting 
urokinase in the fibrin plate te st .
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Figure 26* Caseinolytic activity produced by urokinase
activation of purified plasminogen, with serum added in one 
ser ies  of experiments before the plasminogen and in the other 
experim ents after the plasminogen* The figure is prepared
from  table 43*
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Figura ZB shows separation of the urokinase preparation by 
eiectrophoreaia on colluiose acetate into at least 4 components 
in the buffer system  used (acetate buffer 0 , 1 Molar, pH 4. 5). 
These components have differing levels of fibrinolytic activity 
and may have differing coagulative properties,
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F ig u re  E9, Effect in  subject 1# chapter 6, of infusion of 
40, 000 units of u rokinase over I hour» shown with hatching* 
The figure is  p rep ared  from  tab le 6*
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Figure 32. E££éct i n  subject 4* chapter 6» o£ infusion of 
60*000 units of urokinase over 30 minutes» shown with 
hatching. The figure is  prepared from table 9*
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EUGLOBULIN LYSIS.
F igure  35 ehow0 the of£ect on euglobuHn ly s is  activity  of 
th ree  in travenous Injections of 150 mg* Com plam in given 
to a healthy subject at hourly  in te rv a ls . The figure is 
p rep ared  from  table 47,
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EXERCISE EXERCISE
c
3
EXERCISE COMPLAMIN
42
c
3
TIME,MINUTES.
Figttre 38 show^ in two subjects * the effect on euglobulin ly sis  
activity of 5 minutes exercise  followed at 30 minutes by a 
further 5 minutes exercise  (upper part of diagram) and on another 
occasion the effect of B minutes exercise followed at 30 minutes
by 100 mg# Complamin intravenously (lower part of diagram.)
The figure :1s prepared from  table 49^
\c o m p l a m in ; I “c o m p l a m in ."
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Figure 39 shows* in the same two subjects as figure 38, the 
effect on euglobulin ly s is  activity of ISO m g, Complamin in jected  
intravenously followed in 30 minutes by a second intravenous
injection of ISO mg, Complamin (upper part of diagram) and on
another occasion  the effect of ISO m g, Com plam in in jected  
in travenously  followed in 30 m inutes by 5 m inutes ex e rc ise  
(lower p a rt of d iagram ).
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PRECIPITATE)
EUGLOBULIN LYSIS 
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PLASMINOGEN
FIBRINOGEN
THROMBIN CLOTTING 
TIME
F ig u re  40 ^howe th e  e ffec t o%i th e  plaBm inpgen*-plasrniu s y s te m  
of e%ciàio$ï of the  r e c tu m  in  10 patieu ts*  M ean v a lu e s  aud 
s ta n d a rd  d ev ia tio n s  a r e  show n. The f ig u re  is  p re p a re d  f ro m  
tables 50 54.
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FIBRIN PLATE
( a r e a  of ly s is , m m ^)
EUGLOBULIN LYSIS
(m in u te s )
PLA SM IN O G EN
(c a se in  u n its /m l)
FIBRIN O G EN  
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W H O LE BLOOD 
C LO TTIN G  TIME
(m in u te s )
Figure 43 shows the course of a pathological ‘'fibrinolytic” 
state arising after spleno*»renal anastomosis and splenectomy 
for haem atem esis due to hepatic cirrhosis and portal 
hypertension (patient 12* chapter 9)# Ten gm, EACA were 
given over 4 hours# The figure is  prepared from table 56.
F ig u re  43 show s an a r tif ic ia l throm bus (length about 2 c m .)  
m ade in a C handler's tube by reca lc ifica tio n  of p la te let*rich  
p la sm a . The w hite head and the fibrin  ta il can be se en .
i# 'Æ
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# # «
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#
Figure 44 shows a longitudinal section through the thrombus 
illustrated in figure 43. The contrast between the organised  
cpral*like platelet head and the fibrin tail can be seen. 
Original magnification x 10. Stain p icro-M allory. 
(Photomicrograph prepared by Dr* F* Walker).
PUMP
THROMBUS 
HELD BY
SALINE
with STREPTOKINASE
STAINLESS STEEL 
GAUZE BASKET
200 units/m l.
Figure 45 is a diagramatic representation of the circulation  
used for perfusion of thrombi prepared in the Chandler’s 
tube.
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Figure 49. Naked eye appeaarance o i  iragïiiente released
into the artificial circulation after Z4  hours perfusion with 
streptokinase of a ^^normat" thrombus.
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APPENDIX 2 .
MAIN TABLES.
Tablo 1* Streptokinase in fu sion ss d e ta ils  of i n i t i a l  doses
.w .  'jA ’Ji AMsniaLU WL*,?#— . I.L
Estimated Streptokinase I n i t i a l
P a tien t
Number
plasma 
volume, ml.
concentration, 
im its/m l.
8 ti’ept okinase 
dosage, un its
1 5120 30 135,000
2 3620 240 750,000
3 2280 36 80,000
4 2290 200 460,000
3 3100 80 250,000
6 2028 SCO 350,000
Shoim are d e ta ils  of estim ated plasma volumes, streptokinase 
concentrations in  the s e n s it iv ity  te s t  giving a ly s is  time 
of 15-20 minutes, and i n i t i a l  doses adm inistered, for the s ix  
p a tien ts  given in travascu la r strep tok inase.
fab le  2 . Hydrolysis of TMle by urokinase,
(iM TAMe lysed in  50 minutes 
Without serum With serum
ta-Tw*TiI'liM * p j '# # iiw#i M"j 1 Wir 'M  W i x l ËËfëf NWW: ##!  *1 m ' ii'i  r  w  4i( " ........
160 153
160 75
210 20
153 95
145 160
165 56
160 170
15a 160
Motm t  ÜD 160.9  Î  32.6 114.4 -  57 .4
►ATK:;s<AamrSlTm^ïièef:.r*a*==:iç-a<ltfl*prTKU*ak.'*i
8hovjn are f#  TM@ lysed in  30 minutes by 
1 mg. urokinasog and the e ffec t of d iffe ren t 
sera  in  in h ib itin g  th is  a c tiv i ty . Mean 
values and standard deviations are a lso  
shown.
fa b le  3# Inhib itory action  of plasma on
urokinase iiii the rad ioactive c lo t  system
Percentage in h ib itio n  of 
urokinase a c tiv ity
w
32
10
6
28
26
34
12
19 
27 
22 
29
20
31
16
1
21
23
Mean t  SD 22.3 -  9 .6
Shoim i s  the in h ib ito ry  e ffec t on 
urokinase of plasma from 20 d iffe ren t 
su b jec ts§ te s ted  ixi the rad ioactive c lo t 
system• in  each ease 0*3 ml. urokinase,
20 im its/m lç v;as assayed a f te r  addition of 
0*1 ml, plasma g and a c tiv ity  coinpai'ed with 
th a t produced by itrokiiiase to  which sa lin e  
had been added*
Sable 4. Goagulatlve a c tiv ity  of urokinase with 
normal and Hagemanmfactor d efic ien t plasma.
'Urokinase H ecalcification time, seconds
c oncentration  ^  Normal Hageman
(u n its) in  te s t  system Plasma plasma
0  246 825
2  -  5 8 5
5  -  540
1 0 461
2 0 333
4 3 *?> 3 1 3
9 0 2 3 0
1 8 3 2 2 0
373 1 3 0
750 248 1 3 8
1 3 0 0 2 2 8 1 3 0
3 0 0 0 2 1 0 w#
6 2 3 0 2 0 3
12300 1 9 2 «5t
2 3 0 0 0 173 »
3 0 0 0 0 1 6 8
1 0 0 0 0 0 1 6 3
Shown i s  the e ffe c t of urokinase on the re c a lc if ic a tio n  
times of fresh  normal plasma axicl Hageaian-factor d e fic ien t 
plasma. In each case a saliJiio contro l i s  a lso  shovm. 
l^eats were carried  out in  the presence of EACA a t  a 
concentration of 10-2 Molar to  in h ib it  ly s is ,  The data for 
the normal plasma are graphically  displayed in figure 27®
CÇabXo .3* The e f fe c t  o f lu-oklnaso in  the tliromhoplastin generation t e s t
3}hroiïîboplastiïi gen era tio n  te a t  
G lottlxig tim es (seconds)
Incubation time5 mina, 1 2 3 4 3 6
Normal plasma* Normal serum» 3^ 10#3 , 10#3 11 11 11
P la te le t s
Normal plasma* Without
UhristfBàB serum UK 171 l 4 l  139 l4 0  11? 84
Platelets With UK 113 100 96 80 ?0 34
Haemophilio plasma* Without r  -^i
Normal serum UK 29 >1 :>0.5  31
P la te le t s  With UK 74 42 . 43 2 6  26*3 26
Normal plasma and serum on in
(d ilu ted  1:4) P la te le ts  21 17
Moriiial plasma and Without „ o  , , ,q .j.f, ,,.,.|
serum (d ilu ted  1:4) UK  ^  ^ ^27 101
Wo p la te le t s  With UK 112 106 100 92 92 88
UK « Urokinase
Effect of urokinase (10,000  m iita/m l) in  the thromboplastin 
generation te s t  in  p a r tia l ly  correcting  defects duo to  a n ti-  
haemophilio globulin* Christmas facto r and p la te le t  deficiency* 
Ihe te s ts  wore carried  out in. the pjrosonce of ÉACA a t  a 
concentratioxi of 10^^ Mqlar*
Sable 6* Biochemical e f fe c t s  of urokinase infusion*
'sSiO of Sampling thoura?
0 X a '^  3 #
o 159 0 0
Fibrin p la te  ^ 2,,o g4 q 0
teat (mmrV
îiiiAglôbulia lyaia  
(un its) 0,85 1.53 1.07 0.81 0.76
'1 u n l t % S
I'ibrtaogen gyq 262 268 271
(% A % i)
10 .5  10.3  9 .5  9.5 10.5
16.5  16 16.5  15.5  15.5
134 135 131 128 l48
ilix^ombin time 
(sees)
Prottoombin time 
( secs.)
R ecalcificatlon  
time (eecsi *
143 168 173 174
Ctea-stmae fac to r ^^2 I I 9 104 IO6 126 
assay VaecsJ
Bffect in  subject X* Chapter 6 * of infusion of
40,000 u n its  of urokinase over 1 hour* % e data 
are displayed in  p a rt in  figure H9*
Cephalin added
2?able 7# BioohemieaS, e f f e c t s  o f uroklnaae infusion
Sifae of sampling (hours)
0 1 2  3 4 .
Activator Aasay ^ n
(oom W l O O  sou) ® °
Fibrin plate >. ,v
te s t  Cmra2 ) 0 0 100 0 0
^^^f«nlt-)” 0 .72  1.45  1.52  ' 0.84
% % )  2,9 1.8 ^ 1.4 2.3 2.6
' S / S i )  240 235 220 198 210
Frotlirombin time 
(secva) 16*5 16*0 16,0 15.5 15.5
ReoaXoification „qn it-n irinlo7 1 3 0  Xp5 I p ?  172
171 176  160  174  17a
1 4 9  1 4 7  105 106  X I5
time (aeosd
AECI assay 
(seco-)
Ghriatmae fac to r 
aeaay (sooa)
.##*l#;.3XW kiA=ï:Ÿ3ka45aia&;3a*#K3U^):LaLM#t#3M«à#W «-f
E ffect in  subject a@ Chapter 6, of infusion of
80,000 u n its  of urokinase over a hours, lîhe data 
are displayed in  p a rt In  figure 50*
liable 8# Biochemical o f fo o ts  of urokinase Infusion
Time of sampling (hours,
0  i  2  3  4  2 1
Fibrin  p la te  0 70 0 0 0 Q
t e s t  (mm^)
m globum i 0 *96 ' 2*5 1*06 O.99 1,09  0.99
ly s is  (im its)
Plasminogen" 2*6 2*5 2*5 2 .3  2 .4  2 .5
(units/m l)
Fibrinogen 167 172 I58 I 68 I 72 181
(mg/lOOml) ,
B ecalolfication 82 52 44 37 66 108
time (seasj *
Thrombin time 10|  11 11 11 11 11
(secs)
Factor V assay 100 33 45 18 100 100
(per cent)
Am assay 126 85 86 87 119 111
(seca)
Christmas facto r 115 66 56 62 105 110
assay (sees.)
E ffect in  subject 3^ Chapter 6 , of infusion of 
. 80 , 000. u n its  of l^rokinasa over 1 hour* The data 
are displayed ân p a rt in  figure 31*
* Cephalin added.
Table 9 , Biocliemical e f f e c t s  of urokinase infusion,
Time of sampling (hours)
0 I  1 13- 2& 34
A ctivator assay 0 97O 16B 209 36 0
(coimte/lOO eea)
F ibrin  p la te  0 210) , A n
test ( « 2 ) :i9S) 24 9  0  0
Etiglobulin ly s is  1*03 2,82  1,92 1.33 I . I 8 I .03
(un its)
Plasminogen 3*4 2.9 2,1 2,2 2,6 2.8
(units/m l)
Fibrinogen BlS 208 154 I 96 2l4 220
(mg/loOml)
Protbï'pmbin l6*0 16*5 15*5 15*5 15 15*5
time (secs')
AEG assay 1?8 1?3 . 1?8 180 182 179
(secs')
Christmas fac to r 156 152 155 16O 155 151
assay (secs)
E ffect in  subject 4  ^ Chapter 6, of infusion of 
80I000 u n its  urokinase over 30 minutest The data 
are displayed In pai$ in  figux^e. 32 i
Table 10, ÎJfrokânaso se n s itiv ity  te s ts  
before tmâ 10 days a f te r  urokinase isifusion
Bubjeot ly s is  times in  urokinase se n s itiv ity  te s ts
Numbex*   __ 10 days a f te r
infusionBefore isifusion
1 , 12 miïXSs 15 sees* 10 mins# 45 aeca .
a l 4  mine* 25, aOOSa 12 mins# 10 se e s .
3 10 mine* 3 0 see a* ,11 mine# 30  eeca.
4 9 mins* 4o sees# 8 minse 55 8GC8.
SîiQvm fo r the 4 subjects (Ghaptor 6) given urokinase 
infusions ai'o the urokinase se n s itiv ity  te s ts  before 
and 10 days a f te r  in fusion .
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Table 3.2^  F ibrin p la te  t e s t e  with streptokinase and Aotaee,
Test BubBkmoe toea of ly s is ,
©m
Sti’optokinaoe solution# 10® 44o
10 units/ml* # with human 3® 380
plasminogen# 1*3 unite/m l S3% 288
12*3^ 180
6 *23# 110
çÈkLiiliûtïTr#3r»*î»t¥M0*5e«5^7'«<?$«^.^*SlPS'G=VecArs^î#7!riaL*v:$T^
Aotnss so lu tion  ls l,5 P 0 360
iB#ooo 256
Aotivator^^fi'ee plasmln^
I B  units/ml 20
i  I 'Iff lift
Bho\m are experiments designed to  aseoaa the • 
atreptoklnaae content, o f a v ia l of Actase,
Cornea of I j a l s  with a e r ia l  dlXutlona of a streptokinase 
so lu tion , 10 m its /m l, to  wMoh 1*3 im lta/m l of human" 
plaeaîinogon had been added to  simulate the plaamln 
content of Actaae, are shorn together \rith  aonoa of 
lyaiB with two cuiutions of m  Aétaàe s^olution ©ado by 
diaaolvlng the contents of 1 Vial in  10 ml saline*
Also Ghom i s  the neg lig ib le  ly s is  produced by plasniin 
on i t s  Qvm* By intex’pol.ation in to  thé d ilu tio n  curve# 
the 1s i #500 d ilu tio n  of Aot|^e appears to  have a 
streptokinase conaontm tlon ' of 4*2 units/m l and the 
10#000 d ilu tio n  2*25 im its/m l giving a streptokinase 
concentration per v ia l  of 63#000 and 6?#300 u n its  
respectively*
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Table 15* Plasaiiiogeii assays a fter  Gomplamin Injection*
Subject Plasminogen aeaay# imits/m3, at varying times (mins*)
Number a f te r  ^Injection 
0 5 10 30 60 120
1 2,8 2*3 3.0 2*7 3.2 2.8
2 5.0 2.8 2.2 2.3 2.6 3*0
5 2.8 2f S 2.2 2.4 2.4
4 2.9 2.3 2.3 2*3 2.4 2*7
5 1.9 2.1 2*0 2.0 2.2 1*9
6 3.2 3.6 3*4 3.2 3.3 3.1
7 2.7 2.5 2,9 . 2,8 2.7 2,6
Mean - i.U. 2.8 -  0.4 2.5 2 0.5 2,6 t  0.5 ■2*5 “ 0.4 217 ” 0.5 2*6 ” 0.4
Plasminogen levels in 7 healthy subjects before and at varying 
times after intravenous :lnjeation of 150 mg Gomplamin. Mean 
values and atmdard deviation are also shoim* The fall in 
plasminogen levels from the ^êro saiîiple to the 5 minute sample 
is not significant (t 1*871, 0#4 < p > 0*5)*
Table l 6 .  Fibrinogen a fter  Oomplamln in je c t io n .
Subject
Number
Fibrinogen assay, (mg/2.00 mi) a t  varying 
times (irtiiîs.) a f to r  in jec tio n
0 5  Î 0 30 60 120
1 240 227 213 226 248 246
2 207 205 203 206 196 206
2 250 236 240 .255 260 232
4 228 196 220 244 214 244
5 267 194 200 ,203 229 263
6 348 356 372 , , 321 345 301
? 287 294 276 269 292 298
Mean * 8,D« 261 “ 48 244 Î  60 2% X 61 247 -  39 255 -  51 259 -  :
Flbrm ogm  levcla  in  ? h ea ltlg  aubjêots before and a t  varying 
times a f te r  intravenous in jec tio n  of 150 mg, Oomplainin*
Mean values and standard deviations are also  shown® The f a l l  
in  fibr^xaogen lev e ls  from the sero sample to  the 5 minute 
sample I s  not s ig n if ican t ( t  ^ O^ ÎpSS# O.5  < p > 0 .6 ).
Table 1 ? . E ffe c t o f exoroieô on plasminogen lev e ls*
S ub jec t Plasminogeii a s sa y , « n its /ra l , a t  vary ing  tim es (m lns) 
Number l a  r e la t io n  to  e x e rc ise
B efore 0 5 20 5 5
1  2 .8 2*6 2*9 2 .7 3 .0
2 3 .0 5 .1 2 .9 3 .0 3 .2
3 3 .1 5 ,6 3 .2 2 .8 2 .9
4 3 .0 3 .1 3 .1 3 .2 2*8
S  2 .1 2*3 2 .2 - 2*2
6 3 .3 2*9 3 .6 3 .2 3 .1
?  2 .6 2 .3 2 .4 2 .7 2*3
Mean -  8.D . 2 .8  -  0 .4 2*8 1 0*4 2*8 Î  0 .4  2 .9  -  0 .2 2*8 — 0 .4
m t l f i mlMTWuAkT I »# 4*<W#:^ #3RapW!*A.i * ,* ', i] I ■ , B'l 'idNM   ...........................................  Wita#EiaW3m OV^ W«2Xy*^!\V nTW %#WA##**#a:»w
Pl&isndjnogen le v e ls  in  7 h ea ltîiy  eu b je c ts  b efo re  mid a t  
Varying tim es a f t e r  S  m inutes exercise*  Mean v alues and 
standm^d d e v ia tio n s  a re  a ls o  ahovEi
Table l8* E ffect o f exorcise o n  fibrinogen le v e ls .
Subject
Number
1
a
3
4
3
6
Fibrinogen assay#, mg/lOOml# a t  varying times 
(m:lùBç) in  re la tio n  to  exercise
20Before 0
, 242 .220 231
2G4 .221 207
. 24? .229 251
, 211 207 220
; 245 ,256 251
. 330 .340 321
296 
254 t  38
285 
251 Xl
292
:-7 253 -  ^
209
256
205
T
532
55
245
198
266
199
240
315
W£aW3T«»iJ*.
253  “ 46
Fibrinogen levels In 7 healthy subjects before and at 
varying times after 5 minutes exercise* Mean values and 
standard deviations are also shown*
Table 19# F ib r in o ly tic  e f fe c t  o f  Gomplamin infusion*
t*Œs4fisa«-nebï>wîïj*®wrfrrf.te*
Time Subject 
(mins*) Number
Fibr:ln p la te
sest
0
10
1
2
1
2
imnr)
0 
0
289 
380
Radioactive 
c lo t te s t  
(cotmts/lQO seca)
Buglobulin 
Xyaio a c tiv ity  
(tm ite)
0 
0
479
332
30
60
1
a
1
2
4 a
3 6
30
23
103
52
97
17
0*9
1 .7
'ik"M*i It W MtW ÊirÈiP
• 6 .7  
8.1
i' i^ ni# n iii|-i n i w i'W MViin
1.9
2*3
1*1 
2.1
■ ■ I ' l i i't f T i v w m n i i r i i i ' a i ' i i i i ' p N i P  •> * ' i ii # # i  n r  r  ' j r i i T i i n #  ' r j r i f  • t i t t i — y - # ' - - - - - - - - - - - - - - - - - - - - - - - ^ n — * " - i * T # - r ^ ' i n r - r # i " i  m  r  j ~ ~ ~ r ~ f ~ r T  ~ r r ^ i r  i i  i m  • '  i ' ^      n y i r  h i i r  - i  i  • ~ i i ~ ~ r - - - - - - - - - - - 1 - - - - - - - - - - '- - - - - ' - - - - - - - - - " i  r ° i n f h r r
90
120
X
2
1
2
0
0
0
0
0
0
0
1.0
1 .9
1*0
1*8
Shovjri are  the e ffe c ts  on f ib rin o ly tic  assays of 
intravenous infusion of Ooinplamin in  two subjects*
In each case* fo r the f i r  e t  30 àins*', 15O rng was 
infused# 300 mg fo r the second 30 mlns*# and 6QQ mg 
fo r the th ird  30 min* period. The data fo r p a tien t 
1 are presented graphically  in  figure 37. For both 
subjects# v aria tio n s  in  ono-stago protiirombia time 
and ^lirombin c lo ttin g  times a t  no point were greater 
théùi 1 second.
Table 20* The effect on euglebuXia lyais activity 
of Oomplaniln taken by mouth*
Subject Wuiïiber of Euglobuliii Xyaie Cimita) at vtaryitig 
Humber tablets tinios (mmutea) after Ingestion
1
0 10 
a  2 # o
30
2*5
6o
2.0
120
1 .9
240
2.1
2 2 l .X 1*2 1.0 0 .9 1.1 1;2
3 a 1*0 0 ,9 1.3 1.0 1.2 1;1
h a 1#5 1 . 4 1.6 1,5 1 .4 1 . 4
a 4 1 . 4 1 . 3 1 .5 1 .4 1.2 l ; 3
3 4 1*1 1 .4 1 .5 1 .9 1 .3
4 4 1 . 3 1*4 2.6 2.5 1 .5 1 .4
w ii  ni •: y u *  a ;w L *i .î*njAi*LftCTj-p*te»
Table SI. Comparison of the e ffe c ts  of a v ario ty  of 
plaismilnogon activât ora*
lïXiglobulin Pla&mi&ogon Fibrinogen Riao in  
lyniD a c tiv ity  (unita/m l*) (mg./lOO ml*) thrombin 
(u n ita ) time (secc .)
Btx’optoklnaao 
(to,bio 41 )
Urokinase 
( ta b le  9)
Ociiîplamin 
tab les  13ÿ16*45)
Exercice
( ta b le s  17 , 18 , 46)
Bnrgieal operation* 
mean of lo  p a tien ts  
( ta b le s  50-54)
Bargl oal oporation 
(tab le  55)
6*0
7^ 9
5*6
3*S
10*
1*0
D’,9
S‘5
2,8
2,4
0
m
244
251
45
0
0
1*0
8T
Shovni 6iro oug’lobulin  ly a ie  a c t iv i ty , plaominogon and fibrinogen lev e ls  
and the rieo  in  thrombin c lo ttin g  time from pro^treatment or normal 
lev e ls , in  m bjoote with fib n in o iy tio  a c tiv ity  induced by a v a rie ty  
of oiroamotanoeç*
Whole c lo t ly s is  time, expressed in  the same m&ts,
22* Flasminogen and fibrinogen lev e ls  in  
normal subjoots from whom Chandler* s 
thrombi were prepared*
# a a p a * * * w i K * " * j
C*.Subject 
nuïtîbor
Fladminogon #brinogon  
(units/m l*) (mg./lOO m l,)
1 2.9 384
2 8.1 , 296
3 8.4 310
4 2 .6 293
5 2.3 225
6 .2,7 270
7 2*3 286
Xyais o f  thmnhi i n  tW  n r t l f i o l a l
Typo of % #ont% ga of t o t a l  m d io a o tlv i ty
thrombus
Ï 11 G oiution Xn fragtnonto' At s i t e  o f
inoortio#
1 0  t  g , 5( t  subjects) 
f o im l , a
i  6
8
88 #
without BIC b la 6
Normal, a 93 ?
plasminogen
enriched b 9 5 . 4
Nonaalj a 8 10
with EAOâ h 1 18
Bhovm a re  p a t te rn s  o f  d ie t r iM t io n  o f r a d io a c t iv i ty  
a f t e r  perfuE&o# in  tlxo a r t i f i c i a l  o ir c u la tio n  o f thrombi 
prepared  in  th e  GhaWior* a tube* For th e  normal thrombi ^ 
mean V alues and standard  d o v ia tlo w  a re  #own$ c a lc u la te d  
from th e  d a ta  p resen ted  i n  ta b ic  5?# T*>e date, a re  
d isp lay ed  in  p a r t  i n  f ig u re s  4 8 # 58 and 53*
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Kbçperlmmt
oWbor
A ’É i l l  l i )
Poroo^taga o f  toto% trailloaàtiviisr'' 
in  a o la ilo #  a t  varÿ log  tiRiao (hou rs) 
a f t e r  0 ta r t  of porfuoiomb
' 1 - 2  ’ 3 4
a i n fip L?.!li < ^ '  m* M *1 j  i ,ifcp> ■»■< i n h<i #1#
3& (><J 93
42 72 83 95
Bhowr^  are  the povo^ ntugm of to ta l  raâ io ao tiv ity  
in mlxitUm a t  ' V ar# %  timoo a f t e r  the 8 ta r t  of 
poifuoion with mtroptokl^aso of pla^mimogom 
em*iched thromM# % e data are presented in  
part in  figu re  53*
86$ hyeiè o f thi?on)bi in  tho a r t i f i c i a l
o lrm la tlo n *
%_P8 of 
thrombus
Porcentag’a of to ta l  ra d io a c tiv ity  -
Xn so lu tion  In  fragments At s i te  of
InBortlon
Thromhof. a 3? 12 1
cyfeopenio b *f€ IT 7
#hrombo^ 0 kl 47 12
oythaemio d 45 39 16
Shov'm 03^  patt&rno of d istribu tion , of ra d io ac tiv ity  
a f te r  perfusion in  the  a r t i f i o i a l  o ira tila tio n 'o f thrombi^ 
prepared in  the  Chandler*# tube^ froiii two patien t#  with 
a low p la te le t  count ami from two with a high p la te le t  
count* • R em its from patien ta  a  and c are  shown in  
figure 93#
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% bl8 88,4 byoi# o f thrombi in  tho a r t i f i c i a l
c ircu la tio n .
rp o Percentage of to ta l  rad io ac tiv ity
u irom no in  so lu tion  In  fragraento At s i te  of
insertion
lipidaemio
patient#
1 43 9 48
2 30 20 42
3 ^ 87 81 52
b 33 25 42
4 82 17 61
y * " * ( k t »#w# j i #X ,L$,
ai    „ ------ --- - -..-. , .....   -........ , .
c ircu la tio n  of thrombi ^  prepared ao described in  the 
toasts from 4 patien t#  with raised  scrum lip id  level# 
(aoG tabloB 24 and 2?)+ P atien t 3 warn studied on 
two occasions*
f a m e  2 9 ' of tWombl in  tho a r t if ic ia l  circulation.
P ercen tage o f t o t a l  r a d io a c t iv i ty  In  s o lu t io n  
Bubioet a t  v a ry in g  tim es (hours) a f t e r  th e  s ta r t-  of
number perfusion*
4 8 12 20 24
1 38 SI SB 62 64
? 30 42 SO 56 58
3 32 47 58 65 61
4 43 S7 0 61 69 (70)
5 38 52 60 65 61
6 21 40 47 38 53
7 31 43 47 34 56 (55)
4Mean t  8.D# 34 ~ 5*5 47 & 6 .3  54 ^ 5,9 60 t  6 , 1 2 t  6.3
Bhovm f o r  thrombi from 7 n o m a l àubjootrj a re  noroentageo 
o f t o t a l  r a d io a c t iv i ty  in  so lu tio n  a t  v a ry in g  tlmoo a f t e r  
s t a r t  o f poi^*u#ion w ith  stroptokiim eo* % e  d a ta  a re  
g ra p h ic a lly  d io p la y #  in  f ig u re  0 »  Por ouh jao t 4» th e  
f ig u re  in  braoketo in  th o  24 hour column r e l a t e s  to  th e  
fin d in g #  a t  30 heure in  th in  m h je c t ,  xvrokinaee^ 800 un ito /m l*  
having h em  added to  tîio perfim ion f lu id  a t  84 hour## and 
f o r  m h jo c t 7 th e  f ig u re  in  h raek e te  r e fe r#  to  th e  30 hour 
fin d in g #  ^  f u r th e r  ntaTeptoî^mee» 200 un lta /m l*  h av l%  been 
added to  th e  p erfu e lo n  f lu id  a t  24 hours*
a p p e n d i x  3.
SUPPORTING TABLES.
m m e  3 0 * EügloWliii ly s l#  a c tiv ity  and aBaoelated fac to rs  
in  p a tien ts  witli ronaX disease*
P atloat Etglobulin D%brln
ITutnbcg ly s is  a c tiv i ty p la te  te s t l^brinogen Plasminogen
(u n its ) (area og lyaio  
■ m  )
(mg./lGO BÛ.#) (u n its /m l.)
1 <  0 .2 a 854
2 0,47 54 260 0 .6
3 0 »4i^ 0 487 1 ,8
4 0,38 83 395 1 ,6
3 0.62 Î5 307 2 ,1
6 1 ,10 90 204 2 .7
1 0 ,63 90 143 3 .0
8 2.60 90 495 2.1
9 1.62 83 315 2,8
10 1.30 30 . 490 3 .6
3.1 1,33 148 387 3 .5
12 <  0 ,2 0 307 1.6
<  0 ,2 0 347 2 .9
14 0,79 3 338 1 .5
15 1,36 115 173 2*2
16 1,36 105 330 2 .8n 1.50 144 226 2,8
18 0.80 Ù 283 3,2
19 0*73 0 145 0 ,8
20 1.23 53 270 8 .9
81 1.20 115 230 2 .7
22 -c  0 ,2 0 517 2 .4
23 0.97 0 875 3 .7
24 •c 0*8 0 # 8 2.4
25 0.87 2B 190 1.5
26 0.77 33 430 2.2
2% 0.94 38 238 1 .7
28 <  0.8 0 632 2,4
29 0.23 0 280 2,0
30 2*0 126 240 2.2
31 1.23 63 835 2 .5
32 0,93 0 812 1*4
33 0,21 0 493 1,0
34 1.67 25 385 1.2/
35 <  0 ,2 83 45s 1*4
36 0.88 0 510 ' 1 .8
37 0,23 49 323 2.0
38 0,51 83 227 1 .7
39 0.82 84 418 8,0
40 <  0.2 23 333 2,5
Shown fo r  each of 40 p a tim te  with a  v a rie ty  of acuto and ohron: 
renal d iseases i s  tho ro la tionsh ip  between euglobuiin ly si 
f ib r in  p la te  t e s t ;  and fibrinogen and plaominogen levola* 
are  graph!oaliy displayed in  fig u re s  4$5 and 6#
s aotiv ity ; 
%io data
fabXe HeXationship betweon fibrinogen levels
‘and thrombin clotting time#
G lotti^  time Relative concentration 
(sece#) of fibrinogen (per cent)
14 100
33 50
50 65
U5
Shown i f  the relationship between thrombin 
clotting time and fibrinogen concentration 
using a purified fibrinogen solution# The 
fibrinogen concentration of the undiluted 
solution was ^62 mg#/lOO ml* %e data 
are graph!cally displayed in  figure 7*
Sable Reiationship in # h a # o #
$ #  ré % # fe  o f ru d io a o tiv ity  i n  th e  
m d io à ù # #  q l #  test.f.
s.
Oeonte/iOO aeoondo after varying incubation times (mine*)
Î0 ao 30 40 50 60
sa? 821 1098 978 1588 15#
§97 946 1359 1876 1202 1455
471 1043 # 7 6 13.27 1072 1106
§73 1136 819 1252 1423 1263
706 693 1105 i l l ! 1331 1551
662 870 1010 I486 1404 1646
487 774 116© 1238 1 0 9 1392
0 3 830 1089 1237 1 0 0 1415
# 2 181
Shorn are pattome of m # o a # iv ity  r e l# e e  in  the 
plasminogen e n r io h #  m dioaotive o io t # W  n f te r  
intubation # tb  0*5 mi* atreètôkinaee oointion» go units/mls
The -d a ta  .a re  d i s p la y e d ,  g r a p h i c a i i y  i n  f i g u r e  13 #
31# She correlation betweon radioactivity release  
mà  ty ro s in e  re im é o  in  th e  ra d io a c tiv e  o lo t  
àoeay eyetém#
5 724
*1 m  49,2
'",3 . 1359 51,9
45,6
100 8&Q, ' , eonteïit 1 #  bci'o»
i m > )  W e,) '
0 , 8  407 35,6 . .978
# , 5  471 37,5
397 0 , 4  1232
21.,2 662 43.0
27,5  706 49 ..I i 486
527 36,8 1072
17,3 573 36,4 1.202
#.,8  693 ■ 43.7
33,7 1043 46.7 1252
33,4 110 42*0
24.8 870 51,1
24*1 821 46,0 1405
29.8 819 32*5 1106
35,6 1010 49*3
37*4 # 7 6  43*2 1392
35,6 1109 49*6
34.9 109s  56,3
®i© MBisl-fes w s  d ia p l^ a d  gm pkioaliy  in f l ^ ? e  14»
S a b le ,34* R e la tio n sh ip  betwçen plasminogen co n ten t 
and l y s i s  o f  rn d lo ao tlv a  c lo ts#
IW loâotlve c lo t toots fXg* fibrin  
Volit# of lÿoM/hénr \7ithl
Mdoct (mlf) M in e ■ Stroptokimoo llroitimOB
$op  iti/mif ‘ 500 u#/mlf
0 2 7 1 0 0 2 1 5
m 5 4 2 0 3  . 3 3 9
0 » S 5 5 2 2 4 0 4 2 1
0 ,3 5 5 1 3 9 5 5 3 4
0 ,4 5 5 6 4 5 0 616
% e e f f e c t  i n  th e  ra d io a c tiv e  c lo t  t e a t  of in c re a s in g  
ooncontmtionç of pleminogen #  the clot# The 
plaeminogen need m n  # Kline type preparation# 
conoentratlon 9*0 linite/ml# The data ere graphically 
d i# iayed  in  figure ig#
35* b.oiweeh urokinase oDucentration
mû lysis of radioaotivo clots#
Urolçinaso pg# fib rin  lyaed/ml# tost solution/hour
(tiBltè/mlf) l\ip lioatê Mêan
amsagm* value*
g 32 60
80
149
i n
609
?ao
6 #
740
gp6
# 3 6
50 U76 I4)g
Siiom i s  thé effect of imoreaei% quantities of utohAitase 
in  t h e  p l$ # im o g e m  e n r i c h e d  m d i o a o t i v a  i o d i n e  l a b e l l e d  
0lot syetm# %m the same e^porimont plamin, oouqantratiou 
T unite/ml 9^ : produced ly e ié  of a moan of 81  ^ ug*. fibrin/hour 
(23E miû 19s ug*)* The data are gmphloally diepleyed in 
figure 16*
Table 36# B io e te é o a l e f f e c t s  o f  stroptofeinae.a Infusion#
, 'f im ç 'o f  sampiing 
O' êO 'fô in s#  6 0  m ina#  8  h r s *  4  hpm 04  t e a *
Activator
a e # y  0 0 40I Si 0 0
{oouats/iOD 0ÔOU#} 
wiielo oXot
ly e ie  time 7 48 > 48 18 : Î4 >  0  7> 48
(hours)
W ia  time 0 0  3gO 1® IS i ()80 355
)
8Si2%îo 3.4 0.0 # 0  1*2 3.2
FiW m gen
[mgè/100 ml
m
140 1<)0 155 ^10
Êbwa'bin Urn #  19 18 16 10
iseoe#/
8 h#m  a?a i& m  M o o h m io u l changes induced in  p a t ie n t  1 by etroptokim m # 
in fusion#  Am. i n i t i a l  dose# 155.#Q00 u n its#  tim  given- over th e  f i r a t  
00 roiimtea and 4$#0# unité oyer - thé suçeseding 40 miuut#* # e  
d a ta  o re  g ra p h ic a lly  p resen ted  im übxvù # *
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e f f e o t  o f  .Blasma m% t$%*oîd,mo0 in  
% m  plato tOBt.f
Pias^sa - 
ïiimboi? voMime of
of urQlciiiaoo a # iv l ty  with tlio 
piaoiaa p m  miiit of laWclmGo,
3 pi* 10 pi* 15 pi# 80 pi* S3 fil* 30 pi*
1 ■ 03 f l 91 100 100 100
2 . 6a 09 98 100 100 100
3 55 04 98 100 mo 100
h 25 50 98 80 100 100
5 ■ 51 03 '  90 ÎQO 100 100
6 6 go 94 96 100 100
? 59 08 97 100" 100 100
Q g6 48 9Z 100 loo 100
9 i f 84 m 52 ■ 88 90
10' 0 10 - 08 64 92 99
11 a i f 76 68 90 99
im 17 41 93 88 lOQ 100
13 40 31 93 100 100 100
14 10 86 88 76 100 100
19 ■ 18 37 98 100 100 100
M 3S 48 93 84 100 100
i f 45 58 94 91 100 100
18 0 49 45 # 93
mmA$, sa*  Î  ga 43 * ao 8# 2f 15 8g % 18
iL'i f UM 11# r f | n.'
9 9 - 3  99 % 3
SIwêi fm  %8 plam iae I0  tlio pero0#tago â tih ib itio ii o f
%oki%80 1# f l# W  pW o to$% pszD&w# % varying
prapa#lom 0 o f  plooma and nrokWaoow Witti more # m  30 n l» '/m ilt 
o f  ^mkimàBÿ % # p a r  o#nt In b fM tlo n  was alt/ayo àoea» Porcontogo 
in h ib i t io n  w o  o a lo u la to d  by roforenoo to  3 iirolsim oo d i lu t io n  
%0 data are gmphioaliy praoonted in  f l^ r a  2k*
# #  -action on nroWimsa in  a
oaoainoiytla a a o #  a y # # #
numbQr
OptWai d m a i#
before ^ m ^ û im ^ é n
I n  oaoolnoiytlQ aemy
Sortit # # d , 
after  -plaeminogen
1 0430 0,175
a . 0-460 0,185
1 8,170 0.808
4 ,0*155, 0*163
5 . 0*157 0460
Ô 0414 0*140
? 0493 0*872
8 0*240 0*863
9 ■ '0,191 0,220
m 0*204 0*875
# 0,215 0.830
12 0,810 0496
13 0,804 0,829
14 , 0,158 0472
.15 0438 0*172
16 0*125 0,127
17 ' 0*107 0,113
10 . 0. 168-■ 0,152 ■
19 ■ ■ 0425 ' 8.167
20 0433 8,113
21 0,030 0410
'  2,2 ■ , 'OilgS - 0,128
■23 . 0436 0468
24 0*099 0*180
,25.„-,'. .  ^ .0460 : , -■ ■... ........... . - ............0 4 # ._ _ _ -
Ifean  ^8*9, 0*13# 0*043 0476- 0*048
Comparison of ïnixturoa of pXasnia v/ith 
streptokimiso# .uroîvinaao and plasmin in  
the fib rin  plate to&t*.
foot
oubatanoe
Urplcinaao 
solution  
10 unita/mX.
50Jo
12.3#
6.25:
Plama t  oaXina 
Plasma atraptokinaaa 
Plasma t  uroldLnasa 
Plasma + p |a # in
ârea^of^Iyain
iïi^ '
4Ô0
380
212
IBO
100
f* kW fuW M# *
0
432
378
16
Bhov/n are  areas of ly s is  in  the f ib r in  p la te  toa t 
with a d ilu tio n  oarve of a  atandard urokinase 
solution# 10 units/ml*» ami tho areas of ly s is  
found with mixtures of X ml# plasma and 1 ml# of 
respective ly  saline# streptokinase (500 units/m l#)# 
urolcinaso (ioo unlts/m l#) and plasmin ( l4  units/m l#) 
From the data shown tho percentage a c t iv i t ie s  of 
the various plasma. mixtu3?es in  terms of the 
standard luxîkinase so lu tion  wore calculated mtd are 
okovm in  Table 11#
ly s is  activ ity  foilovdixg 
fiomplàmin injeotion*
Sabâoot MagioWlln ly s is  a c tiv ity  (ukita) at va# ln g
mmber tim es (etIbs#) a f t e r  üùmplmïïln in jectiêm *
0 3. 10 30 60 120
% 0,8 21*3 8,8 0,8 0.8 0*9
a 2,3 5,3 4.9 2*3 2.2 2.1
3 1,8 8,6 8.6 1,8 2.0 1.4
4 1*4 8,8 1,9 1.6 1,3 1,8
S 0,3 4,3 3,3 1*8 0,3 0.3
6 1,1 3.9 3,6 3*8 1,8 1,3
Î 1.0 13,8 10.3 1,0 0*9 1.1
Mean 1,2 7.9 4,1 1,7 1.3 1,2
Sho^m i s  euglobullB  ly e ie  a c t iv i ty  in 1 h m lth y  aubjocW  
bofeya and at vary in g  intorvais a fter  ImtmveBous Injection  
of 1 3 0  tm * CmplomlB# Mean m l m a  are a i m  shovm# The 
d a ta  a re  g ra p h ic a lly  d isp layed  in  f l g u #  %# in  no 
su b je c t d id  th e  onematage prothvombiB tim e o r  th e  throm bin 
clottin g  time change from oomtrol values by more than 
I  àGçoadê-
faî)lQ 46* Ssgloînjtliïl ly s ls  activ ity  fô 3,ÎQ(,viiag ôxesolsoi
Subjeàt l'kglobulin lysis QO-Sivity (unité) ai varying
number. times (mine.) in relation to sKoroloe.
Before 0
1 1»51 7*84
2 1*99 4 ,54
3 1,86  ■ 5.81
4 1,89  7,89
9 1.43 5.86
g 1. 8a 4.01
? 1*58 ' 3*95
5 SO 53
6*47 2. 3s 2.03
4*30
4*45
2.31
2*46
1*96
8.10
5,81 3*13 2.11
5*13 2.61 2.12
3*35 8.43 2,03
2,76  2*02 1,46 
4*61 2.5 1,98lean 1*69 5*61
Bhixm %B suglçlMlIn ly a is  activ ity  in  7 Waltlay subjects 
before and a t  varying In te rv a ls  # t e r  5 minutes strenuous 
exercise# lean  vabwe are  also  Bhoxnu fhe data are 
g raphically  displayed in  figure In  no subject did 
the one#8tàge prothromMn. time or the tliroriiMn c lo ttin g  
tlii# change from control values by mere than I  second#
fsM é  W f o o t  o f  repeated Gomplamla dêjectiona
fima of
0 1*7
§ 5*5
60 1,4
65 3 .8
ISO , 1.2
8,6
Bimm% IB tho effeot on ouglolmlin Xyoie ootivity 
in  a  n o m a l au b jeô t o f 3 in travonôua in je e t io n e  
o f %$Q % # O m p lm ln  g iven  a t  hourly  in te rv a ls  
(l*e* a fter  the moro* 60 and 1 2 0  minute eomploe 
had boom witMmim) # %e data are ehovm 
grapMoeX-ty in  figure 35#
lë fù o t ù i  OompîwiE
%m# afterC^dmplmiiîi" ^^^0lot>ü!lin ly&l# ( m i t a )  on aüéceaalvo # y a $
in^éction , « ,  ^ „ . p,
<mins*'' '*• ^ ^ ^
0 ï»2 0 .9  î» î  0*9 "i.O
3 18.8 13.6 5.5 3*6 4 ,3
10 15.0 ' 7.5 ' 8*5 1 ,6 1.1
go 3.6 1.0 1,1 1,8 l.Q
30 1*7 1.1 1.0 1.1 0*9
Bjiglolxiîin a o t lv it j  indiicod % imtmvemoue Injaotiot)
üf 150 mgf Omplom^n on 5 oticooBsive <3.ày8# #w  data 
a ra  g ra p M m lïy  d iap lay eâ  in  fl^%ro 3^*
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' É N
go# B ffoot o f Burgorys f i b r i n  p la te  to e t,
P atien t F ib rin  p la te  to e t (area of I jn ie
I^efore during a f te r  
operation operation operation
1 30 289 130
8 24 340 96
3 ISO 320 84
4 49 210 96
5 96 856 19s
6 144 196 156
7 150 39s 192
8 88 870 100
9 13s 460 280
10 100 398 120
Itean t  S .» , 93 i  46 313 i  Qg. 145 t  61
##P^ Wv M 'k#  "If  "A* W  'JW 64*ti*K ÿK  n*  I  iU i|j4 I'lliiii il Vt.\ uiP. iiiji ilritm
Areae of lyein  in  the f ib r in  p la te  too t (rosuépended 
engXobulin p re c ip ita te )  from 10 pationto  etadied 
before^ during a #  after exoioion of the rectum. 
Mean vaXuee and etandax^ deviations a re  aloe ehovm, 
*fho data are g raph ically  displayed In  fimvé%Ow
fab lo  gl# ISffeot o f  surgery^' oitfXobulin ly s io
Patient BuglobuXin I y # s  a ctiv ity  ( w i # ) .  
Before dnring a fter
operatidtt opésâtion opération
i 1*4 2*7 1*7
s 1.3 3,6 2.0
3 1.4 8*6 1.4
4 1*3 1.5 1*3
5 1*0 8*5 1*9
6 0*9 1.8 1*5
T 1*1 4*8 8*9
8 1,1 2*7 2*1
9 1,0 6'il 3.8
10 1*5 3*5 2*5
i t .m  «  8»D*- 1*2 s  0 .g  3,2 t. 1,4 8,1 z 0,8
% g lo W iin  ly a ia  a c t i v i t y  f o r  ID p a t ie n te  atudiocl 
'before^ d a rin g  and a f t e r  exo lo ion  o f th e  rectum#, 
loan values md standard deviations are a lso  ahomx* 
% e  d a ta  a rc  g m p h lc a iiy  d isp lay ed  i n  f ig u re  W*'.
fâ b le  ïSffo0t o f  plasminogen assaya»
t h ^ W k t w  *Anr f
Patièrjit Plasma plamlnogen (imita/ml#)
Bofpré • Auring aJ’tOs?
cjp6K£itâ.0iî opQ«it(ioft oxjer&iîioH
S
5
8.7  
3»3 
8*4
3*6
8*8
8.8 
3*1
3*3
8*8
8,6
3*0
2*8
8*0
8,J
8.8
1*7
îfeisn % S.B* 8*9 Z  0 ,4  2*4 S 0*5
2*4
8*9
1*9
2.‘
2*1
2*6
8*4
1*6
1 £  
8*4 ” 0*5
PlBSîSiïi jilasçalïïegôa levolm fe’osn 10 pî^leatts àtuSiôiJ 
TbgfoïfSj dWi’in® aaS aftoi’ ©JEOiaion of rootoro* Soan 
values &aâ stenàtwà dovistlOBs &t& êiIso shoBit,
Îiîs data ase grapMcalljr âisplaÿeâ iii fig&vo. 40*
febl'é 53* S ffa et o f surgery^ fibrinogen  aasayéi
Patient Plasma Ifibrlnogèn (mg$/lOO ml*-)
Before during. a fter
. opomtlom . oparatioB operation
l  870 835 820
8 ' 310 860 8gO
3 846 250 830
4 468 470 430
5  3 8 0  8 8 0  2 5 0
6 ■ 313 ' 850 876.
273 820
8 889 ' 215 196
9 846 190 210
10 248 210
-  s*»* 306 * 67 264 % 78 853 ^ 69
Mmma f i b r i n o g e n  l e v e l a  f ro m  .to  p a t i e n t a  s t u d i e d  
before, d u r i n g  a n d  after exoiaion of re o tu m *
Mean •v a lu e s  a n d  standard d e v i a t i o n s  are a l s o  eho%m# 
fho d a t a  are gmpM dally d i s p l a y e d  in figure 40*
54% of surgotys thrombin slo ttin g '
time*
Patlont WiirçHîrtîii^  olottiog' time (seoB*)
Before during ' aftor  
operation operation oporation
1 10*3 11*0 10,5
8 10*0 11,5 10,0
3 9*0 11.0 9*5
4 9*3 10*5 10.0
S 10*3 10,0 10,0
6 10*0 10,0 11*0
1 10*3 13*0 11*0
8 11*3 10*5 ■ 13,0
9 9*5 10*5 10,0
.0 10,0 13*5 10.3
3,0,1  £  0*7 i i * i  ±  i . i  10*5 » 0*7
%rombim s lo t t i n g  tim es from Î0  p a t ie n ts  otudiod 
b e fo re , d u rin g  and  a f t e r  essoiolon o f  th e  reotira# 
Meari v a lu e s  and etandord  d ev ia tio n s  a re  a i m  #orm * 
#m  d a ta  a re  d isp lay ed  g ra p h ic a lly  in  f ig u re  ''40* .
s ta te , com pllaatitig  
aurgieel operation#
Iiji r *i.Wi i.iiiiiiiiiit.i,iHiTim»t#i
Before
mm
4 W#@
after BâGA
10' Wwa
cU’teî? ITAGA
Bhole olot 
lyeie time 30 tBÎftg. J>34 hre# J?24  hre.
Plaeminogen
(mite/ml*-) m i m i ■ •' 1 ,6  ■
Fibrinogen 
Cïî^ **/|00 ml#} 43 ■ 110 ' 165
Whole' bio# 
flatting time 
(mine# )
lïjflnlte: St 5
f  hrombin 
clotting t;lme
(s#OS,)
97 IT 11
O oegulation and e.tudilee in  a  p a t ie n t  w ith
a  }]yperplaemlT#emiG s ta te , a f t e r  ^ e l e io n  o f rootum* 
fhe e ffec t e# #0A t^^mtment %b #.#m* She data 
a r e  g r a p h i c a l l y  ■ .p re sen ted  i n  f i g u r e  41*
fab le  gë# ItyperplaBmlnaemio é ta ts  complioating 
surgical operation#
fimo of SE?jBpliiig (hours)
0 4 14
Flbx*iu p la te  te a t  
(area lyaia 115 $ 8
IMglobulin ly a la  ooPi
PlaBUiinogen  ^  ^ *i ? o
(u n itû /m l.)
l?*ibr:lnogen ««o
(mg./lOO m l.)
Whole blood
c lo ttin g  time ï î i f in i te  12 10
(mima*)
Goagulatiou and f ib r in o ly tio  studios in  a pa tien t 
with a hyporplaaminaomib s ta te  trea ted  v?ith BkOA 
(lO gmb* I#V* given over 4 hours)* fhe data
are  g raph ically  displayed in  figu re  48*
^ b l e  57* ly o ié  o f  thrombi I n  tho a r t i f i c i a l
oiroulation»
Sabâoot
number
Percentage of to ta l  ra d io a c tiv ity
â t  s i t e  o f ia a o r t lo n
2
>
Ï
Moavi % a .» .
S6
21
,82
10
T
10
11
14
12
t 5 10 *  2.5
D is tr ib u tio n  o f t o t a l  r à d io à o t iv i tÿ  vrith throttibi from 
ncA l^aX m ib jocts 6t f t e r  84. houro poxfueion w ith  
atreiitoMnaèé* ' ‘ "'Mcah- 'vâWcà # m % #  deviations 
a lço  chovm# and a re  p raaen tcd  in  ta b le  83%
